
<html lang="en"     class="pb-page"  data-request-id="772f10e2-c7ed-4ec8-9f42-ba1a647f9fb1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/jm5010336;issue:issue:10.1021/jmcmar.2014.57.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles" /></meta><meta name="dc.Creator" content="John  Skidmore" /></meta><meta name="dc.Creator" content="Jag  Heer" /></meta><meta name="dc.Creator" content="Christopher N.  Johnson" /></meta><meta name="dc.Creator" content="David  Norton" /></meta><meta name="dc.Creator" content="Sally  Redshaw" /></meta><meta name="dc.Creator" content="Jennifer  Sweeting" /></meta><meta name="dc.Creator" content="David  Hurst" /></meta><meta name="dc.Creator" content="Andrew  Cridland" /></meta><meta name="dc.Creator" content="David  Vesey" /></meta><meta name="dc.Creator" content="Ian  Wall" /></meta><meta name="dc.Creator" content="Mahmood  Ahmed" /></meta><meta name="dc.Creator" content="Dean  Rivers" /></meta><meta name="dc.Creator" content="James  Myatt" /></meta><meta name="dc.Creator" content="Gerard  Giblin" /></meta><meta name="dc.Creator" content="Karen  Philpott" /></meta><meta name="dc.Creator" content="Umesh  Kumar" /></meta><meta name="dc.Creator" content="Alexander  Stevens" /></meta><meta name="dc.Creator" content="Rino A.  Bit" /></meta><meta name="dc.Creator" content="Andrea  Haynes" /></meta><meta name="dc.Creator" content="Simon  Taylor" /></meta><meta name="dc.Creator" content="Robert  Watson" /></meta><meta name="dc.Creator" content="Jason  Witherington" /></meta><meta name="dc.Creator" content="Emmanuel  Demont" /></meta><meta name="dc.Creator" content="Tom D.  Heightman" /></meta><meta name="dc.Description" content="The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P1 receptors, while a ..." /></meta><meta name="Description" content="The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P1 receptors, while a ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 15, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm5010336" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm5010336" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm5010336" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm5010336" /></link>
        
    
    

<title>Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm5010336" /></meta><meta property="og:title" content="Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0029.jpeg" /></meta><meta property="og:description" content="The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P1 receptors, while a variety of side effects have been ascribed to its S1P3 receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P1 receptor agonism. Here we describe a study of the tolerance of the S1P1 and S1P3 receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P1 receptor agonists with good selectivity vs S1P3 receptors, efficacy at &lt;1 mg/kg oral doses, and developability properties suitable for progression into preclinical development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm5010336"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm5010336">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm5010336&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm5010336&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm5010336&amp;href=/doi/10.1021/jm5010336" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 10424-10442</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm501207r" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm501313x" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++Skidmore">John Skidmore</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jag++Heer">Jag Heer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+N.++Johnson">Christopher N. Johnson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Norton">David Norton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sally++Redshaw">Sally Redshaw</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Sweeting">Jennifer Sweeting</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Hurst">David Hurst</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Cridland">Andrew Cridland</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Vesey">David Vesey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ian++Wall">Ian Wall</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mahmood++Ahmed">Mahmood Ahmed</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dean++Rivers">Dean Rivers</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James++Myatt">James Myatt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gerard++Giblin">Gerard Giblin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Philpott">Karen Philpott</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Umesh++Kumar">Umesh Kumar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander++Stevens">Alexander Stevens</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rino+A.++Bit">Rino A. Bit</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Haynes">Andrea Haynes</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Taylor">Simon Taylor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Watson">Robert Watson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Witherington">Jason Witherington</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emmanuel++Demont">Emmanuel Demont</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tom+D.++Heightman">Tom D. Heightman</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">Â§</span> <span class="aff-text">Neurology Center of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â </span> <span class="aff-text">Immuno Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, U.K.</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">â¡</span> <span class="aff-text">Neural Pathways DPU, GlaxoSmithKline, 11 Biopolis Way, Singapore 138667</span></div><div class="corresp-info"><strong>*</strong>E.D. Tel: +44 1438 764319. Fax: +44 1438 768302. E-mail: <a href="/cdn-cgi/l/email-protection#6f0a02020e011a0a034107410b0a0200011b2f081c04410c0002"><span class="__cf_email__" data-cfemail="51343c3c303f24343d7f397f35343c3e3f251136223a7f323e3c">[emailÂ protected]</span></a></div><div class="corresp-info"><strong>*</strong>T.D.H. Tel: +44 1223 226200. Fax: +44 1223 226201. E-mail: <a href="/cdn-cgi/l/email-protection#3f4b505211575a5658574b525e517f5e4c4b47115c5052"><span class="__cf_email__" data-cfemail="6b1f040645030e020c031f060a052b0a181f1345080406">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm5010336&amp;href=/doi/10.1021%2Fjm5010336" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 10424â10442</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 28, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 August 2014</li><li><span class="item_label"><b>Published</b> online</span>15 December 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 December 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm5010336" title="DOI URL">https://doi.org/10.1021/jm5010336</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10424%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJohn%2BSkidmore%252C%2BJag%2BHeer%252C%2BChristopher%2BN.%2BJohnson%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D24%26contentID%3Djm5010336%26title%3DOptimization%2Bof%2BSphingosine-1-phosphate-1%2BReceptor%2BAgonists%253A%2BEffects%2Bof%2BAcidic%252C%2BBasic%252C%2Band%2BZwitterionic%2BChemotypes%2Bon%2BPharmacokinetic%2Band%2BPharmacodynamic%2BProfiles%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10442%26publicationDate%3DDecember%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm5010336"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2438</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm5010336" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Skidmore&quot;},{&quot;first_name&quot;:&quot;Jag&quot;,&quot;last_name&quot;:&quot;Heer&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;N. Johnson&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Norton&quot;},{&quot;first_name&quot;:&quot;Sally&quot;,&quot;last_name&quot;:&quot;Redshaw&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Sweeting&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Hurst&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Cridland&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Vesey&quot;},{&quot;first_name&quot;:&quot;Ian&quot;,&quot;last_name&quot;:&quot;Wall&quot;},{&quot;first_name&quot;:&quot;Mahmood&quot;,&quot;last_name&quot;:&quot;Ahmed&quot;},{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;Rivers&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Myatt&quot;},{&quot;first_name&quot;:&quot;Gerard&quot;,&quot;last_name&quot;:&quot;Giblin&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Philpott&quot;},{&quot;first_name&quot;:&quot;Umesh&quot;,&quot;last_name&quot;:&quot;Kumar&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;Stevens&quot;},{&quot;first_name&quot;:&quot;Rino&quot;,&quot;last_name&quot;:&quot;A. Bit&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Haynes&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Taylor&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Watson&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Witherington&quot;},{&quot;first_name&quot;:&quot;Emmanuel&quot;,&quot;last_name&quot;:&quot;Demont&quot;},{&quot;first_name&quot;:&quot;Tom&quot;,&quot;last_name&quot;:&quot;D. Heightman&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;10424-10442&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm5010336&quot;},&quot;abstract&quot;:&quot;The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P1 receptors, while a variety of side effects have been ascribed to its S1P3 receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P1 receptor agonism. Here we describe a study of the tolerance of the S1P1 and S1P3 receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P1 receptor agonists with good selectivity vs S1P3 receptors, efficacy at &lt;1 mg/kg oral doses, and developability properties s&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5010336&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5010336" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5010336&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5010336" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5010336&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5010336" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm5010336&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5010336&amp;href=/doi/10.1021/jm5010336" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm5010336" /></input><a href="/doi/pdf/10.1021/jm5010336" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm5010336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm5010336%26sid%3Dliteratum%253Aachs%26pmid%3D25431977%26genre%3Darticle%26aulast%3DSkidmore%26date%3D2014%26atitle%3DOptimization%2Bof%2BSphingosine-1-phosphate-1%2BReceptor%2BAgonists%253A%2BEffects%2Bof%2BAcidic%252C%2BBasic%252C%2Band%2BZwitterionic%2BChemotypes%2Bon%2BPharmacokinetic%2Band%2BPharmacodynamic%2BProfiles%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D24%26spage%3D10424%26epage%3D10442%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291240" title="Cyclization">Cyclization</a>,</li><li><a href="/action/doSearch?ConceptID=292553" title="Ethanol">Ethanol</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jmcmar.2014.57.issue-24/20141226/jmcmar.2014.57.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P<sub>1</sub> receptors, while a variety of side effects have been ascribed to its S1P<sub>3</sub> receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P<sub>1</sub> receptor agonism. Here we describe a study of the tolerance of the S1P<sub>1</sub> and S1P<sub>3</sub> receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in <i>in vitro</i> and <i>in vivo</i> pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P<sub>1</sub> receptor agonists with good selectivity vs S1P<sub>3</sub> receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for progression into preclinical development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54818" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54818" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The recent FDA approval of fingolimod (<b>1a</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) has provided a novel mechanism of treatment for patients suffering from relapsingâremitting multiple sclerosis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In preclinical species and in patients, administration of fingolimod elicits the sequestration of lymphocytes in secondary lymphoid organs, resulting in a reduction in the count of circulating peripheral lymphocytes and a concomitant amelioration in the frequency and severity of autoimmune-mediated neuroinflammatory lesions.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Fingolimod is an aminodiol and is phosphorylated enantioselectively <i>in vivo</i> by sphingosine kinase-2.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> The resulting phosphate (<b>1b</b>) mimics the endogenous agonist sphingosine-1-phosphate (S1P, <b>2</b>), displaying agonist activity at S1P<sub>1</sub> and S1P<sub>3â5</sub> G-protein coupled receptor subtypes.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> A significant body of evidence indicates that the action of fingolimod and other small molecule agonists on the S1P<sub>1</sub> receptor alone is both necessary and sufficient to elicit effects on lymphocyte localization.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7-9)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0002.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected examples of published S1P<sub>1</sub> receptor agonists or prodrugs thereof.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although fingolimod is generally well tolerated, a variety of adverse events have been noted, some of which were ascribed to activity on S1P<sub>3â5</sub> receptors.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Transient bradycardia is noted in both patients and rodents after the first dose of fingolimod: studies in rodents showed this effect to be primarily mediated by action on S1P<sub>3</sub> receptors,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> but subsequently the S1P<sub>1/5</sub> agonist BAF312 was also shown to affect heart rate in healthy subjects despite being devoid of S1P<sub>3</sub> receptor agonism,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> highlighting a species difference in S1P receptor subtype function. Other fingolimod dose-related adverse events include macular edema, modest hypertension, and pulmonary effects including cough and dyspnea, the latter two being ascribed to action on smooth muscle S1P<sub>3</sub> receptors.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Together, these observations have spurred the quest for compounds showing selective agonism of S1P<sub>1</sub> receptors since this profile appears most likely to show a favorable balance of efficacy vs adverse events.</div><div class="NLM_p">Although both S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, an impressive diversity of chemotypes have been found to show S1P receptor agonism, revealing a relatively tolerant pharmacophore and a rich opportunity for medicinal chemists, as reviewed recently.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Example approaches include alternative scaffolds bearing hydroxy groups that undergo <i>in vivo</i> phosphorylation such as <b>3</b><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), generating a zwitterionic species with S1P receptor activity, and a variety of scaffolds that act as direct agonists without the need for <i>in vivo</i> activation, mimicking the lipophilic tail of S1P together with a negatively charged (<b>4</b>),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> zwitterionic (<b>5</b>),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> or uncharged polar headgroup (<b>6</b>),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> or even with no polar headgroup, such as <b>7</b>.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p last">Encouraged by the emerging preclinical and clinical data supporting the use of S1P<sub>1</sub> agonists as therapeutic agents for the treatment of multiple sclerosis and by the above-described pharmacophore tolerance, we were motivated to seek a high quality clinical candidate with a PK/PD profile suitable for once-daily dosing in man and physicochemical properties likely to minimize attrition arising from safety and tolerability issues. First, we aimed for high selectivity for S1P<sub>1</sub> over S1P<sub>3</sub> receptors to minimize the cardiovascular side effects observed with fingolimod, as discussed above. Second, although to date fingolimod appears reasonably well-tolerated,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> its long clinical half-life (6â9 days)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> could cause difficulties in case of the need to rapidly withdraw treatment; hence, we specifically sought compounds likely to show reversibility within 24 h. Third, we sought to balance on-target activity with favorable molecular weight and lipophilicity, to reduce protein binding and nonspecific binding properties (drug efficiency index),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and to minimize the risk of preclinical or clinical toxicity.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> This report describes our approach to exploring the tolerance of the S1P<sub>1</sub> pharmacophore toward acidic, basic, and zwitterionic compounds, and a comparison of their properties in <i>in vitro</i> and <i>in vivo</i> pharmacokinetic, pharmacodynamic, and safety models.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64676" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64676" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Carboxylic Acids</h3><div class="NLM_p">In the course of recent work targeting selective antagonists of the prostaglandin-E receptor EP1, we noted that pyrazole carboxylic acids showed promising oral exposure <i>in vivo</i>.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Several groups have demonstrated the favorable S1P<sub>1</sub> activity and pharmacokinetic properties of the 3,5-disubstituted oxadiazoles,<a onclick="showRef(event, 'ref16 ref17 ref25'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref25">(16, 17, 25)</a> and merging these chemotypes led to the design of <b>8</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) in which a 1,2,4-oxadiazole is substituted on <i>C</i>-3 with 1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid and on <i>C</i>-5 with a thiophene bearing lipophilic substituents. This compound shows moderate S1P<sub>1</sub> receptor affinity, acting as a full agonist with a pEC<sub>50</sub> of 6.6 in the GTPÎ³S assay, albeit with modest 8-fold selectivity over the S1P<sub>3</sub> receptor (pEC<sub>50</sub> of 5.8), and was therefore progressed to the lymphopenia model in rats, as described previously.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Significant lymphocyte lowering was observed after a 3 mg/kg oral dose, and persisted over 48 h. PK sampling confirmed that this prolonged PD response was driven by high systemic levels of <b>8</b> (2.4 Î¼M at the 48 h time point). The prolonged exposure is presumably a consequence of high plasma protein binding (HSA F<sub>ub</sub> 0.4%, based on chromatographic measurement<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>), and possibly enterohepatic recirculation, a common feature of lipophilic acids.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. S1P Receptor Activity and in Vitro Developability Properties of Heteroaryl-based Carboxylic Acids</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0023.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0024.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">We next sought to identify compounds with reduced lipophilicity, in order to diminish the extent of plasma protein binding, hoping thereby to reduce the prolonged PK half-life and elicit maximal lymphopenia at lower total plasma concentrations. First, we replaced the highly lipophilic trifluoromethyl substituted thiophene with a 3-chloro-4-isopropoxyphenyl group<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and explored the effects of merging the phenyl and pyrazole rings into a series of bicyclic cores (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), an approach also pursued by others.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In this series, both ethylene- and propylene-linked indazole carboxylic acids showed promising potency; the best activity at S1P<sub>1</sub> and selectivity over S1P<sub>3</sub> receptors was observed in the 4-linked indazoles, represented by indazole propionic acid <b>10</b>. The properties of <b>10</b> are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. As expected for a lipophilic acid, some inhibition of CYP2C9 is observed, with high plasma protein binding (>99%) across species. Metabolic stability in microsomal preparations is good, while permeability in MDCK cells is modest. As expected the solubility of <b>10</b> is pH dependent, being below quantifiable levels in simulated gastric fluid (SGF) but reaching 44 Î¼g/mL in fed-state simulated intestinal fluid (FeSSIF).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Despite this limited solubility, <b>10</b> has a superior profile in the rat lymphopenia model compared with <b>8</b>: maximal lowering of lymphocyte levels was achieved following a 1 mg/kg oral dose, and <i>in vivo</i> IC<sub>50</sub> of 117 nM was calculated from PK sampling across the doses.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Importantly, the lymphopenia was found to be reversible within 24 h even after repeat dosing for 7 days (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>a,b). Moreover, indazole acid <b>10</b> shows promising pharmacokinetic properties across species: oral bioavailability values range from 59% to 96% in rats, dogs, and cynomolgus monkeys, with half-lives in the range 1.0â7.6 h, albeit with low volume of distribution generally associated with acidic molecules.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0003.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of indazole propionic acid <b>10</b> on circulating lymphocyte levels in rats after (a) single dose in the range 0.1â3 mg/kg or (b) 7-day repeat dosing at 0.3 and 1 mg/kg, showing reversal within 24 h after the final dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> and <i>in Vivo</i> Properties of Indazole Propionic Acid <b>10</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">MW, PSA, cLogP</td><td class="colsep0 rowsep0" align="left">427, 103, 4.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">CHI log <i>D</i> @ pH 2.0, 7.4, and 10.5</td><td class="colsep0 rowsep0" align="left">4.11, 2.26,1.83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">S1P<sub>1</sub> pEC<sub>50</sub> (<i>n</i>, GTPÎ³S)</td><td class="colsep0 rowsep0" align="left">7.7Â (86)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">S1P<sub>3</sub> pEC<sub>50</sub> (<i>n</i>, GTPÎ³S)</td><td class="colsep0 rowsep0" align="left"><4.5Â (89)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">solubility @ 24 h (mg/mL)</td><td class="colsep0 rowsep0" align="left">SGF (pH 1.2)</td><td class="colsep0 rowsep0" align="left">not detected</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FeSSIF (pH 5)</td><td class="colsep0 rowsep0" align="left">0.044</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FASSIF (pH 6.5)</td><td class="colsep0 rowsep0" align="left">0.011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">CYP IC<sub>50</sub> (Î¼M,; 1A2, 2C9, 2C19, 2D6, 3A4VG, 3A4VR, <i>n</i>Â =Â 2â4)</td><td class="colsep0 rowsep0" align="left">>50, 7Â Â±Â 0.8, >50, >50, 28Â Â±Â 19, 25Â Â±Â 13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">permeability (MDCK type 2, nm/s)</td><td class="colsep0 rowsep0" align="left">203</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">Fu blood (rat, dog, cyno, human)</td><td class="colsep0 rowsep0" align="left">0.0017, 0.0020, 0.0018, 0.0010</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">hepatocyte CLi (mL/(minÂ·g); rat, dog, cyno, human)</td><td class="colsep0 rowsep0" align="left"><0.9, <1.7, 0.9, <0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left"><i>in vivo</i> IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">117</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">rat PK (1Â mg/kg iv<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> or 3Â mg/kg po;<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a><i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">CLb (mL/(minÂ·kg))<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">2Â Â±Â 0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1.0Â Â±Â 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (iv, h)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">7.5Â Â±Â 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F, po, %<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">96Â Â±Â 16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">dog PK (1Â mg/kg iv<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> or 2Â mg/kg po;<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a><i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">CLb (mL/(minÂ·kg))<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">4Â Â±Â 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1.0Â Â±Â 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (iv, h)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">3.9Â Â±Â 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F, po, %<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">94Â Â±Â 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">cyno PK (1Â mg/kg iv<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> or 3Â mg/kg po;<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a><i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">CLb (mL/(minÂ·kg))<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">3Â Â±Â 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.4Â Â±Â 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (iv, h)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1.2Â Â±Â 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F, po, %<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">59Â Â±Â 18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">DMSO/10%(w/v) Kleptose, 0.9% saline(aq) (2%/98%).</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Methylcellulose(aq), 1% (w/v), po suspension.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Basic Heterocycles</h3><div class="NLM_p">We next replaced the heteroaryl pyrazole core with fused aromaticâaliphatic systems that would introduce a basic center to explore effects on plasma protein binding, tissue distribution, and solubility. We based these molecules on the 5-(4-isopropoxyphenyl)-1,2,4-oxadiazole unit, substituted <i>ortho</i>- to the isopropoxy substituent with either a nitrile or a chloride, which had delivered good agonist activity in the indazole series. We systematically introduced regioisomers of phenyl-fused five-, six-, and seven-membered basic heterocycles, as summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. These compounds were found to have a range of activities at the S1P<sub>1</sub> receptor even when lacking the alkyl-carboxylate headgroup previously present in the aromatic heterocyclic series. The highest activities (pEC<sub>50</sub> > 8) were observed with isoindoline <b>11a</b>, benzazepines <b>12a</b>,<b>b</b>, and tetrahydroisoquinoline <b>13b</b>. The tetrahydroisoquinoline isomer <b>14a</b>, the benzoxazepine isomers <b>15a</b> and <b>16a</b>,<b>b</b> and the benzazepine isomers <b>17a</b>,<b>b</b> showed intermediate potency, while the benzoxazepine isomers <b>18a</b>,<b>b</b> and benzazepine isomers <b>19a</b>,<b>b</b> and <b>20a</b> showed the lowest levels of activity (pEC<sub>50</sub> < 7), although still at submicromolar levels. All these compounds showed excellent selectivity for S1P<sub>1</sub> over S1P<sub>3</sub> receptors. Interestingly, where comparisons were made, all compounds containing the <i>ortho-</i>nitrile substituent showed significantly greater potency than the corresponding <i>ortho-</i>chloro analogues. The use of aromatic nitrile as a chloride isostere in medicinal chemistry<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and the benefits of the nitrile functionality<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> have been reviewed recently. As might be expected, <i>in vivo</i> these basic derivatives showed very different pharmacokinetic behavior to their acidic counterparts, as exemplified by the benzazepines <b>17a</b> and <b>17b</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). In particular, significantly higher volumes of distribution were observed, offsetting the higher clearance to give relatively long half-lives in rodents. Interestingly, despite this difference in volume of distribution, compounds from this series showed similar pharmacodynamic profiles to indazole acid <b>10</b>, as exemplified by the data for <b>17b</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>): as for <b>10</b>, <b>17b</b> exhibited maximal lowering of lymphocyte levels following a 1 mg/kg oral dose, which was found to be reversible within 24 h.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. S1P<sub>1/3</sub> Receptor Activities for Phenyl-Fused Basic Heterocycles</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0025.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">pEC<sub>50</sub> (<i>n</i>, GTPÎ³S assay)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">S1P<sub>1</sub></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">S1P<sub>3</sub></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">core heterocycle</th><th class="colsep0 rowsep0" align="center" char=".">Y = Cl</th><th class="colsep0 rowsep0" align="center" char=".">Y = CN</th><th class="colsep0 rowsep0" align="center" char=".">Y = Cl</th><th class="colsep0 rowsep0" align="center" char=".">Y = CN</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="char" char=".">8.1Â (10)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (9)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b>,<b>b</b></td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="char" char=".">7.8Â (8)</td><td class="colsep0 rowsep0" align="char" char=".">8.7Â (15)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (8)</td><td class="colsep0 rowsep0" align="char" char=".">5.1 (1/10)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13b</b></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">8.4Â (2)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">4.5 (3/4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14a</b></td><td class="colsep0 rowsep0" align="left">D</td><td class="colsep0 rowsep0" align="char" char=".">7.4Â (11)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">4.8 (6/12)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15a</b></td><td class="colsep0 rowsep0" align="left">E</td><td class="colsep0 rowsep0" align="char" char=".">7.1Â (4)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (4)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16a</b>,<b>b</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">6.9Â (4)</td><td class="colsep0 rowsep0" align="char" char=".">7.6Â (4)</td><td class="colsep0 rowsep0" align="char" char=".">4.8 (3/4)</td><td class="colsep0 rowsep0" align="char" char=".">5.2Â (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b>,<b>b</b></td><td class="colsep0 rowsep0" align="left">G</td><td class="colsep0 rowsep0" align="char" char=".">6.8Â (13)</td><td class="colsep0 rowsep0" align="char" char=".">7.6Â (17)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (6)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (10)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18a</b>,<b>b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">6.5Â (7)</td><td class="colsep0 rowsep0" align="char" char=".">7.1Â (4)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (4)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b>,<b>b</b></td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="char" char=".">6.4Â (8)</td><td class="colsep0 rowsep0" align="char" char=".">6.9Â (11)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (6)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (8)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b></td><td class="colsep0 rowsep0" align="left">J</td><td class="colsep0 rowsep0" align="char" char=".">6.2Â (4)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (2)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">In parentheses is the number of test occasions out of all tests when a pEC<sub>50</sub> was obtained; otherwise the value was <4.5.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic and Pharmacodynamic Parameters for Benzazepines <b>17a</b> and <b>17b</b> Following Oral Dosing</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center">Â </th><th class="colsep0 rowsep0" align="center"><b>17a</b></th><th class="colsep0 rowsep0" align="center"><b>17b</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">mouse PK (<i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">CLb (mL/(minÂ·kg))<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">10.9</td><td class="colsep0 rowsep0" align="left">18.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">7.6</td><td class="colsep0 rowsep0" align="left">9.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">9.5</td><td class="colsep0 rowsep0" align="left">6.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>, po, (%)</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">rat % lymphopenia at time point<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">4 h</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8 h</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">24 h</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Dose of 1 mg/kg iv DMSO/1% methylcellulose 1:99 (w/v).</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Dose of 3 mg/kg po. For <b>17a</b>, DMSO/1% (w/v) methylcellulose 1:99. For <b>17b</b>, 1% (w/v) methylcellulose.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Following 1 mg/kg oral dose.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Zwitterions</h3><div class="NLM_p">Next, we explored the effect of introducing carboxyalkyl groups of varying length to the ring nitrogen of the more active basic heterocycles described above, generating zwitterions that mimic both the amino and phosphate moieties of S1P and phospho-fingolimod. Data are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. In this form, compounds containing the 4-substituted isoindoline (<b>21a</b>â<b>c</b>), 6-linked benzazepine (<b>22a</b>,<b>b</b>), and benzoxazepine (<b>23a</b>â<b>c</b>) gave only moderate potencies (S1P<sub>1</sub> GTPÎ³S pEC<sub>50</sub> 5.6â7.3), regardless of the length of the carboxyalkyl chain. We surmised that the L-shape imposed on these compounds by cores A, B, and F is less well tolerated by the S1P<sub>1</sub> receptor. Better results were achieved with the 5- and 6-linked isoquinoline cores in <b>24a</b> and <b>25a</b> and 7-linked benzazepine in <b>27a</b>â<b>c</b>, which can adopt a more linear conformation, and in this context, the <i>N</i>-acetic, -propanoic, and -butanoic acid analogues all showed similar S1P<sub>1</sub> agonist activity with pEC<sub>50</sub> values >8. The 9-linked benzoxazepine <b>26a</b> showed intermediate potency. Notably, for the benzazepines <b>27a</b>â<b>c</b>, introduction of the carboxyalkyl group introduced weak but measurable S1P<sub>3</sub> activity, which was not observed for the smaller fused-ring derivatives. Similar derivatization of templates H and I (which had shown inferior activity in the basic heterocycle series) did not lead to improved activity (data not shown).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. S1P<sub>1/3</sub> Receptor Activities for Phenyl-Fused Basic Heterocycles Bearing an N-Linked Carboxyalkyl Group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0026.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">pEC<sub>50</sub> (<i>n</i>)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (GTPÎ³S)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">core heterocycle</th><th class="colsep0 rowsep0" align="center" char="."><i>n</i></th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center" char=".">S1P<sub>1</sub></th><th class="colsep0 rowsep0" align="center" char=".">S1P<sub>3</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21a</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">A</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">6.5Â (4)</td><td class="colsep0 rowsep0" align="char" char=".">5.1 (3/6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21b</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">6.3Â (4)</td><td class="colsep0 rowsep0" align="char" char=".">5.7 (5/7)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21c</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="char" char=".">6.4Â (4)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22a</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">B</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">6.8Â (4)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">5.6Â (2)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">6.9Â (6)</td><td class="colsep0 rowsep0" align="char" char=".">5.7 (1/6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="char" char=".">7.3Â (8)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (7)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23c</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="char" char=".">7.2Â (6)</td><td class="colsep0 rowsep0" align="char" char=".">4.6 (1/6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24a</b></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="char" char=".">8.2Â (11)</td><td class="colsep0 rowsep0" align="char" char=".">5.4Â (11)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25a</b></td><td class="colsep0 rowsep0" align="left">D</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="char" char=".">8.1Â (6)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26a</b></td><td class="colsep0 rowsep0" align="left">E</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">7.4Â (19)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (10)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27a</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">G</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="char" char=".">8.4Â (16)</td><td class="colsep0 rowsep0" align="char" char=".">5.7 (5/12)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27b</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">8.1Â (11)</td><td class="colsep0 rowsep0" align="char" char=".">5.0 (7/9)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27c</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="char" char=".">8.1Â (44)</td><td class="colsep0 rowsep0" align="char" char=".">5.1 (34/45)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">In parentheses, the number of test occasions out of all tests when a pEC<sub>50</sub> was obtained; otherwise the value was <4.5.</p></div></div></div><div class="NLM_p">Having noted that an L-shape is unfavorable for the S1P<sub>1</sub> receptor activity of 4-substituted isoindoline (<b>21a</b>â<b>c</b>), 6-linked benzazepine (<b>22a</b>,<b>b</b>) and benzoxazepine (<b>23a</b>â<b>c</b>), we also explored the introduction of C-linked carboxyalkyl substituents to produce molecules based on these templates that lacked the unfavorable L-shape. Initially we explored the 1-substituted tetrahydroisoquinoline system bearing the oxadiazole ring on <i>C</i>-5: in this template with an acetic acid headgroup both the chloro (<b>28a</b>) and nitrile (<b>28b</b>) compounds were found to have good potency against S1P<sub>1</sub> and selectivity over S1P<sub>3</sub> (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). A consequence of this structural change is the incorporation of an additional hydrogen bond donor and a concomitant reduction in lipophilicity (clogP is predicted to drop by 0.5, Daylight calculation). In addition, a chiral center is introduced, which might be expected to reduce the planarity of the compounds and could thereby improve solubility.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. S1P<sub>1/3</sub> Receptor Activities for Phenyl-Fused Basic Heterocycles Bearing a C-Linked Carboxyalkyl Group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0027.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">pEC<sub>50</sub> (<i>n</i>)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> (GTPÎ³S)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">structure</th><th class="colsep0 rowsep0" align="center" char="."><i>n</i></th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center" char=".">S1P<sub>1</sub></th><th class="colsep0 rowsep0" align="center" char=".">S1P<sub>3</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28a</b></td><td class="colsep0 rowsep0" align="left">K</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">7.7Â (25)</td><td class="colsep0 rowsep0" align="char" char=".">5.3 (16/20)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28b</b></td><td class="colsep0 rowsep0" align="left">K</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">8.3(11)</td><td class="colsep0 rowsep0" align="char" char=".">4.9 (8/12)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29a</b></td><td class="colsep0 rowsep0" align="left">L</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">8.3Â (11)</td><td class="colsep0 rowsep0" align="char" char=".">6.1 (5/8)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29b</b></td><td class="colsep0 rowsep0" align="left">L</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">8.6Â (12)</td><td class="colsep0 rowsep0" align="char" char=".">6.6Â (6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30a</b></td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">8.3Â (2)</td><td class="colsep0 rowsep0" align="char" char="."><4.5Â (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30b</b></td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">8.0Â (4)</td><td class="colsep0 rowsep0" align="char" char=".">4.6 (1/3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31a</b><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">7.4Â (2)</td><td class="colsep0 rowsep0" align="char" char=".">4.7 (2/6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31b</b><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">7.3Â (12)</td><td class="colsep0 rowsep0" align="char" char=".">5.0Â (12)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">In parentheses, the number of test occasions out of all tests when a pEC<sub>50</sub> was obtained; otherwise the value was <4.5.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Compounds <b>31a</b>,<b>b</b> are enantiomers.</p></div></div></div><div class="NLM_p">Extending this approach to the isoindoline and benzazepine templates A and B proved synthetically challenging, but we did identify efficient routes to the benzoxazepine templates (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Interestingly, the benzoxazepines <b>29a</b>,<b>b</b> delivered high S1P<sub>1</sub> receptor potency, but S1P<sub>3</sub> receptor agonist activity also increased such that selectivity dropped to â¼100-fold. By contrast, the THIQs <b>28a</b>,<b>b</b> and benzoxazepines <b>30a</b>,<b>b</b> and <b>31a</b>,<b>b</b> showed both S1P<sub>1</sub> potency and selectivity against S1P<sub>3</sub> receptors. These findings are consistent with the structure-based observation that the S1P<sub>1</sub> receptor is more tolerant to steric hindrance than the S1P<sub>3</sub> receptor;<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> the substitution pattern of the benzoxazepines <b>29a</b>,<b>b</b> leads to a relatively linear overall shape, while the THIQ (<b>28a</b>,<b>b</b>) or benzoxazepines (<b>30a</b>,<b>b</b> and <b>31a</b>,<b>b</b>) possess a more step-like shape with increased steric bulk between the acid and oxadiazole groups, as illustrated by the low energy conformations of <b>29b</b> vs <b>30a</b> shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0004.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Three-dimensional rendering highlighting difference in overall shape of different templates represented by benzoxazepines <b>29b</b> (âlinearâ) and <b>30a</b> (âsteppedâ).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These investigations identified a number of zwitterionic S1P<sub>1</sub> agonists, containing either C- or N-linked carboxyalkyl groups, with promising <i>in vitro</i> activity and selectivity profiles, which were progressed to <i>in vivo</i> studies. Initially we profiled the pair of closely related compounds <b>28a</b> and <b>28b</b>, both based on a 6-aryl-substituted tetrahydroisoquinoline scaffold, differing in the nature of the substituent <i>ortho</i> to the isopropoxy group on the terminal aryl ring. While <b>28b</b>, possessing the <i>ortho-</i>nitrile, has the higher <i>in vitro</i> potency, it showed only moderate lymphopenia in the rat following a 1 mg/kg oral dose (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). This result was rationalized by the associated pharmacokinetic data; the blood concentration of <b>28b</b> peaked at only 16 nM at the 4 h time point. In contrast <i>ortho-</i>chloride <b>28a</b> proved effective in the rat lymphopenia assay following a 1 mg/kg oral dose despite possessing inferior <i>in vitro</i> potency. This result is consistent with the improved pharmacokinetic properties of <b>28a</b>, which showed a peak concentration of 120 nM at 4 h.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Comparison of Lymphopenia and Oral Exposures for Cl- and CN-Substituted Tetrahydroquinonlines <b>28a</b> and <b>28b</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0028.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center"><b>28a</b></th><th class="colsep0 rowsep0" align="center"><b>28b</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MW, PSA, cLogP</td><td class="colsep0 rowsep0" align="left">427, 97, 2.05</td><td class="colsep0 rowsep0" align="left">418, 121, 1.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHI log <i>D</i> @ pH 2.0, 7.4, and 10.5</td><td class="colsep0 rowsep0" align="left">1.47; 2.02; 1.73</td><td class="colsep0 rowsep0" align="left">1.17; 1.58; 1.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">S1P<sub>1</sub> pEC<sub>50</sub> (<i>n</i>) (GTPÎ³S)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">7.7Â (25)</td><td class="colsep0 rowsep0" align="left">8.3Â (11)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">S1P<sub>3</sub> pEC<sub>50</sub> (<i>n</i>) (GTPÎ³S)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">5.3 (16/20)</td><td class="colsep0 rowsep0" align="left">4.9 (8/12)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lymphocyte count @ 0, 4, 8, 12, 24 h<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">99, 24, 12, 58, 99</td><td class="colsep0 rowsep0" align="left">105, 46, 69, 108, 132</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[blood] @ 0, 4, 8, 12, 24 h<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a> (Î¼M)</td><td class="colsep0 rowsep0" align="left">NQ, 0.120Â Â±Â 0.016, 0.086Â Â±Â 0.022, NQ, NQ</td><td class="colsep0 rowsep0" align="left">NQ, 0.016, NQ, NQ, NQ</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">rat PK, <b>28a</b> (1Â mg/kg iv<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a> or 3Â mg/kg po;<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a><i>n</i>Â =Â 1)</td><td class="colsep0 rowsep0" align="left">CLb (mL/(minÂ·kg))<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (iv, h)<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F, po, %<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">10, 18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">In parentheses, the number of test occasions out of all tests when a pEC<sub>50</sub> was obtained; otherwise the value was <4.5.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">1 mg/kg po.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last"><i>n</i> = 1; DMSO/10% (w/v) Kleptose, 0.9% saline(aq) (5%/95% v/v).</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last"><i>n</i> = 2; 1% (w/v) methylcelluslose(aq) po suspension.</p></div></div></div><div class="NLM_p">The superior <i>in vivo</i> profile of the chloro-substituted <b>28a</b> over its nitrile counterpart <b>28b</b> proved to be representative of a general phenomenon in the zwitterionic series, with chloro-analogues showing increased exposure over the corresponding nitriles on a number of occasions (data not shown). Several parameters could account for this trend: first the chloroânitrile switch elicits a decrease in lipophilicity (chromatographic log <i>D</i><a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> difference of ca. 0.5 units between <b>28a</b> and <b>28b</b>, see Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>), which could influence permeability or interaction with transporters present in the gut;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> alternatively, the chloroânitrile switch might adversely affect solubility, which could compromise oral absorption.</div><div class="NLM_p">Mindful of the importance of keeping a balance between a high enough log <i>D</i> to ensure effective absorption while maintaining acceptable levels of solubility, we profiled further compounds of similar chromatographic log <i>D</i> to <b>28a</b> (CHI log <i>D</i> 2.02). Compound <b>26a</b> based on the âsteppedâ N<i>-</i>linked benzoxazepine template (CHI log <i>D</i> 2.39) was profiled in the rat lymphopenia assay at 0.1, 0.3, 1, and 3 mg/kg. At the 3 mg/kg dose, <b>26a</b> caused a reduction of lymphocyte count to <20% of control levels between 2 and 12 h before returning to baseline levels at 24 h. At a 1 mg/kg dose, <b>26a</b> was only marginally less effective, whereas at doses lower than this the compound showed little or no effects in the assay (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The <i>in vivo</i> IC<sub>50</sub> based on PK sampling was calculated at 127 nM.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0005.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CD3+ lymphocyte counts in rat blood after oral dose with benzoxazepine <b>26a</b> (0.1â3 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further profiling of <b>26a</b> was undertaken to explore its developability profile (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). IC<sub>50</sub> values against a panel of CYP450 enzymes were all greater than 26 Î¼M. Consistent with the presence of the carboxylate functionality, <b>26a</b> was found to have a relatively low free fraction in blood; values from a range of species were <2.5%. Intrinsic clearance, determined in hepatocytes, was low in rats and in man but moderate in dogs and cynomolgus monkeys. Compound <b>26a</b> was also found to have moderate permeability across a layer of MDCK cells.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Consistent with these <i>in vitro</i> data, <b>26a</b> showed low clearance following a 1 mg/kg iv dose in rats and excellent bioavailability when dosed orally at 3 mg/kg. In line with the higher <i>in vitro</i> clearance values in dog and cynomolgus monkey, the <i>in vivo</i> clearance following a 1 mg iv dose was somewhat higher resulting in lower bioavailabilities in both species after a 3 mg/kg oral dose. Based on this good correlation and the data obtained in the three different species, this compound was predicted to have a good pharmacokinetic profile in man (data not shown).</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Selected <i>in Vitro</i> and <i>in Vivo</i> Properties of Zwitterionic Benzazepines and Benzoxazepines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center">properties</th><th class="colsep0 rowsep0" align="center"><b>26a</b></th><th class="colsep0 rowsep0" align="center"><b>27c</b></th><th class="colsep0 rowsep0" align="center"><b>31a</b></th><th class="colsep0 rowsep0" align="center"><b>31b</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">MW, PSA, cLogP</td><td class="colsep0 rowsep0" align="left">472, 98, 1.74</td><td class="colsep0 rowsep0" align="left">460, 112, 2.27</td><td class="colsep0 rowsep0" colspan="2" align="left">473, 120, 1.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">CHI log <i>D</i> @ pH 2.0, 7.4 and 10.5</td><td class="colsep0 rowsep0" align="left">2.39<a class="ref internalNav" href="#t8fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">1.26, 1.78, 1.50</td><td class="colsep0 rowsep0" colspan="2" align="left">1.02, 1.74, 1.57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">S1P<sub>1</sub> pEC<sub>50</sub> (<i>n</i>) (GTPÎ³S)</td><td class="colsep0 rowsep0" align="left">7.4Â (19)</td><td class="colsep0 rowsep0" align="left">8.1Â (44)</td><td class="colsep0 rowsep0" align="left">7.4Â (2)</td><td class="colsep0 rowsep0" align="left">7.3Â (12)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">S1P<sub>3</sub> pEC<sub>50</sub> (<i>n</i>) (GTPÎ³S)</td><td class="colsep0 rowsep0" align="left"><4.5Â (10)</td><td class="colsep0 rowsep0" align="left">5.1 (34/45)</td><td class="colsep0 rowsep0" align="left">4.7 (2/6)</td><td class="colsep0 rowsep0" align="left">5.0Â (12)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">solubility @ 24 h (mg/mL)</td><td class="colsep0 rowsep0" align="left">SGF (pH 1.2)</td><td class="colsep0 rowsep0" align="left">>1.32</td><td class="colsep0 rowsep0" align="left">0.02</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FeSSIF (pH 5)</td><td class="colsep0 rowsep0" align="left">0.03â0.05</td><td class="colsep0 rowsep0" align="left">0.10</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FASSIF (pH 6.5)</td><td class="colsep0 rowsep0" align="left">0.32â1.20</td><td class="colsep0 rowsep0" align="left">0.03</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">p<i>K</i><sub>a</sub> amine</td><td class="colsep0 rowsep0" align="left">7.39</td><td class="colsep0 rowsep0" align="left">9.15</td><td class="colsep0 rowsep0" align="left">7.98</td><td class="colsep0 rowsep0" align="left">8.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">CYP IC<sub>50</sub> (Î¼M; 1A2, 2C9, 2C19, 2D6, 3A4VG, 3A4VR, <i>n</i>Â =Â 2â4)</td><td class="colsep0 rowsep0" align="left">>50, 27Â Â±Â 7, >50, > 50, 40Â Â±Â 14, 39Â Â±Â 16</td><td class="colsep0 rowsep0" align="left">>50, >50, >50, >50, >50, 43Â Â±Â 7</td><td class="colsep0 rowsep0" align="left">all > 50</td><td class="colsep0 rowsep0" align="left">all > 50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">permeability (MDCK type 2, nm/s)</td><td class="colsep0 rowsep0" align="left">155</td><td class="colsep0 rowsep0" align="left">155</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">Fu blood (rat, dog, human)</td><td class="colsep0 rowsep0" align="left">0.012, 0.018, 0.02</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">0.004, 0.010, 0.014</td><td class="colsep0 rowsep0" align="left">0.004, 0.015, 0.016</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">hepatocyte CLi (mL/(minÂ·g); rat, dog, cyno, human)</td><td class="colsep0 rowsep0" align="left">1.0, 8.3, 4.2, 1.3</td><td class="colsep0 rowsep0" align="left"><0.85, <1.70, <0.85, <0.85</td><td class="colsep0 rowsep0" align="left"><0.9, 4, <0.9, <0.9</td><td class="colsep0 rowsep0" align="left"><0.9, 1.7, <0.9, <0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left"><i>in vivo</i> IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">127</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">rat PK (1Â mg/kg iv<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> or 3Â mg/kg po;<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a><i>n</i>Â =Â 2â3)</td><td class="colsep0 rowsep0" align="left">CLb (mL/(minÂ·kg))<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">7Â Â±Â 1</td><td class="colsep0 rowsep0" align="left">7Â Â±Â 1</td><td class="colsep0 rowsep0" align="left">1.03</td><td class="colsep0 rowsep0" align="left">0.71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1.2Â Â±Â 0.2</td><td class="colsep0 rowsep0" align="left">1.5Â Â±Â 0.21</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (iv, h)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">3.0Â Â±Â 0.7</td><td class="colsep0 rowsep0" align="left">2.6Â Â±Â 0.3</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">6.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F, po, %<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">83Â Â±Â 16</td><td class="colsep0 rowsep0" align="left">62Â Â±Â 13</td><td class="colsep0 rowsep0" align="left">87Â Â±Â 39</td><td class="colsep0 rowsep0" align="left">78Â Â±Â 12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">dog PK (1Â mg/kg iv<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a> and 1<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a>Â orÂ 2<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a>Â mg/kg po;<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a><i>n</i>Â =Â 2â3)</td><td class="colsep0 rowsep0" align="left">CLb (mL/(minÂ·kg))<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">26Â Â±Â 4</td><td class="colsep0 rowsep0" align="left">3Â Â±Â 0</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.0Â Â±Â 1</td><td class="colsep0 rowsep0" align="left">1.6Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (iv, h)<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.4Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="left">8.0Â Â±Â 2.0</td><td class="colsep0 rowsep0" align="left">0.84</td><td class="colsep0 rowsep0" align="left">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F, po, %<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a>,<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">57Â Â±Â 6<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">69Â Â±Â 11<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">50<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">67<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">cyno PK (1Â mg/kg iv<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> or 3Â mg/kg po;<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a><i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">CLb (mL/(minÂ·kg))<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">30Â Â±Â 2</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">4.0Â Â±Â 1.1</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (iv, h)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">3.2Â Â±Â 1.1</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F, po, %<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">39Â Â±Â 19</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last"><b>26a</b> and <b>27c</b>, DMSO/10% (w/v) Kleptose, 0.9% saline (aq) (2%/98% v/v); <b>31a</b>,<b>b</b>, DMSO/10% (w/v) Kleptose HPB, 0.9% saline (aq) (5%/95% v/v).</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last"><b>26a</b>, <b>27c</b>, and <b>31a</b>,<b>b</b>, 1% (w/v) methylcellulose (aq) po suspension.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last"><b>26a</b> and <b>27c</b>, DMSO/10% (w/v) Kleptose, 0.9% saline (aq) (2%/98% v/v); <b>31a</b>,<b>b</b>, DMSO/10% (w/v) Kleptose HPB, 0.9% saline (aq) (2%/98% v/v).</p></div><div class="footnote" id="t8fn4"><sup>d</sup><p class="last"><b>26a</b> and <b>27c</b>, 1% (w/v) methylcellulose (aq).</p></div><div class="footnote" id="t8fn5"><sup>e</sup><p class="last"><b>31a</b>,<b>b</b>, 1% (w/v) methylcellulose 400 (aq).</p></div><div class="footnote" id="t8fn6"><sup>f</sup><p class="last">Determined only at pH 7.4.</p></div></div></div><div class="NLM_p">Overall it was felt that the profile of <b>26a</b> showed excellent promise from a development perspective. One remaining concern with this compound was its limited solubility: for example, solubility in fasted-state simulated intestinal fluid (FaSSIF) (pH 6.5) was found to be only 0.03â0.05 mg/mL although higher solubility was seen in both SGF and FeSSIF.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> We had hoped that the presence of the seven-membered ring adjacent to the oxadiazole ring might reduce the planarity of compounds in the benzoxazepine series; however, as can be seen from a small molecule X-ray crystal structure of <b>26a</b>, this arrangement of rings still adopts a predominantly planar conformation, with torsion angles between the rings of only 4.9Â° and 7.1Â° (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0006.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of benzoxazepine <b>26a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since the cyano group frequently delivered superior <i>in vitro</i> potency compared with the chloride, we also explored whether a more lipophilic core template such as benzazepine would deliver improved pharmacokinetics for compounds possessing this more polar substituent. The N-linked benzazepinyl butanoic acid <b>27c</b> showed a pEC<sub>50</sub> value of 8.0 against S1P<sub>1</sub> and â¼1000-fold selectivity over S1P<sub>3</sub> receptors (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). The CHI log <i>D</i> for <b>27c</b> was found to be 1.78 at pH 7.4, in between the value for poorly active <b>28b</b> and efficacious compounds such as <b>28a</b> and <b>26a</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). Promisingly, <b>27c</b> was found to have similar <i>in vitro</i> permeability to <b>26a</b> and was found to be stable in hepatocytes across all four tested species. Moreover, following 1 mg/kg iv and 3 mg/kg oral doses in rats, it was found to have low blood clearance and good bioavailability. A similar study in the dog also revealed low clearance and good bioavailability. In the lymphopenia assay the excellent pharmacokinetics and higher <i>in vitro</i> potency of <b>27c</b> delivered a superior profile to <b>26a</b>, with the 0.3, 1, and 3 mg/kg doses delivering a full, prolonged lymphopenia (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). PK/PD calculations indicated a higher <i>in vivo</i> potency for <b>27c</b> with an IC<sub>50</sub> of 15 nM. However, solubility screening for <b>27c</b> revealed no significant improvement when compared with <b>26a</b>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0007.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of a range of doses of compound <b>27c</b> on CD3+ lymphocyte counts in rat blood.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another approach to improving the solubility of these compounds was to introduce a heteroatom into the terminal phenyl ring. Replacement of the terminal phenyl ring of <b>30b</b> with a pyridyl ring gave <b>31</b>, which lowered the CHI log <i>D</i> from 2.02 to 1.74. Although this led to a modest loss of potency in the S1P<sub>1</sub> GTPgS assay, potency was largely maintained in the Î²-arrestin assay developed toward the end of this program (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Selectivity for S1P<sub>1</sub> over S1P<sub>3</sub> remained >100-fold. Compound <b>31</b> is stable in the intrinsic clearance assay in the presence of rat, mouse, cynomolgus monkey, and human hepatocytes, with some turnover in the dog; as with compound <b>26a</b>, plasma protein binding was high (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). Compound <b>31</b> showed low clearance and a significantly reduced volume of distribution in the rat compared with <b>26a</b>, and good bioavailability was achieved following a 3 mg/kg oral dose. This compound was separated into enantiomers <b>31a</b> and <b>31b</b>, which showed similar potencies vs S1P<sub>1</sub> receptors and were both progressed to the rat lymphopenia assay. At a dose of 1 mg/kg both enantiomers delivered a >80% reduction in lymphocyte count from 2 to 12 h (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). Compound <b>31a</b> exhibited a prolonged lympophenia, with effects on lymphocyte counts lasting at least 48 h,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> whereas the lymphocyte counts for <b>31b</b> returned to baseline levels by 30 h. At 0.3 mg/kg, <b>31a</b> showed a similar profile to <b>31b</b> at the 1 mg/kg dose, whereas <b>31b</b> showed a slightly weaker effect with lymphocyte levels of 20â40%. <i>In vivo</i> IC<sub>50</sub>âs for <b>31a</b>,<b>b</b> were 91 and 99 nM, respectively, reflecting somewhat lower <i>in vitro</i> potencies compared with <b>27c</b>.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0008.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of single oral doses of compounds <b>31a</b> and <b>31b</b> on CD3+ lymphocyte counts in rat blood.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Synthesis</h3><div class="NLM_p">The synthesis of compounds <b>8</b>â<b>31</b> is summarized in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a>â<a class="ref internalNav" href="#sch14" aria-label="14">14</a>, with the exception of compounds <b>13</b> and <b>17b</b>, which have been described previously.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The pyrazole-containing compound <b>8</b> was prepared by converting the known alcohol <b>33</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> to the corresponding benzylic bromide <b>34</b>, followed by displacement of the bromide with pyrazole-4-carboxylic acid ethyl ester and saponification to give the desired carboxylic acid derivative (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). The 5-substituted indazole <b>9</b> was prepared starting from commercially available 5-cyanoindazole <b>35</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). First, the propanoic ester group was introduced by reaction with ethyl 3-bromopropanoate, and the cyano group was converted to the amidoxime <b>36</b> using hydroxylamine. Coupling to 3-chloro-4-isopropoxybenzoic acid using EDC and HOBt followed by heating effected cyclization to the oxadiazole, and finally saponification gave the desired acid <b>9</b>. The isomeric 4-substituted indazole <b>10</b> was prepared starting from 2-amino-6-bromotoluene <b>37</b> (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). Conversion to 4-bromoindazole <b>38</b> was effected by diazotization of the aminotoluene with isoamyl nitrite and cyclization under basic conditions. Next, the 4-bromoindazole was substituted as above using ethyl 3-bromopropionate, and Pd-catalyzed reaction with zinc cyanide gave the 4-cyanoindazole intermediate <b>39</b>. This was converted to the amidoxime <b>40</b> as before, and reaction with 3-chloro-4-isopropoxybenzoyl chloride followed by heating in DMF gave the oxadiazole intermediate, which was saponified to give the desired compound <b>10</b>.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Compound <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PPh<sub>3</sub>, NBS, THF, 0 Â°C; (b) H<sub>2</sub>SO<sub>4</sub>, EtOH, reflux, 97%; (c) KO<sup>t</sup>Bu, EtOH, 60 Â°C, 63% (2 steps); (d) LiOH, H<sub>2</sub>O, EtOH, 40 Â°C, 62%.</p></p></figure><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Compound <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BrCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Et, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 Â°C, 66%; (b) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 50 Â°C, 87%; (c) EDC, HOBt, DMF, 120 Â°C, 58%; (d) NaOH, EtOH, room temperature, 55%.</p></p></figure><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) Ac<sub>2</sub>O, AcOK, isoamyl nitrite, CHCl<sub>3</sub>, 0â60 Â°C; (ii) conc. HCl then NaOH, 0â30 Â°C, 91%; (b) ethyl acrylate, DBU, CH<sub>3</sub>CN, 70 Â°C, 78%; (c) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 1,4-dioxane, reflux, 78%; (d) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, reflux, 80%; (e) (i) acid, (COCl<sub>2</sub>)<sub>2</sub>, DMF cat., CH<sub>2</sub>Cl<sub>2</sub>, room temperature; (ii) hydroxyimidate, DMF, room temperature to 120 Â°C, 78%; (f) NaOH, EtOH/H<sub>2</sub>O, 60 Â°C, 99%.</p></p></figure><div class="NLM_p">The synthesis of compounds <b>11a</b>,<b>b</b> and <b>21a</b>â<b>c</b> required preparation of the 4-substituted isoindoline template (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>). This was effected by double radical bromination of 2,3-dimethylbenzonitrile <b>41</b>, followed by cyclization with benzylamine to give <b>43</b>. Next, the benzyl group was removed using chloroethyl chloroformate, and the nitrogen was reprotected using Boc anhydride. Conversion of the nitrile to the amidoxime <b>44</b> as above followed by acylation with 3-chloro-4-isopropoxybenzoic acid and cyclization gave the oxadiazole, and finally deprotection with TFA gave the desired isoindoline <b>11a</b>. Compounds <b>21a</b>â<b>c</b> were synthesized by reaction of the corresponding isoindoline with either ethyl 3-bromopropionate or ethyl 4-bromobutyrate followed by saponification.</div><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Compounds <b>11a</b>,<b>b</b> and <b>21a</b>â<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NBS, (PhCO<sub>2</sub>)<sub>2</sub>, CCl<sub>4</sub>, 80 Â°C; (b) PhCH<sub>2</sub>NH<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, MeCN, 80 Â°C, 25% (2 steps); (c) ClCH<sub>2</sub>CH<sub>2</sub>OCOCl, 4 Ã sieves, PhCl, 90 Â°C, 79%; (d) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, 34%; (e) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 50 Â°C, 58%; (f) EDC, HOBt, DMF, room temperature to 120 Â°C, 28% (<b>11a</b>), 11% (<b>11b</b>); (g) TFA, DCM, room temperature, 96% (<b>11a</b>), 88% (<b>11b</b>) ; (h) Br(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Et, EtN(iPr)<sub>2</sub>, MeCN, 80 Â°C, 93% (<b>21a</b>); (i) NaOH, EtOH/water, room temperature, 41% (<b>21a</b>); (j) Br(CH<sub>2</sub>)<sub>3</sub>CO<sub>2</sub>Et, EtN(iPr)<sub>2</sub>, MeCN, 80 Â°C, 92% (<b>21b</b>), 83% (<b>21c</b>); (k) NaOH, EtOH/water, room temperature, 33% (<b>21b</b>), 16% (<b>21c</b>).</p></p></figure><div class="NLM_p">Benzazepines <b>12a</b>,<b>b</b> and <b>22a</b>,<b>b</b> were prepared starting from Boc-protected 6-hydroxybenzazepine <b>45</b> (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Reaction with triflic anhydride gave the triflate ester, which allowed Pd-catalyzed introduction of the nitrile substituent with zinc cyanide to give <b>46</b>. Conversion to the amidoxime <b>47</b> as before followed by reaction with either 3-chloro- or 3-cyano-4-isopropoxybenzoic acid methyl ester in the presence of sodium hydride effected cyclization to the corresponding oxadiazoles, and deprotection with TFA gave the desired benzazepines <b>12a</b> or <b>12b</b>. Compounds <b>22a</b>,<b>b</b> were prepared by alkylation of <b>12a</b> with <i>t</i>-butyl 3-bromopropionate or <i>t</i>-butyl 4-bromobutyrate, followed by acidic deprotection.</div><figure id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Compounds <b>12a</b>,<b>b</b> and <b>22a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Tf<sub>2</sub>O, Et<sub>3</sub>N, DCM, â10 Â°C, 51%; (b) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 150 Â°C, 99%; (c) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 50 Â°C, 39%; (d) NaH, 3-Cl-4-<sup>i</sup>PrO-PhCO<sub>2</sub>Me or 3-CN-4-<sup>i</sup>PrO-PhCO<sub>2</sub>Me, THF, reflux, 96% (<b>12a</b>), 86% (<b>12b</b>); (e) TFA, DCM, reflux (100%, <b>12a</b>,<b>b</b>); (f) Br(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>tBu, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 Â°C, 25% (<b>22a</b>); (g) HCl, 1,4-dioxane, room temperature, 54% (<b>22a</b>); (h) BrCH<sub>2</sub>CO<sub>2</sub>tBu, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 Â°C, 92% (<b>22b</b>); (i) HCl, 1,4-dioxane, room temperature, 94% (<b>22b</b>).</p></p></figure><div class="NLM_p">The 5-substituted tetrahydroisoquinolines <b>14a</b>,<b>b</b> were prepared starting from commercially available 5-cyanotetrahydroisoquinoline <b>48</b> (Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>). Boc protection and conversion to the amidoxime <b>49</b> followed by reaction with 3-chloro-4-isopropoxybenzoic acid methyl ester in the presence of sodium hydride effected cyclization to the corresponding oxadiazole, and deprotection with TFA gave the desired THIQ <b>14a</b>. N-alkylation of <b>14a</b> with ethyl bromoacetate followed by saponification gave the amino acid <b>25</b>. The C-linked amino acids <b>28a</b>,<b>b</b> were prepared by NBS-mediated oxidation of <b>14a</b> or <b>14b</b> to give the corresponding dihydroisoquinoline, followed by addition of mono <i>t</i>-butyl malonate and acidic ester hydrolysis or of monoethyl malonate and saponification, respectively.</div><figure id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0014.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Compounds <b>14a</b>,<b>b</b>, <b>25</b>, and <b>28a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Boc<sub>2</sub>O, DCM, room temperature, 66%; (b) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 65 Â°C, 91%; (c) NaH, 3-Cl-4-<sup>i</sup>PrO-PhCO<sub>2</sub>Me, THF, reflux, 80% (<b>14a</b>) or 3-CN-4-<sup>i</sup>PrO-PhCOCl, DIPEA, DMAP, DMF, 95 Â°C, 31% (<b>14b</b>); (d) HCl, 1,4-dioxane, room temperature, 90% (<b>14a</b>), 76% (<b>14b</b>); (e) BrCH<sub>2</sub>CO<sub>2</sub>Et, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 60 Â°C, 32%; (f) LiOH, THF/MeOH/water, 100 Â°C, 85%; (g) NBS, DCM, microwave, 100 Â°C for (<b>28a</b>), or NBS, DCM, reflux for (<b>28b)</b>, 45%; (h) <b>28a</b>, tBuO<sub>2</sub>CCH<sub>2</sub>CO<sub>2</sub>H, K<sub>2</sub>CO<sub>3</sub>, MeCN, microwave 100 Â°C, 51% (2 steps) followed by HCl, 1,4-dioxane, room temperature, 92%; <b>28b</b>, EtO<sub>2</sub>CCH<sub>2</sub>CO<sub>2</sub>H, K<sub>2</sub>CO<sub>3</sub>, THF, microwave 100 Â°C followed by LiOH, MeOH/THF/water, microwave 100 Â°C, 21% (2 steps).</p></p></figure><div class="NLM_p">The 6-substituted benzoxazepine <b>15a</b> was prepared from the previously described amidoxime <b>50</b><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>) by cyclization with 3-chloro-4-isopropoxybenzoyl chloride to give the oxadiazole followed by deprotection with hydrochloric acid. N-alkylation of <b>15a</b> with ethyl 4-bromobutyrate followed by saponification gave the N-linked acid <b>26</b>.</div><figure id="sch7" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0015.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Compounds <b>15a</b> and <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) 3-Cl-4-<sup>i</sup>PrO-PhCO<sub>2</sub>Cl, (COCl<sub>2</sub>)<sub>2</sub>, DMF cat., DCM, room temperature; (ii) amidoxime, DMF, room temperature to 120 Â°C, 82% (2 steps); (b) HCl, 1,4-dioxane, room temperature, 99%; (c) Br(CH<sub>2</sub>)<sub>3</sub>COOC<sub>2</sub>H<sub>5</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 Â°C, 70%; (d) NaOH, EtOH/H<sub>2</sub>O, room temperature, 79%.</p></p></figure><div class="NLM_p">Synthesis of the isomeric benzoxazepines <b>16a</b>,<b>b</b> and <b>23a</b>â<b>c</b> required preparation of the corresponding template (Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a>). Starting with methyl 2-hydroxy-5-bromobenzoate <b>51</b>, Mitsunobu condensation with N-Boc ethanolamine <b>52</b> followed by acidic deprotection and cyclization under basic conditions gave the benzoxazepinone <b>54</b>. Next, reduction with boraneÂ·THF complex followed by Boc protection of the resulting benzoxazepine allowed Pd-catalyzed introduction of the nitrile group using zinc cyanide. Conversion to the amidoxime <b>55</b> as before followed by EDC/HOBt mediated coupling with 3-chloro- or 3-cyano-4-isopropoxybenzoic acid and heat effected cyclization to the oxadiazole, and deprotection with hydrochloric acid gave the desired benzoxazepines <b>16a</b> or <b>16b</b>. N-alkylation of <b>16a</b> with ethyl 3-bromopropionate or of <b>16b</b> with ethyl 3-bromopropionate or ethyl 4-bromobutyrate followed by saponification gave the acids <b>23a</b>â<b>c</b>, respectively.</div><figure id="sch8" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0016.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Compounds <b>16a</b>,<b>b</b> and <b>23a</b>â<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DIAD, PPh<sub>3</sub>, THF, room temperature, 55%; (b) TFA, DCM, room temperature; then Et<sub>3</sub>N, toluene, 100 Â°C, 59%; (c) BH<sub>3</sub>.THF, THF, room temperature to 65 Â°C, 97%; (d) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, room temperature, 89%; (e) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 Â°C, 90%; (f) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 60 Â°C, 78%; (g) 4-Cl-3-iPrOPhCO<sub>2</sub>H or 4-CN-3-iPrOPhCO<sub>2</sub>H, EDC, HOBt, DMF, room temperature to 120 Â°C, 31% (<b>16a</b>,<b>b</b>); (h) HCl, 1,4-dioxane, room temperature, 71% (<b>16a</b>), 73% (<b>16b</b>); (i) Br(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Et, EtN(iPr)<sub>2</sub>, MeCN, 80 Â°C, 97% (<b>23a</b>), 72% (<b>23b</b>); (j) NaOH, EtOH/water, room temperature, 47% (<b>23a</b>), 10% (<b>23b</b>); (k) Br(CH<sub>2</sub>)<sub>3</sub>CO<sub>2</sub>Et, EtN(iPr)<sub>2</sub>, MeCN, 80 Â°C, 62%; (l) NaOH, EtOH/water, room temperature, 28%.</p></p></figure><div class="NLM_p">The 7-substituted benzazepine <b>17a</b> was prepared from the previously described 5-cyanobenzazepine <b>56</b><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (Scheme <a class="ref internalNav" href="#sch9" aria-label="9">9</a>). Conversion to the amidoxime followed by coupling to 4-chloro-3-isopropoxybenzoic acid using EDC/HOBt and heating effected cyclization to the oxadiazole, and Boc deprotection using hydrochloric acid gave <b>17a</b>. N-alkylation of <b>17a</b> with <i>t</i>-butyl acrylate followed by acidic deprotection gave the acid <b>27b</b>. N-alkylation of <b>17b</b> with ethyl bromoacetate or ethyl 4-bromobutyrate followed by saponification gave the acids <b>27a</b> and <b>27c</b>, respectively.</div><figure id="sch9" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0017.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Compounds <b>17a</b>,<b>b</b> and <b>27a</b>â<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 60 Â°C, 93%; (b) 4-Cl-3-iPrOPhCO<sub>2</sub>H, EDC, HOBt, DMF, room temperature to 120 Â°C, 29% (<b>17a</b>) or (i) 4-CN-3-iPrOPhCO<sub>2</sub>H, (COCl<sub>2</sub>)<sub>2</sub>, DMF cat., CH<sub>2</sub>Cl<sub>2</sub>, room temperature; (ii) hydroxyimidate, toluene/pyridine, room temperature to reflux, 78%, (<b>17b</b>); (b) HCl, 1,4-dioxane, room temperature, 82% (<b>17a</b>), 95% (<b>17b</b>); (c) BrCH<sub>2</sub>CO<sub>2</sub>Et, Cs<sub>2</sub>CO<sub>3</sub>, DMF, room temperature to 60 Â°C, 62%; (d) NaOH, EtOH/H<sub>2</sub>O, 40 Â°C, 89%; (e) <i>t</i>-butyl acrylate, EtN(iPr)<sub>2</sub>, MeOH, 90 Â°C; (f) HCl, 1,4-dioxane, room temperature, 46% (2 steps); (g) Br(CH<sub>2</sub>)<sub>3</sub>COOC<sub>2</sub>H<sub>5</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, 90 Â°C, 90%; (h) NaOH, EtOH/H<sub>2</sub>O, room temperature, 63%.</p></p></figure><div class="NLM_p">The benzoxazepine isomers <b>18a</b> and <b>18b</b> were prepared starting from 4-methoxysalicylic acid methyl ester <b>57</b> (Scheme <a class="ref internalNav" href="#sch10" aria-label="10">10</a>). Mitsunobu condensation with N-Boc ethanolamine followed by acidic deprotection and cyclization under basic conditions gave the benzoxazepinone <b>59</b>. Next, the methyl ether was hydrolyzed using HBr, the resulting hydroxy group was reprotected by reaction with benzyl bromide, and reduction of the lactam with lithium aluminum hydride then gave the benzoxazepine <b>60</b>. Boc N-protection, hydrogenolytic deprotection of the benzyl group, and conversion of the resulting hydroxy group to the triflate ester allowed Pd-catalyzed introduction of the nitrile group using zinc cyanide to give <b>61</b>. Conversion to the amidoxime as before followed by EDC/HOBt mediated coupling with 3-chloro- or 3-cyano-4-isopropoxybenzoic and heat effected cyclization to the oxadiazole, and deprotection with hydrochloric acid gave the desired benzoxazepines <b>18a</b> or <b>18b</b>.</div><figure id="sch10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0018.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Compounds <b>18a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DIAD, PPh<sub>3</sub>, THF, 0 Â°C to room temperature; (b) TFA, DCM; then Et<sub>3</sub>N, toluene, 100 Â°C, 44% (2 steps); (c) HBr, 110 Â°C; (d) BnBr, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 Â°C, 75% (2 steps); (e) LiAlH<sub>4</sub>, THF, 0â60 Â°C, 95%; (f) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, room temperature, 70%; (g) H<sub>2</sub>/Pd/C, THF/EtOH, room temperature, 100%; (h) Tf<sub>2</sub>O, Py, 0 Â°C, 100%; (i) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 Â°C, 72%; (j) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 60 Â°C, 96%; (k) 4-Cl-3-iPrOPhCO<sub>2</sub>H or 4-CN-3-iPrOPhCO<sub>2</sub>H, EDC, HOBt, DMF, room temperature to 120 Â°C, 56% (<b>18a</b>), 92% (<b>18b</b>); (l) HCl, 1,4-dioxane, room temperature, 76% (<b>18a</b>), 90% (<b>18b</b>).</p></p></figure><div class="NLM_p">The 7-substituted benzazepines <b>19a</b> and <b>19b</b> were prepared according to Scheme <a class="ref internalNav" href="#sch11" aria-label="11">11</a>. Starting with 7-amino-benzazepinone <b>62</b>, diazotization and reaction with triiodomethane followed by reduction of the lactam with BH<sub>3</sub>Â·THF complex afforded the 7-iodobenzazepine <b>63</b>. Boc-protection of the nitrogen followed by Pd-catalyzed reaction with zinc cyanide gave the nitrile, which was converted as before to the amidoxime <b>64</b>. EDC/HOBt mediated coupling with 3-chloro- or 3-cyano-4-isopropoxybenzoic and heat effected cyclization to the oxadiazole, and deprotection with hydrochloric acid gave the desired benzazepines <b>19a</b> or <b>19b</b>.</div><figure id="sch11" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0019.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Compounds <b>19a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CHI<sub>3</sub>, tBuONO, THF, room temperature to 50 Â°C, 68%; (b) BH<sub>3</sub>Â·THF, THF, reflux, 76%; (c) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, room temperature, 100%; (d) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 Â°C, 74%; (e) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 55 Â°C, 82%; (f) 4-Cl-3-iPrOPhCO<sub>2</sub>H or 4-CN-3-iPrOPhCO<sub>2</sub>H, EDC, HOBt, DMF, room temperature to 90 Â°C, 16% (<b>19a</b>), 46% (<b>19b</b>); (g) HCl, 1,4-dioxane, room temperature, 69% (<b>19a</b>), 86% (<b>19b</b>).</p></p></figure><div class="NLM_p">The benzazepine isomer <b>20</b> was prepared starting from 2,6-dicyanotoluene <b>65</b> (Scheme <a class="ref internalNav" href="#sch12" aria-label="12">12</a>). Reaction with hydroxylamine gave the monoamidoxime, which was acylated by 3-chloro-4-isopropoxybenzoic methyl ester in the presence of sodium hydride and heated to form the oxadiazole <b>66</b>. Next, the methyl group was deprotonated with LDA, and the resulting anion was treated with allyl bromide. The resulting alkene <b>67</b> was converted to the alcohol by ozonolysis followed by treatment with boraneÂ·DMS complex, which also effected reduction of the nitrile to the benzylic amine <b>68</b>. This amino alcohol was cyclized under Mitsunobu conditions to give the desired benzazepine <b>20</b>.</div><figure id="sch12" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0020.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Compound <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 60 Â°C, 51%; (b) NaH, 4-Cl-3-iPrOPhCO<sub>2</sub>Me, THF, room temperature to reflux, 90%; (c) LDA, THF, AllBr, â78 Â°C, 60%; (d) O<sub>3</sub>, DCM, â78 Â°C; then THF, BH<sub>3</sub>Â·DMS, room temperature to 40 Â°C, 19%; (e) DIAD, PPh<sub>3</sub>, DCM, room temperature, 13%.</p></p></figure><div class="NLM_p">The C-linked benzoxazepine acids <b>29a</b>,<b>b</b> were prepared using a similar sequence to compounds <b>16a</b>,<b>b</b> (Scheme <a class="ref internalNav" href="#sch13" aria-label="13">13</a>). Starting with methyl 2-hydroxy-5-bromobenzoate <b>51</b>, Mitsunobu condensation with protected propanediol <b>69</b> followed by acidic deprotection and cyclization under basic conditions gave the hydroxymethyl benzoxazepinone <b>71</b>. Next, reduction with boraneÂ·THF complex followed by Boc protection of the resulting benzoxazepine allowed Pd-catalyzed introduction of the nitrile group using zinc cyanide to give <b>72</b>. Conversion to the amidoxime as before followed by EDC/HOBt mediated coupling with 3-chloro-4-isopropoxybenzoic effected cyclization to the oxadiazole <b>73</b>. Oxidation of the hydroxymethyl group under Jones conditions and acidic deprotection gave the desired benzoxazepine <b>29a</b>. Alternatively, the hydroxymethyl group was oxidized to the aldehyde using DessâMartin periodinane, allowing Wittig chain extension, hydrogenation, and saponification to give the C-linked propionic acid <b>29b</b>.</div><figure id="sch13" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0021.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Compounds <b>29a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DIAD, PPh<sub>3</sub>, toluene, 80 Â°C, 57%; (b) p-TsOH, MeOH, room temperature, 81%; (c) TFA, DCM, room temperature; then Et<sub>3</sub>N, toluene, 100 Â°C, 73%; (d) BH<sub>3</sub>Â·THF, THF, room temperature to 65 Â°C, 86%; (e) Boc<sub>2</sub>O, aqueous Na<sub>2</sub>CO<sub>3</sub>, THF, room temperature, 88%; (f) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 Â°C, 82%; (g) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 50 Â°C, 95%; (h) 4-Cl-3-iPrOPhCO<sub>2</sub>H, EDC, HOBt, DMF, room temperature to 100 Â°C, 28%; (i) CrO<sub>3</sub>, H<sub>2</sub>SO<sub>4</sub>, acetone, 0 Â°C, 68%; (j) HCl, 1,4-dioxane, room temperature, 64%; (k) DessâMartin, DCM, room temperature, 88%; (l) Ph<sub>3</sub>PCHCO<sub>2</sub>Et, THF, 40 Â°C, 71%; (m) H<sub>2</sub>/Pd/C, EtOH, room temperature, 54%; (n) aq NaOH, EtOH, room temperature, 98%; (o) HCl, 1,4-dioxane, room temperature, 61%.</p></p></figure><div class="NLM_p">The C-linked benzoxazepine acids <b>30a</b>,<b>b</b> and <b>31a</b>,<b>b</b> again required de novo synthesis of the template (Scheme <a class="ref internalNav" href="#sch14" aria-label="14">14</a>). Starting from 6-bromosalicylaldehyde <b>74</b>, Wittig condensation followed by Mitsunobu reaction gave the cinnamate ester <b>75</b>, and acidic Boc deprotection followed by heating under basic conditions effected a 7-exo cyclization to generate the benzoxazepine ring, which was then reprotected to give <b>76</b>. Next, the bromo substituent was replaced by cyano using palladium catalysis, and the ester group was converted to the alcohol <b>77</b> by lithium borohydride reduction. Pyridine sulfur trioxide oxidation to the corresponding aldehyde followed by Wittig homologation and PCC oxidation gave the C-propionyl ester <b>78</b>, which was converted to <b>30a</b> by the usual sequence of amidoxime formation, cyclization, and deprotection. Alternatively, Wittig reaction of the aldehyde gave the unsaturated ester <b>79</b>, which was reduced by hydrogenolysis to the C-butyryl ester and converted to <b>30b</b> or <b>31a</b>,<b>b</b> using the usual sequence of amidoxime, cyclization, and deprotection. Compound <b>30b</b> was isolated as the racemate, while the enantiomers <b>31a</b> and <b>31b</b> were separated by chiral chromatography prior to deprotection.</div><figure id="sch14" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0022.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Compounds <b>30a</b>,<b>b</b> and <b>31a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Ph<sub>3</sub>PâCHCOOC<sub>2</sub>H<sub>5</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 Â°C, 95%; (b) BocNH(CH<sub>2</sub>)<sub>2</sub>OH, PPh<sub>3</sub>, DIAD, THF, 0 Â°C, 94%; (c), CF<sub>3</sub>COOH, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 100%; (d) DBU, THF, 60 Â°C, 97%; (e) Boc<sub>2</sub>O, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 92%; (f) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 96 Â°C, 92%; (g) LiBH<sub>4</sub>, EtOH/Et<sub>2</sub>O, room temperature, 96%; (h) DMSO, DIPEA, then Py.SO<sub>3</sub>, Py, 0 Â°C, 100%; (i) Ph<sub>2</sub>POCH<sub>2</sub>OMe, LDA, THF, â78 Â°C to room temperature, then NaH, THF, room temperature, 42% (2 steps); (j) PCC, DCM, room temperature, 56% ; (k) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, MeOH, reflux, 100%; (l) 4-Cl-3-iPrOPhCO<sub>2</sub>Cl, Et<sub>3</sub>N, MeCN, room temperature to 100 Â°C, 10%; (m) aqueous NaOH, EtOH, 60 Â°C, 85%; (n) HCl, 1,4-dioxane, room temperature, 35%; (o) Ph<sub>3</sub>PâCHCOOC<sub>2</sub>H<sub>5</sub>, 0 Â°C to room temperature, 94%; (p) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, Pd/C, H<sub>2</sub> (1 atm), EtOH, room temperature, 100%; (q) aqueous NH<sub>2</sub>OH, EtOH, reflux, 96%; (r) 4-Cl-3-iPrOPhCO<sub>2</sub>Cl, Et<sub>3</sub>N, MeCN, room temperature to 100 Â°C, 12%; (s) aqueous NaOH, EtOH, 50 Â°C, 94%; (t) HCl, 1,4-dioxane, room temperature, 17%; (u) (i) acid, (COCl<sub>2</sub>)<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temperature; (ii) hydroxyimidate, NEt<sub>3</sub>, DMF, room temperature to 120 Â°C, 60%; (v) Separation of enantiomers by chiral chromatography, 95%; (w) NaOH, EtOH/H<sub>2</sub>O, 50 Â°C, 93%; (x) HCl, 1,4-dioxane, room temperature, 76%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62051" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62051" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, we have identified a range of novel S1P<sub>1</sub> receptor agonists with promising developability properties. Starting with a carboxylic acid-based template, we found that reducing lipophilicity and enhancing potency by using the bicyclic indazole template allowed maximal sustained lymphopenia in rats to be achieved at 1 mg/kg. Replacement of the fused aromatic bicyclic template with basic aromatic-saturated fused bicycles also afforded compounds showing maximal lymphopenia at 1 mg/kg, despite their significant differences in volumes of distribution compared with the acidic analogues. Design of related bicyclic zwitterionic compounds allowed further enhancement of properties, such that similar lymphopenia could be achieved at the lower dose of 0.3 mg/kg with either the N-linked benzoxazepine <b>26a</b> or the C-linked benzoxazepines <b>31a</b>,<b>b</b>. The N-linked benzazepine <b>27c</b> even demonstrated efficacy at doses as low at 0.1 mg/kg po. This progress was aided by systematically exploring the effects of molecular properties on permeability, free fraction, and solubility. Establishing a correlation between <i>in vitro</i> and <i>in vivo</i> potency<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> accelerated compound selection and enabled the prioritization of compounds for <i>in vivo</i> studies. Definitive PK/PD relationships were established using the rat lymphopenia model, which also facilitated an early estimation of human dose.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Overall, solubility for the different chemotypes discussed here remained low, despite efforts to introduce charged groups and break the planarity of the compounds to reduce crystal lattice energy. However, despite this shortcoming, good bioavailability was achieved, most likely due to good permeability, which compensated for the low solubility. This campaign resulted in the identification of several potent S1P<sub>1</sub> receptor agonists with appropriate developability properties suitable for further progression to preclinical development.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86023" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86023" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General</h3><div class="NLM_p last">All solvents were purchased from Romil Ltd. (Hy-Dry anhydrous solvents), and commercially available reagents were used as received. Melting points were recorded on a Buchi B-545 apparatus and are uncorrected. All reactions were followed by TLC analysis (TLC plates GF254, Merck) or LCMS (liquid chromatography mass spectrometry) using a Waters ZQ instrument. NMR spectra were recorded on a Bruker AVANCE 400 spectrometer and are referenced as follows: <sup>1</sup>H (400 MHz), internal standard TMS at Î´ = 0.00; <sup>13</sup>C (100.6 MHz), internal standard CDCl<sub>3</sub> at Î´ = 77.23 or DMSO-<i>d</i><sub>6</sub> at Î´ = 39.70. Column chromatography was performed on prepacked silica gel columns (3090 mesh, IST) using a biotage SP4. Mass spectra were recorded on Waters ZQ (ESI-MS) and Q-Tof 2 (HRMS) spectrometers. Mass directed auto prep was performed on a Waters 2767 instrument with a MicroMass ZQ mass spectrometer using a Supelco LCABZ++ column. GLOBAL gradients for chromatography are as follows (solvent B, polar component; CV = column volume): 10% GLOBAL, 3% B for 2 CV, 3â13% B over 10 CV, then 13% B for 5 CV; 20% GLOBAL, 5% B for 2 CV, 5â20% B over 10 CV, then 20% B for 5 CV; 30% GLOBAL, 8% B for 2 CV, 8â38% B over 10 CV, then 38% B for 5 CV; 40% GLOBAL, 10% B for 2 CV, 10â50% B over 10 CV, then 50% B for 5 CV; 50% GLOBAL, 13% B for 2 CV, 13â63% B over 10 CV, then 63% B for 5 CV; 100% GLOBAL, 25% B for 2 CV, 25â100% B over 10 CV, then 100% B for 10 CV. Abbreviations for multiplicities observed in NMR spectra are as follows: s, singlet; br s, broad singlet; d, doublet; t, triplet; q, quadruplet; p, pentuplet; spt, septuplet; m, multiplet. All compounds reported are of at least 95% purity according to LCMS (conditions described in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>E</i>)-Ethyl 3-(3-Bromo-2-(2-((tert-butoxycarbonyl)amino)ethoxy)phenyl) Acrylate (<b>75</b>)</h3><div class="NLM_p last">A solution of 3-bromo-2-hydroxybenzaldehyde <b>74</b> (10.05 g, 50 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) at 0 Â°C under nitrogen was treated with ethyl (triphenyl-15-phosphanylidene)acetate (17.4 g, 50 mmol), and the resulting mixture was stirred at this temperature for 30 min and then was concentrated <i>in vacuo</i>. Purification of the residue by flash chromatography on silica gel (5â25% EtOAc in hexanes) gave ethyl (2<i>E</i>)-3-(3-bromo-2-hydroxyphenyl)-2-propenoate (12.85 g, 95%) as a white solid. LCMS (method formate): retention time 0.82 min, [M + H]<sup>+</sup> = 273, 275 (1 Br). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.93 (d, <i>J</i> = 16.2 Hz, 1H), 7.48 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.44 (dd, <i>J</i> = 7.8, 1.3 Hz, 1H), 6.84 (t, <i>J</i> = 8.0 Hz, 1H), 6.58 (d, <i>J</i> = 16.2 Hz, 1H), 6.01 (s, 1H), 4.27 (q, <i>J</i> = 7.2 Hz, 2H), 1.34 (t, <i>J</i> = 7.2 Hz, 3H). A solution of this material (4.07 g, 15.0 mmol) and triphenylphosphine (4.33 g, 16.50 mmol) under nitrogen in THF (100 mL) at room temperature was treated with 1,1-dimethylethyl (2-hydroxyethyl)carbamate (2.32 mL, 15.0 mmol). The resulting yellow solution was cooled to 0 Â°C, and then DIAD (3.21 mL, 16.50 mmol) was added dropwise over 5 min. After 10 min, the ice bath was removed, and the mixture was stirred at room temperature for 1.5 h and then was concentrated <i>in vacuo</i>. The residue was dissolved in EtOAc, and the organic phase was washed three times with brine, dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. Purification of the residue by flash chromatography on silica gel (5â25% EtOAc in hexanes) gave <b>33</b> (5.87 g, 14.17 mmol, 94% yield) as a white solid. LCMS (method formate): retention time 1.01 min, [M + H]<sup>+</sup> = 414, 416 (1 Br). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.91 (d, <i>J</i> = 16.2 Hz, 1H), 7.45â7.65 (m, 2H) 7.03 (t, <i>J</i> = 8.0 Hz, 1H), 6.46 (d, <i>J</i> = 16.2 Hz, 1H), 5.15â5.37 (m, 1H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 4.01 (t, <i>J</i> = 4.8 Hz, 2H), 3.57 (d, <i>J</i> = 5.1 Hz, 2H), 1.47 (s, 9H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>tert</i>-Butyl 9-Bromo-5-(2-ethoxy-2-oxoethyl)-2,3-dihydrobenzo[<i>f</i>][1,4]oxazepine-4(5<i>H</i>)-carboxylate (<b>76</b>)</h3><div class="NLM_p last">A solution of ethyl (2<i>E</i>)-3-(3-bromo-2-{[2-({[(1,1-dimethylethyl)oxy]carbonyl}amino)ethyl]oxy}phenyl)-2-propenoate, <b>75</b> (58.1 g, 140 mmol), in CH<sub>2</sub>Cl<sub>2</sub> (150 mL) at room temperature was treated with CF<sub>3</sub>COOH (108 mL, 1.4 mol), and the resulting mixture was stirred for 14 h at this temperature and then was concentrated <i>in vacuo</i>. The residue was suspended in water (300 mL), and the mixture was basified with a 2 N NaOH aqueous solution to pH 10. The aqueous phase was then extracted with EtOAc (2 Ã 200 mL). The combined organic phases were dried over MgSO<sub>4</sub> and concentrated <i>in vacuo</i> to give (<i>E</i>)-ethyl 3-(2-(2-aminoethoxy)-3-bromophenyl)acrylate (48.2 g, 153 mmol, 109% yield) as a white solid, which was carried through as is to the next step without purification. LCMS (method formate): retention time 0.61 min, [M + H]<sup>+</sup> = 314, 316 (1 Br). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.96 (d, <i>J</i> = 16.2 Hz, 1H), 7.59 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 7.51 (dd, <i>J</i> = 7.8, 1.3 Hz, 1H), 7.05 (t, <i>J</i> = 8.0 Hz, 1H), 6.46 (d, <i>J</i> = 16.2 Hz, 1H), 6.28 (br s, 2H), 4.25 (q, <i>J</i> = 7.1 Hz, 2H), 4.10â4.19 (m, 2H), 3.40 (t, <i>J</i> = 4.9 Hz, 2H), 1.29â1.33 (t, <i>J</i> = 7.1 Hz, 3H). A solution of this material (48.4 g, 137 mmol) in THF (200 mL) at room temperature was treated with DBU (25 mL, 166 mmol), and the resulting mixture was stirred at 60 Â°C for 16 h and then cooled to room temperature and concentrated <i>in vacuo</i>. The residue was dissolved in EtOAc (300 mL), and the organic phase was washed with water (2 Ã 300 mL) and then brine (100 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i> to give ethyl (9-bromo-2,3,4,5-tetrahydro-1,4-benzoxazepin-5-yl)acetate (41.9 g, 97%) as a pale yellow oil, which was used in the next step without further purification. LCMS (method formate): retention time 0.59 min, [M + H]<sup>+</sup> = 314, 316 (1 Br). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.46 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.10 (dd, <i>J</i> = 7.6, 1.3 Hz, 1H), 6.81â6.97 (m, 1H), 4.50 (dd, <i>J,</i>=,9.3, 5.8 Hz, 1H), 4.08â4.25 (m, 3H), 4.00 (ddd, <i>J</i> = 12.3, 7.5, 2.5 Hz, 1H), 3.44 (ddd, <i>J</i> = 14.7, 7.5, 2.5 Hz, 1H), 3.16 (ddd, <i>J</i> = 14.8, 5.8, 2.4 Hz, 1H), 3.07 (dd, <i>J</i> = 15.7, 9.3 Hz, 1H), 2.80 (dd, <i>J</i> = 15.5, 5.7 Hz, 1H), 1.75 (br s, 1H), 1.15â1.34 (m, 3H). A solution of this material (41.9 g, 133 mmol) and Et<sub>3</sub>N (22.31 mL, 160 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (600 mL) was treated at room temperature with di-<i>tert</i>-butyl dicarbonate (34.1 mL, 147 mmol), and the resulting mixture was stirred for 18 h at room temperature. The organic phase was successively washed with water (400 mL), a 0.5 N HCl aqueous solution (300 mL), and brine (300 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. Purification of the residue by flash chromatography on silica gel (0â30% EtOAc in hexanes) gave <b>76</b> (50.7 g, 92%) as a white solid. LCMS (method formate): retention time 1.32 min, [M + H]<sup>+</sup> = 414, 416 (1 Br). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 7.52 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.22 (dd, <i>J</i> = 7.6, 1.5 Hz, 1H), 6.99 (t, <i>J</i> = 7.7 Hz, 1H), 5.52 (s, 1H), 4.36 (d, <i>J</i> = 9.9 Hz, 1H), 4.07 (q, <i>J</i> = 7.1 Hz, 2H), 3.98â4.04 (m, 1H), 3.73 (s, 1H), 3.63â3.68 (m, 1H), 3.10 (d, <i>J</i> = 8.1 Hz, 1H), 2.91â2.98 (m, 1H), 1.40 (s, 9H), 1.15â1.19 (m, 3H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>tert</i>-Butyl 9-Cyano-5-(2-hydroxyethyl)-2,3-dihydrobenzo[<i>f</i>][1,4]oxazepine-4(5<i>H</i>)-carboxylate (<b>77</b>)</h3><div class="NLM_p last">1,1-Dimethylethyl 9-bromo-5-[2-(ethyloxy)-2-oxoethyl]-2,3-dihydro-1,4-benzoxazepine-4(5<i>H</i>)-carboxylate, <b>76</b> (70 g, 169 mmol), and Zn(CN)<sub>2</sub> (23.80 g, 203 mmol) were suspended in DMF (400 mL), and the resulting mixture was placed under vacuum for 5 min, then the flask was flushed with nitrogen. Pd(PPh<sub>3</sub>)<sub>4</sub> (19.52 g, 16.90 mmol) was added, and the resulting mixture was stirred at 96 Â°C for 16 h under nitrogen and then was cooled to room temperature. The mixture was diluted with EtOAc (1 L) and filtered through Celite. The filtrate was washed with water (2 Ã 1 L) and brine (500 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i> to give a yellow oil. Purification of the residue by flash chromatography on silica gel (0â80% EtOAc in hexanes) gave <i>tert</i>-butyl 9-cyano-5-(2-ethoxy-2-oxoethyl)-2,3-dihydrobenzo[<i>f</i>][1,4]oxazepine-4(5<i>H</i>)-carboxylate (56.1 g, 92%) as pale yellow solid. LCMS (method formate): retention time 1.32 min, [M + H]<sup>+</sup> = 361. <sup>1</sup>H NMR (250 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 7.60â7.66 (m, 1H), 7.52â7.57 (m, 1H), 7.18â7.27 (m, 1H), 5.65 (s, 1H), 5.53â5.63 (m, 1H), 4.42â4.54 (m, 1H), 4.10 (m, 2H), 3.85â3.99 (m, 1H), 3.61â3.75 (m, 1H), 2.93â3.16 (m, 2H), 1.40 (s, 9H), 1.18 (t, <i>J</i> = 7.1 Hz, 3H). This material (59 g, 164 mmol) was dissolved in EtOH (200 mL) by heating to 60 Â°C, and the cooled solution (room temperature) was then diluted with Et<sub>2</sub>O (900 mL). Lithium borohydride (2 M in THF, 246 mL, 491 mmol) was added under nitrogen, and the solution was stirred for 2 h at room temperature, giving a thick suspension. The mixture was treated slowly with MeOH (20 mL) and then added very cautiously to vigorously stirred water (300 mL). The mixture was extracted with EtOAc (200 mL). The organic phase was dried over MgSO<sub>4</sub> and concentrated <i>in vacuo</i> to give <b>77</b> (50.2 g, 96%), which was used in the next step without further purification. LCMS (method formate): retention time 0.92 min, [M + H]<sup>+</sup> = 318. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.36â7.61 (m, 2H), 7.13 (t, <i>J</i> = 7.7 Hz, 1H), 5.55 (d, <i>J</i> = 5.6 Hz, 1H), 4.53 (dd, <i>J</i> = 12.6, 2.3 Hz, 2H), 4.08â4.36 (m, 1H), 3.81â4.01 (m, 1H), 3.45â3.70 (m, 3H), 2.27 (m, 1H), 1.96â2.16 (m, 1H), 1.46 (br s, 9H).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>E</i>)-<i>tert</i>-Butyl 9-Cyano-5-(4-ethoxy-4-oxobut-2-en-1-yl)-2,3-dihydrobenzo[<i>f</i>][1,4]oxazepine-4(5<i>H</i>)-carboxylate (<b>79</b>)</h3><div class="NLM_p last">A solution of 1,1-dimethylethyl 9-cyano-5-(2-hydroxyethyl)-2,3-dihydro-1,4-benzoxazepine-4(5<i>H</i>)-carboxylate, <b>77</b> (36 g, 102 mmol), in CH<sub>2</sub>Cl<sub>2</sub> (300 mL) at 0 Â°C was treated with DMSO (35 mL) and DIPEA (62.2 mL, 356 mmol). In a separate flask, pyridine sulfur trioxide (32.4 g, 204 mmol) and pyridine (16.46 mL, 204 mmol) were mixed in DMSO (35 mL) for 10 min, and the mixture was added to the mixture of alcohol, base, and DMSO at 0 Â°C. The resulting mixture was stirred for 2 h at this temperature, until the alcohol was fully converted to the corresponding aldehyde. Ethyl 2-(triphenylphosphoranylidene)acetate (46.1 g, 132 mmol) was then added, and the resulting mixture was stirred at room temperature for 18 h. The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (500 mL), washed successively with water (1 L), 10% citric acid in water (1 L), and water (1 L), and then dried over MgSO<sub>4</sub> and concentrated <i>in vacuo</i> to a pale yellow gum. Purification of the residue by flash chromatography on silica gel (0â30% EtOAc in hexanes) gave <b>79</b> (37.1 g, 94%) as pale yellow solid. LCMS (method formate): retention time 1.20 min, [M + H]<sup>+</sup> = 387. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.31â7.63 (m, 2H), 7.13 (t, <i>J</i> = 7.1 Hz, 1H), 6.72â6.86 (m, 1H), 5.89 (d, <i>J</i> = 15.7 Hz, 1H), 5.32 (m, 1H), 4.55 (d, <i>J</i> = 12.4 Hz, 1H), 4.08â4.33 (m, 4H), 3.84 (m, 1H), 3.57 (d, <i>J</i> = 11.6 Hz, 1H), 2.96â3.15 (m, 1H), 2.59â2.76 (m, 1H), 1.44 (s, 9H), 1.29 (t, <i>J</i> = 6.6 Hz, 3H).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>tert</i>-Butyl 5-(4-Ethoxy-4-oxobutyl)-9-(<i>N</i>â²-hydroxycarbamimidoyl)-2,3-dihydrobenzo[<i>f</i>][1,4]oxazepine-4(5<i>H</i>)-carboxylate (<b>80</b>)</h3><div class="NLM_p last">Ethylenediamine (20 mL, 296 mmol) was added to a suspension of Pd/C (10% w/w, 50% wet, 10 g, 9.40 mmol) in EtOH (40 mL) under nitrogen, and the mixture was stirred for 16 h and then filtered, and the solid washed with EtOH (40 mL) and MTBE (40 mL). Compound <b>79</b> (92 g, 238 mmol) was dissolved in THF (400 mL) and was treated with activated charcoal (Norit, SC123792) for 1 h; then the solution was filtered through a filter cup and added to the solid palladium catalyst (10 g) under nitrogen. The vessel was purged, and the solution was hydrogenated at atmospheric pressure for 18 h. The expected hydrogen uptake was not achieved (only 800 mL consumed compared with expected approximately 6 L). The suspension was filtered under nitrogen and then added to fresh catalyst (8 g, prepared as above), giving very rapid hydrogen uptake. After 2 h, the mixture was filtered under nitrogen, and the filter pad was washed with EtOAc. The combined filtrates were evaporated <i>in vacuo</i> to give <i>tert</i>-butyl 9-cyano-5-(4-ethoxy-4-oxobutyl)-2,3-dihydrobenzo[<i>f</i>][1,4]oxazepine-4(5<i>H</i>)-carboxylate (92.5 g, 238 mmol, 100%) as a colorless oil, which crystallized on standing to a colorless crystalline solid. LCMS (method formate): retention time 1.20 min, [M + H]<sup>+</sup> = 389. <sup>1</sup>H NMR (250 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 7.57 (m, 2H), 7.11â7.31 (m, 1H), 5.14 (t, <i>J</i> = 7.7 Hz, 1H), 4.49 (d, <i>J</i> = 12.3 Hz, 1H), 4.00â4.22 (m, 2H), 3.87 (t, <i>J</i> = 10.7 Hz, 1H), 3.50â3.71 (m, 1H), 2.34 (t, <i>J</i> = 7.1 Hz, 2H), 2.05â2.21 (m, 1H), 1.56â1.92 (m, 4H), 1.41 (s, 9H), 1.21 (t, <i>J</i> = 6.9 Hz, 3H). A solution of this material (7.8 g, 20.08 mmol) in EtOH (40 mL) was treated with aqueous hydroxylamine (50% w/w, 10.6 g, 161 mmol), and the resulting mixture was stirred at reflux for 3 h and then cooled to room temperature and concentrated <i>in vacuo.</i> The residue was dried under vacuum at 40 Â°C for 16 h to give <b>80</b> (8.1 g, 19.22 mmol, 96%) as colorless gummy foam, which was used in the next step without further purification. LCMS (method formate): retention time 0.79 min, [M + H]<sup>+</sup> = 421. <sup>1</sup>H NMR (250 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.94â9.06 (m, 1H), 7.33â7.44 (m, 1H), 7.17â7.26 (m, 1H), 6.97â7.09 (m, 1H), 5.33 (br s, 2H), 5.01â5.13 (m, 1H), 4.27â4.42 (m, 1H), 3.98â4.17 (m, 3H), 3.66â3.82 (m, 1H), 3.47â3.63 (m, 1H), 2.28â2.40 (m, 1 H), 2.06â2.24 (m, 1H), 1.73â1.90 (m, 1H), 1.46â1.69 (m, 1H), 1.38â1.44 (m, 2H), 1.43 (s, 9H), 1.21 (m, 3H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>tert</i>-Butyl 9-(5-(5-Chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)-5-(4-ethoxy-4-oxobutyl)-2,3-dihydrobenzo[<i>f</i>][1,4]oxazepine-4(5<i>H</i>)-carboxylate (<b>81</b>)</h3><div class="NLM_p last">A mixture of 5-chloro-6-hydroxy-3-pyridinecarboxylic acid (13.85 g, 80 mmol), silver carbonate (44 g, 160 mmol), and 2-iodopropane (27.1 g, 160 mmol) in CHCl<sub>3</sub> (200 mL) was stirred at reflux for 3 days, and then was cooled to room temperature. The mixture was filtered through Celite and evaporated to give 1-methylethyl 5-chloro-6-[(1-methylethyl)oxy]-3-pyridinecarboxylate (16.44 g, 63.8 mmol, 80% yield) as a colorless liquid. LCMS (method formate): retention time 1.47 min, [M + H]<sup>+</sup> = 258. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 8.69 (d, <i>J</i> = 2.3 Hz, 1H), 8.19 (d, <i>J</i> = 2.3 Hz, 1H), 5.45 (spt, <i>J</i> = 6.3 Hz, 1H), 5.25 (spt, <i>J</i> = 6.3 Hz, 1H), 1.42 (d, <i>J</i> = 6.3 Hz, 6H), 1.37 (d, <i>J</i> = 6.3 Hz, 6H. Sodium hydroxide (2 N in water, 63.5 mL, 127 mmol) was added to a solution of this material (16.4 g, 63.6 mmol) in EtOH (200 mL) at 0 Â°C, and the solution was then allowed to warm to room temperature and stirred for 1 h. Most of the solvent was evaporated <i>in vacuo</i>, and the aqueous residue was diluted with water and washed with Et<sub>2</sub>O (100 mL) and then acidified with a 5 N HCl aqueous solution to pH 2. The precipitate was collected by filtration and dried under vacuum at 40 Â°C to give 5-chloro-6-[(1-methylethyl)oxy]-3-pyridinecarboxylic acid (13.3 g, 61.7 mmol, 97%) as a colorless solid. LCMS (method formate): retention time 1.05 min, [M + H]<sup>+</sup> = 214. <sup>1</sup>H NMR (250 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 13.28 (br s, 1H), 8.65 (d, <i>J</i> = 2.0 Hz, 1H), 8.21 (d, <i>J</i> = 2.0 Hz, 1H), 5.41 (spt, <i>J</i> = 6.2 Hz, 1H), 1.36 (d, <i>J</i> = 6.2 Hz, 6H). Oxalyl chloride (12.18 mL, 139 mmol) was added to a suspension of this material (10g, 46.4 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (200 mL)m and the mixture was stirred at room temperature for 16 h. The solvent was then evaporated <i>in vacuo</i> to give 5-chloro-6-[(1-methylethyl)oxy]-3-pyridinecarbonyl chloride (10.7 g, 99%) as a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 8.82 (d, <i>J</i> = 2.3 Hz, 1H), 8.26 (d, <i>J</i> = 2.3 Hz, 1H), 5.51 (spt, <i>J</i> = 6.3 Hz, 1H), 1.45 (d, <i>J</i> = 6.3 Hz, 6H). A solution of this material (4.40 g, 18.8 mmol) in DMF (10 mL) was added to a solution of <b>80</b> (7.2 g, 17.1 mmol) and Et<sub>3</sub>N (4.76 mL, 34.2 mmol) in DMF (80 mL) at room temperature. After 10 min, the resulting mixture was stirred at 80 Â°C for 1 h, then at 120 Â°C for 2 h, and then cooled to room temperature. The solution was diluted with water (600 mL) and then extracted with EtOAc (3 Ã 200 mL). The combined organic phases were washed with water (3 Ã 300 mL), dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. Purification of the residue by flash chromatography on silica gel (0â30% EtOAc in hexanes) gave racemic <b>81</b> (6.2 g, 60%) as a pale yellow oil. LCMS (method formate): retention time 1.61 min, [M + H]<sup>+</sup> = 602. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.90 (d, <i>J</i> = 1.8 Hz, 1H), 8.47 (d, <i>J</i> = 1.8 Hz, 1H), 7.79 (d, <i>J</i> = 7.5 Hz, 1H), 7.46 (d, <i>J</i> = 7.3 Hz, 1H), 7.16â7.31 (m, 1H), 5.43â5.63 (m, 1H), 5.14 (br s, 1H), 4.41 (d, <i>J</i> = 12.5 Hz, 1H), 4.09 (q, <i>J</i> = 6.8 Hz, 3H), 3.79 (br s, 1H), 3.57â3.69 (m, 1H), 2.36 (t, <i>J</i> = 7.3 Hz, 2H), 2.15 (s, 1H), 1.80â1.95 (m, 1H), 1.58â1.73 (m, 1H), 1.34â1.55 (m, 16H), 1.21 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>tert</i>-Butyl 9-(5-(5-Chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)-5-(4-ethoxy-4-oxobutyl)-2,3-dihydrobenzo[<i>f</i>][1,4]oxazepine-4(5<i>H</i>)-carboxylate Enantiomers (<b>81a</b> and <b>81b</b>)</h3><div class="NLM_p last">Analytical method: approximately 0.5 mg of racemic <b>81</b> was dissolved in 50/50 IPA/heptane (1 mL), 20 Î¼L was injected on column; 10% IPA/heptane, <i>f</i> = 1.0 mL/min, wavelength 230 nm, ref 550,100, column 4.6 mm id Ã 25 cm Chiralpak AS, lot no. AS00CE-J040. Preparative method: approximately 600 mg of racemic <b>81</b> was dissolved in 2 mL of IPA and 2 mL of heptane, and the solution was injected onto the column; 10% IPA/heptane, <i>f</i> = 75 mL/min, wavelength 260 nm, ref 550,100, column 5 cm Ã 20 cm Chiralpak AS (20 um) self-packed, total number of injections 2. Fraction collection: Fractions from 7 to 10 min were combined and labeled isomer 1. Fractions from 12 to 30 min were combined and labeled isomer 2. Both combined fractions of isomers 1 and 2 were then concentrated using a rotary evaporator and transferred to weighed flasks for final analysis as described by the analytical method above. Isomer 1, 450 mg; isomer 2, 465 mg. LCMS (method formate): retention time 1.61 min, [M + H]<sup>+</sup> = 602. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.90 (d, <i>J</i> = 1.8 Hz, 1H), 8.47 (d, <i>J</i> = 1.8 Hz, 1H), 7.79 (d, <i>J</i> = 7.5 Hz, 1H), 7.46 (d, <i>J</i> = 7.3 Hz, 1H), 7.16â7.31 (m, 1H), 5.43â5.63 (m, 1H), 5.14 (br s, 1H), 4.41 (d, <i>J</i> = 12.5 Hz, 1H), 4.09 (q, <i>J</i> = 6.8 Hz, 3H), 3.79 (br s, 1H), 3.57â3.69 (m, 1H), 2.36 (t, <i>J</i> = 7.3 Hz, 2H), 2.15 (s, 1H), 1.80â1.95 (m, 1H), 1.58â1.73 (m, 1H), 1.34â1.55 (m, 16H), 1.21 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 4-(9-(5-(5-Chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)-2,3,4,5-tetrahydrobenzo[<i>f</i>][1,4]oxazepin-5-yl)butanoic Acid Hydrochloride Enantiomers (<b>31a</b> and <b>31b</b>)</h3><div class="NLM_p last">This procedure was used for each enantiomer separately. A suspension of <b>81a</b> (450 mg, 0.75 mmol) in EtOH (2 mL) was treated with a 2 N NaOH aqueous solution (2 mL), and the resulting mixture was stirred at 50 Â°C for 2 h and then was cooled to room temperature. Most of the EtOH was removed <i>in vacuo</i>, and the residue was diluted with water and acidified with glacial acetic acid. The mixture was extracted with EtOAc (2 Ã 10 mL). The combined organic phases were dried over MgSO<sub>4</sub> and concentrated <i>in vacuo</i> to give 4-(4-(<i>tert</i>-butoxycarbonyl)-9-(5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)-2,3,4,5-tetrahydrobenzo[<i>f</i>][1,4]oxazepin-5-yl)butanoic acid (398 mg, 93%) as a colorless crispy foam. LCMS (method High pH): retention time 1.17 min, [M + H]<sup>+</sup> = 573. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 11.89â12.34 (m, 1H), 8.92 (d, <i>J</i> = 2.3 Hz, 1H), 8.54 (d, <i>J</i> = 2.0 Hz, 1H), 7.79 (d, <i>J</i> = 6.8 Hz, 1H), 7.38â7.57 (m, 1H), 7.27 (br s, 1H), 5.35â5.58 (m, 1H), 4.92â5.26 (m, 1H), 4.33â4.56 (m, 1H), 3.94â4.16 (m, 1H), 3.65 (br s, 2H), 2.28 (m., 3H), 1.71â1.84 (m, 1H), 1.48â1.64 (m, 1H), 1.29â1.45 (m, 16H). A solution of this material (390 mg, 0.68 mmol) in 1,4-dioxane (3 mL) was treated with HCl (4 N in 1,4-dioxane, 2 mL, 8 mmol), and the resulting mixture was stirred at room temperature for 3 h. Et<sub>2</sub>O (25 mL) was added, and the mixture was stirred for 30 min. The solid formed was filtered off, washed with Et<sub>2</sub>O, and dried under vacuum to give 4-(9-(5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepin-5-yl)butanoic acid hydrochloride (263 mg, 76%) as a white solid. Compound <b>31a</b> is the fast running enantiomer, and compound <b>31b</b> is the slow running enantiomer. LCMS (method high pH): retention time 0.97 min, [M + H]<sup>+</sup> = 473. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.58â8.72 (m, 2H), 8.51 (d, <i>J</i> = 2.0 Hz, 1H), 8.40 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 7.69â7.81 (m, 1H), 7.56 (d, <i>J</i> = 9.1 Hz, 1H), 7.19â7.37 (m, 1H), 5.28 (d, <i>J</i> = 5.1 Hz, 2H), 4.99 (s, 1H), 4.75 (d, <i>J</i> = 18.7 Hz, 2H), 4.24 (br s, 2H), 3.60â3.76 (m, 2H), 3.17â3.29 (m, 2H), 2.94 (m., 2H), 1.33â1.46 (m, 6H).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> S1P<sub>1</sub> and S1P<sub>3</sub> Receptor GTPÎ³S Assays</h3><div class="NLM_p last">Receptor assays were performed as described previously.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Briefly, homogenized S1P<sub>1</sub>-expressing RH7777 membranes or S1P<sub>3</sub>-expressing RBL membranes were adhered to WGA-coated SPA beads in assay buffer. After 30 min precoupling on ice, the bead and membrane suspension was dispensed into white Greiner polypropylene LV 384-well plates (5 Î¼L/well) containing 0.1 Î¼L of compound. [<sup>35</sup>S]-GTPÎ³S (5 Î¼L/well, 0.5 nM for S1P<sub>1</sub> or 0.3 nM for S1P<sub>3</sub> final radioligand concentration) made in assay buffer was then added to the plates. The final assay cocktail was then sealed, spun on a centrifuge, and then read immediately on a Viewlux instrument.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Rat Lymphocyte Reduction Studies</h3><div class="NLM_p last">This procedure was performed as described previously.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Briefly, male Lewis rats had predose blood samples (200 Î¼L) removed by direct venipuncture the day prior to oral dosing. On the study day, rats (<i>n</i> = 4 per group) received either vehicle (1% methycellulose 4 mL/kg po) or compound (0.1â3 mg/kg po) and had further blood samples taken at 0.25, 0.5, 1, 2, 4, 7, 12, 24, 30, 36, 48, and 54 h postdose. From each blood sample, 50 Î¼L was mixed with 50 Î¼L of water for pharmacokinetic analysis. The remainder of the blood samples were analyzed using the Sysmex XT2000iV automatic hematology analyzer for lymphocyte counts.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42"><a href="/doi/suppl/10.1021/jm5010336">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures for the synthesis of compounds <b>8</b>â<b>30</b>, in vitro assay protocols for the determination of EC<sub>50</sub>, and protocols for <i>in vivo</i> studies and data correlations. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm5010336/suppl_file/jm5010336_si_001.pdf">jm5010336_si_001.pdf (1.4 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm5010336" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emmanuel Demont</span> - <span class="hlFld-Affiliation affiliation">Immuno
Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, Gunnels
Wood Road, Stevenage, SG1
2NY, U.K.</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d4b1b9b9b5baa1b1b8fabcfab0b1b9bbbaa094b3a7bffab7bbb9"><span class="__cf_email__" data-cfemail="81e4ecece0eff4e4edafe9afe5e4eceeeff5c1e6f2eaafe2eeec">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tom D. Heightman</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0d796260236568646a6579606c634d6c7e7975236e6260"><span class="__cf_email__" data-cfemail="5723383a793f323e303f233a3639173624232f7934383a">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Skidmore</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jag Heer</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher N. Johnson</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Norton</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sally Redshaw</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Sweeting</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Hurst</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Cridland</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Vesey</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ian Wall</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mahmood Ahmed</span> - <span class="hlFld-Affiliation affiliation">Neural
Pathways DPU, GlaxoSmithKline, 11 Biopolis Way, Singapore 138667</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean Rivers</span> - <span class="hlFld-Affiliation affiliation">Neural
Pathways DPU, GlaxoSmithKline, 11 Biopolis Way, Singapore 138667</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Myatt</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gerard Giblin</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Philpott</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Umesh Kumar</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander Stevens</span> - <span class="hlFld-Affiliation affiliation">Neurology
Center of Excellence for Drug Discovery, GlaxoSmithKline, New
Frontiers Science Park, Harlow CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rino A. Bit</span> - <span class="hlFld-Affiliation affiliation">Immuno
Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, Gunnels
Wood Road, Stevenage, SG1
2NY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Haynes</span> - <span class="hlFld-Affiliation affiliation">Immuno
Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, Gunnels
Wood Road, Stevenage, SG1
2NY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Taylor</span> - <span class="hlFld-Affiliation affiliation">Immuno
Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, Gunnels
Wood Road, Stevenage, SG1
2NY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Watson</span> - <span class="hlFld-Affiliation affiliation">Immuno
Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, Gunnels
Wood Road, Stevenage, SG1
2NY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Witherington</span> - <span class="hlFld-Affiliation affiliation">Immuno
Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, Gunnels
Wood Road, Stevenage, SG1
2NY, U.K.</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. J. Skidmore and J. Heer contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1252e6398-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57158" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57158" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Mr Nigel Quashie, Miss Sapna Desai, Miss Sandra Arpino, and Miss Jenni Cryan for assay support, Dr. Richard Upton and Mr. Nick Waite for NMR support, Dr. Bill Leavens for recording HRMS spectra, Mrs. Helen Tracey for conducting permeability experiments, Mrs. Catherine Cartwright, and Miss Aarti Patel for determining intrinsic clearance, Mr. Nigel Deeks, Mr. Rob Willis, Mr. James Gray, and Miss Tingting Fu for generation of the in vivo DMPK data, and Dr. Colin Campbell, Miss Pam Gaskin, and Mrs. Karen Leavens for supporting the lymphopenia studies. Mrs. Shenaz Nunhuck and Mr. Alan Hill are also acknowledged for p<i>K</i><sub>a</sub> and CHI determination, and Miss Helen Garden is acknowledged for solubility measurements.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i45" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i45"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i46" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i46"> Abbreviations</h2><tr><td class="NLM_term">CHI</td><td class="NLM_def"><p class="first last">chromatographic hydrophobicity index</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMS</td><td class="NLM_def"><p class="first last">dimethylsulfide</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl) carbodiimide</p></td></tr><tr><td class="NLM_term"><i>F</i><sub>ub</sub></td><td class="NLM_def"><p class="first last">unbound fraction</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">HSA</td><td class="NLM_def"><p class="first last">human serum albumin</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropyl amide</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">MadinâDarby canine kidney</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">THIQ</td><td class="NLM_def"><p class="first last">tetrahydroisoquinoline</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88246" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88246" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Singer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobias, K.</span><span> </span><span class="NLM_article-title">Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis</span> <span class="citation_source-journal">Int. J. Clin. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">887</span><span class="NLM_x">â</span> <span class="NLM_lpage">895</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1111%2Fj.1742-1241.2011.02721.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21679286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2011&pages=887-895&author=B.+Singerauthor=A.+P.+Rossauthor=K.+Tobias&title=Oral+fingolimod+for+the+treatment+of+patients+with+relapsing+forms+of+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis</span></div><div class="casAuthors">Singer, B.; Ross, A. P.; Tobias, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">887-895</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1742-1241</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Fingolimod, a sphingosine 1-phosphate receptor modulator, is the first oral treatment approved by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (MS).  The aim of this review was to provide a concise, comprehensive overview of the clin. relevant mechanism of action, efficacy and safety information available for fingolimod.  Key data were derived from two international, Phase III, double-blind, randomised trials (TRANSFORMS and FREEDOMS) performed over 12 and 24 mo, resp., which evaluated fingolimod 0.5 and 1.25 mg daily in 1703 patients with relapsing forms of MS.  In TRANSFORMS, there was a 52% redn. in the annualised relapse rate (ARR) with fingolimod 0.5 mg vs. 30 Î¼g i.m. interferon beta-1a (0.16 vs. 0.33; p < 0.001) at 1 yr.  In FREEDOMS, there was a 55% decrease in ARR at 2 years with fingolimod 0.5 mg vs. placebo (0.18 vs. 0.40; p < 0.001).  Risk of disability progression, confirmed at 3 mo, was also reduced by 30% over the 2-yr study period with fingolimod vs. placebo (p = 0.02).  Significantly fewer new or enlarged lesions on T2-weighted images were seen in both studies (TRANSFORMS, p = 0.002 vs. interferon beta-1a at 1 yr; FREEDOMS, p < 0.001 vs. placebo at 2 years).  Overall, fingolimod 0.5 mg was well tolerated by patients.  Transient, generally asymptomatic bradycardia and infrequent atrioventricular block were seen with the administration of the first dose.  Macular edema and serious infections occurred infrequently.  Reversible, asymptomatic elevations of liver enzymes could also occur.  As the first approved oral disease-modifying treatment, fingolimod offers patients a convenient alternative to regular self-injection for the treatment of relapsing forms of MS.  In addn. to high efficacy with a relatively acceptable safety profile, fingolimod provides a therapy with a new mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVKs1Biiz177Vg90H21EOLACvtfcHk0liN8HSpYs7XkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D&md5=8be8ad56fc253ddccb59597c041b9ff8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2011.02721.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2011.02721.x%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DA.%2BP.%26aulast%3DTobias%26aufirst%3DK.%26atitle%3DOral%2520fingolimod%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520relapsing%2520forms%2520of%2520multiple%2520sclerosis%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2011%26volume%3D65%26spage%3D887%26epage%3D895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Fujino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funeshima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitazawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amemiya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.-K.</span><span> </span><span class="NLM_article-title">Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">â</span> <span class="NLM_lpage">77</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1124%2Fjpet.102.045658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=12649354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1antb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2003&pages=70-77&author=M.+Fujinoauthor=N.+Funeshimaauthor=Y.+Kitazawaauthor=H.+Kimuraauthor=H.+Amemiyaauthor=S.+Suzukiauthor=X.-K.+Li&title=Amelioration+of+Experimental+Autoimmune+Encephalomyelitis+in+Lewis+Rats+by+FTY720+Treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment</span></div><div class="casAuthors">Fujino, Masayuki; Funeshima, Naoko; Kitazawa, Yusuke; Kimura, Hiromitsu; Amemiya, Hiroshi; Suzuki, Seiichi; Li, Xiao-Kang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-77</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Exptl. autoimmune encephalomyelitis (EAE) is a T-cell-dependent autoimmune disease that reproduces the inflammatory demyelinating pathol. of multiple sclerosis (MS).  We investigated the efficacy and mechanism of immunosuppression against EAE by administering 2-amino-[2-(4-octylphenyl) ethyl]-1,3-propanediol hydrochloride (FTY720) in Lewis rats immunized with myelin basic protein together with complete Freund's adjuvant.  FTY720 treatment almost completely protected the rats against disease.  The protection by FTY720 was assocd. with a dramatic redn. in the no. of lymphocytes staining for T-cell receptors in the spinal cord as examd. by immunohistochem.  The mRNA expression of Th1 cytokines interleukin (IL)-2, IL-6, and interferon-Î³ in the spinal cord was also reduced dramatically as assessed by reverse-transcription polymerase chain reaction.  Furthermore, lymphocytes isolated from the spleen of FTY720-treated rats were transferred into naive recipient rats against EAE manifestation by reducing both disease incidence and clin. score.  These results suggested that the protective anti-inflammatory effect of treatment with FTY720 was, to a large extent, due to the inhibition of encephalitogenic T-cell responses and/or their migration into the central nervous system and may be a potential candidate for use in treating patients with MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzq_-OyLLfCrVg90H21EOLACvtfcHk0lj_vklF5lucKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1antb4%253D&md5=fa8fd35f8ce313790e3776a7ab820b0f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.045658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.045658%26sid%3Dliteratum%253Aachs%26aulast%3DFujino%26aufirst%3DM.%26aulast%3DFuneshima%26aufirst%3DN.%26aulast%3DKitazawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DAmemiya%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.-K.%26atitle%3DAmelioration%2520of%2520Experimental%2520Autoimmune%2520Encephalomyelitis%2520in%2520Lewis%2520Rats%2520by%2520FTY720%2520Treatment%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D305%26spage%3D70%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Comi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalban, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radue, E.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohlmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aradhye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FTY720D2201 Study Group</span><span> </span><span class="NLM_article-title">Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results</span> <span class="citation_source-journal">Mult. Scler.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1177%2F1352458509357065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=20028707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFCqu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=197-207&author=G.+Comiauthor=P.+O%E2%80%99Connorauthor=X.+Montalbanauthor=J.+Antelauthor=E.-W.+Radueauthor=G.+Karlssonauthor=H.+Pohlmannauthor=S.+Aradhyeauthor=L.+Kapposauthor=FTY720D2201+Study+Group&title=Phase+II+study+of+oral+fingolimod+%28FTY720%29+in+multiple+sclerosis%3A+3-year+results"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results</span></div><div class="casAuthors">Comi, G.; O'Connor, P.; Montalban, X.; Antel, J.; Radue, E.-W.; Karlsson, G.; Pohlmann, H.; Aradhye, S.; Kappos, L.</div><div class="citationInfo"><span class="NLM_cas:title">Multiple Sclerosis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">MUSCFZ</span>;
        ISSN:<span class="NLM_cas:issn">1352-4585</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">In a 6-mo, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized relapse rate compared with placebo in patients with relapsing multiple sclerosis (MS).  The objectives were to monitor the 36-mo, interim efficacy and safety results of the ongoing extension of this study.  In the extension (months 7-36), placebo-treated patients were re-randomized to either dose of fingolimod; fingolimod-treated patients continued at the same dose.  During months 15-24, all patients receiving fingolimod 5.0 mg switched to 1.25 mg.  Of the 250 patients who entered the extension study, 173 (69%) continued to month 36.  Most patients were free from gadolinium-enhanced lesions (88-89%) or new T2 lesions (70-78%) at month 36.  Patients receiving continuous fingolimod treatment had sustained low annualized relapse rates of 0.20-0.21, and 68-73% remained relapse-free at month 36.  Over 36 mo, nasopharyngitis (34%), headache (30%), fatigue (19%) and influenza (18%) were the most commonly reported adverse events.  Pulmonary function remained stable and blood pressure was stable after an initial increase (3-5 mmHg) during the first 6 mo of fingolimod treatment; serious adverse events included infections and skin cancer.  The low MRI and clin. disease activity at 6 mo were maintained at 36 mo with fingolimod, which was generally well tolerated by most patients.  The efficacy and safety of oral fingolimod are being further evaluated in a large phase III MS study program.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlZ0UpJLK0DrVg90H21EOLACvtfcHk0lj_vklF5lucKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFCqu7c%253D&md5=7509750f7c949e59b23eca7027fa0d47</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1177%2F1352458509357065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1352458509357065%26sid%3Dliteratum%253Aachs%26aulast%3DComi%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DAntel%26aufirst%3DJ.%26aulast%3DRadue%26aufirst%3DE.-W.%26aulast%3DKarlsson%26aufirst%3DG.%26aulast%3DPohlmann%26aufirst%3DH.%26aulast%3DAradhye%26aufirst%3DS.%26aulast%3DKappos%26aufirst%3DL.%26aulast%3D%26atitle%3DPhase%2520II%2520study%2520of%2520oral%2520fingolimod%2520%2528FTY720%2529%2520in%2520multiple%2520sclerosis%253A%25203-year%2520results%26jtitle%3DMult.%2520Scler.%26date%3D2010%26volume%3D16%26spage%3D197%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Billich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornancin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DÃ©vay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechtcheriakova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urtz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumruker, T.</span><span> </span><span class="NLM_article-title">Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">47408</span><span class="NLM_x">â</span> <span class="NLM_lpage">47415</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1074%2Fjbc.M307687200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=13129923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=47408-47415&author=A.+Billichauthor=F.+Bornancinauthor=P.+D%C3%A9vayauthor=D.+Mechtcheriakovaauthor=N.+Urtzauthor=T.+Baumruker&title=Phosphorylation+of+the+Immunomodulatory+Drug+FTY720+by+Sphingosine+Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases</span></div><div class="casAuthors">Billich, Andreas; Bornancin, Frederic; Devay, Piroska; Mechtcheriakova, Diana; Urtz, Nicole; Baumruker, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">47408-47415</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The immunomodulatory drug FTY720 is phosphorylated in vivo, and the resulting FTY720 phosphate as a ligand for sphingosine-1-phosphate receptors is responsible for the unique biol. effects of the compd.  So far, phosphorylation of FTY720 by murine sphingosine kinase (SPHK) 1a had been documented.  We found that, while FTY720 is also phosphorylated by human SPHK1, the human type 2 isoform phosphorylates the drug 30-fold more efficiently, because of a lower Km of FTY720 for SPHK2.  Similarly, murine SPHK2 was more efficient than SPHK1a.  Among splice variants of the human SPHKs, an N-terminally extended SPHK2 isoform was even more active than SPHK2 itself.  Further SPHK superfamily members, namely ceramide kinase and a "SPHK-like" protein, failed to phosphorylate sphingosine and FTY720.  Thus, only SPHK1 and 2 appear to be capable of phosphorylating FTY720.  Using selective assay conditions, SPHK1 and 2 activities in murine tissues were measured.  While activity of SPHK2 toward sphingosine was generally lower than of SPHK1, FTY720 phosphorylation was higher under conditions favoring SPHK2.  In human endothelial cells, while activity of SPHK1 toward sphingosine was 2-fold higher than of SPHK2, FTY720 phosphorylation was 7-fold faster under SPHK2 assay conditions.  Finally, FTY720 was poorly phosphorylated in human blood as compared with rodent blood, in line with the low activity of SPHK1 and in particular of SPHK2 in human blood.  To conclude, both SPHK1 and 2 are capable of phosphorylating FTY720, but SPHK2 is quant. more important than SPHK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR5e-dVWnBT7Vg90H21EOLACvtfcHk0lj_vklF5lucKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D&md5=26820503680682863dc76a69ea02fc7e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307687200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307687200%26sid%3Dliteratum%253Aachs%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBornancin%26aufirst%3DF.%26aulast%3DD%25C3%25A9vay%26aufirst%3DP.%26aulast%3DMechtcheriakova%26aufirst%3DD.%26aulast%3DUrtz%26aufirst%3DN.%26aulast%3DBaumruker%26aufirst%3DT.%26atitle%3DPhosphorylation%2520of%2520the%2520Immunomodulatory%2520Drug%2520FTY720%2520by%2520Sphingosine%2520Kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D47408%26epage%3D47415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Albert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¼ller-Hartwieg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knecht, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streiff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welzenbach, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ZÃ©cri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zollinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francotte, E.</span><span> </span><span class="NLM_article-title">Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5373</span><span class="NLM_x">â</span> <span class="NLM_lpage">5377</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050242f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5373-5377&author=R.+Albertauthor=K.+Hinterdingauthor=V.+Brinkmannauthor=D.+Gueriniauthor=C.+M%C3%BCller-Hartwiegauthor=H.+Knechtauthor=C.+Simeonauthor=M.+Streiffauthor=T.+Wagnerauthor=K.+Welzenbachauthor=F.+Z%C3%A9criauthor=M.+Zollingerauthor=N.+Cookeauthor=E.+Francotte&title=Novel+Immunomodulator+FTY720+Is+Phosphorylated+in+Rats+and+Humans+To+Form+a+Single+Stereoisomer.+Identification%2C+Chemical+Proof%2C+and+Biological+Characterization+of+the+Biologically+Active+Species+and+Its+Enantiomer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm050242f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050242f%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DM%25C3%25BCller-Hartwieg%26aufirst%3DC.%26aulast%3DKnecht%26aufirst%3DH.%26aulast%3DSimeon%26aufirst%3DC.%26aulast%3DStreiff%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWelzenbach%26aufirst%3DK.%26aulast%3DZ%25C3%25A9cri%26aufirst%3DF.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DN.%26aulast%3DFrancotte%26aufirst%3DE.%26atitle%3DNovel%2520Immunomodulator%2520FTY720%2520Is%2520Phosphorylated%2520in%2520Rats%2520and%2520Humans%2520To%2520Form%2520a%2520Single%2520Stereoisomer.%2520Identification%252C%2520Chemical%2520Proof%252C%2520and%2520Biological%2520Characterization%2520of%2520the%2520Biologically%2520Active%2520Species%2520and%2520Its%2520Enantiomer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5373%26epage%3D5377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Adachi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, K.</span><span> </span><span class="NLM_article-title">FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology</span> <span class="citation_source-journal">Perspect. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=19812733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A280%3ADC%252BD1MnnslSgsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=11&author=K.+Adachiauthor=K.+Chiba&title=FTY720+Story.+Its+Discovery+and+the+Following+Accelerated+Development+of+Sphingosine+1-Phosphate+Receptor+Agonists+as+Immunomodulators+Based+on+Reverse+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology</span></div><div class="casAuthors">Adachi Kunitomo; Chiba Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Perspectives in medicinal chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fingolimod (FTY720) is the first of a novel class: sphingosine 1-phosphate (S1P) receptor modulator and is currently in phase 3 clinical trials for multiple sclerosis (MS).  FTY720 was first synthesized in 1992 by chemical modification of an immunosuppressive natural product, ISP-I (myriocin).  ISP-I was isolated from the culture broth of Isaria sinclairii, a type of vegetative wasp that was an 'eternal youth' nostrum in traditional Chinese medicine.  ISP-I is an amino acid having three successive asymmetric centers and some functionalities.  We simplified the structure drastically to find a nonchiral symmetric 2-substitued-2-aminopropane-1,3-diol framework for an in vivo immunosuppressive activity (inhibition of rat skin allograft rejection test or prolonging effect on rat skin allograft survival) and finally discovered FTY720.  During the course of the lead optimization process, we encountered an unexpected dramatic change of the mechanism of action with an in vivo output unchanged.  Since it proved that FTY720 did not inhibit serine palmitoyltransferase that is the target enzyme of ISP-I, reverse pharmacological approaches have been preformed to elucidate that FTY720 is mainly phosphorylated by sphingosine kinease 2 in vivo and the phosphorylated drug acts as a potent agonist of four of the five G protein coupled receptors for S1P: S1P(1), S1P(3), S1P(4) and S1P(5).  Evidence has accumulated that immunomodulation by FTY720-P is based on agonism at the S1P(1) receptor.  Medicinal chemistry targeting S1P(1) receptor agonists is currently in progress.  The FTY720 story provides a methodology where in vivo screens rather than in vitro screens play important roles in the lead optimization.  Unlike recent drug discovery methodologies, such a strategy as adopted by the FTY720 program would more likely meet serendipity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXM2ChGVrbaBgd2Wuil24tfW6udTcc2eZiRGKEUmgOYrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MnnslSgsQ%253D%253D&md5=b07a533e402ebff342a228bcad1ad452</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DK.%26aulast%3DChiba%26aufirst%3DK.%26atitle%3DFTY720%2520Story.%2520Its%2520Discovery%2520and%2520the%2520Following%2520Accelerated%2520Development%2520of%2520Sphingosine%25201-Phosphate%2520Receptor%2520Agonists%2520as%2520Immunomodulators%2520Based%2520on%2520Reverse%2520Pharmacology%26jtitle%3DPerspect.%2520Med.%2520Chem.%26date%3D2007%26volume%3D1%26spage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Matloubian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cinamon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesneski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allende, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyster, J. G.</span><span> </span><span class="NLM_article-title">Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">427</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">â</span> <span class="NLM_lpage">360</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=427&publication_year=2004&pages=355-360&author=M.+Matloubianauthor=C.+G.+Loauthor=G.+Cinamonauthor=M.+J.+Lesneskiauthor=Y.+Xuauthor=V.+Brinkmannauthor=M.+L.+Allendeauthor=R.+L.+Proiaauthor=J.+G.+Cyster&title=Lymphocyte+egress+from+thymus+and+peripheral+lymphoid+organs+is+dependent+on+S1P+receptor+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatloubian%26aufirst%3DM.%26aulast%3DLo%26aufirst%3DC.%2BG.%26aulast%3DCinamon%26aufirst%3DG.%26aulast%3DLesneski%26aufirst%3DM.%2BJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DAllende%26aufirst%3DM.%2BL.%26aulast%3DProia%26aufirst%3DR.%2BL.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26atitle%3DLymphocyte%2520egress%2520from%2520thymus%2520and%2520peripheral%2520lymphoid%2520organs%2520is%2520dependent%2520on%2520S1P%2520receptor%25201%26jtitle%3DNature%26date%3D2004%26volume%3D427%26spage%3D355%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Wei, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheu, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalan, M. D.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1228</span><span class="NLM_x">â</span> <span class="NLM_lpage">1235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1038%2Fni1269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=16273098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlShur3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=1228-1235&author=S.+H.+Weiauthor=H.+Rosenauthor=M.+P.+Matheuauthor=M.+G.+Sannaauthor=S.-K.+Wangauthor=E.+Joauthor=C.-H.+Wongauthor=I.+Parkerauthor=M.+D.+Cahalan&title=Sphingosine+1-phosphate+type+1+receptor+agonism+inhibits+transendothelial+migration+of+medullary+T+cells+to+lymphatic+sinuses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses</span></div><div class="casAuthors">Wei, Sindy H.; Rosen, Hugh; Matheu, Melanie P.; Sanna, M. Germana; Wang, Sheng-Kai; Jo, Euijung; Wong, Chi-Huey; Parker, Ian; Cahalan, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1228-1235</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate type 1 (S1P1) receptor agonists cause sequestration of lymphocytes in secondary lymphoid organs by a mechanism that is not well understood.  One hypothesis proposes that agonists act as "functional antagonists" by binding and internalizing S1P1 receptors on lymphocytes; a second hypothesis proposes instead that S1P1 agonists act on endothelial cells to prevent lymphocyte egress from lymph nodes.  Here, 2-photon imaging of living T cells in explanted lymph nodes after treatment with S1P1 agonists or antagonists has provided insight into the mechanism by which S1P1 agonists function.  The selective S1P1 agonist SEW2871 caused reversible slowing and "log-jamming" of T cells between filled medullary cords and empty sinuses, whereas motility was unaltered in diffuse cortex.  Removal or antagonist competition of SEW2871 permitted recovery of T cell motility in the parenchyma of the medulla and resumption of migration across the stromal endothelial barrier, leading to refilling of sinuses.  The authors' results provide visualization of transendothelial migration of T cells into lymphatic sinuses and suggest that S1P1 agonists act mainly on endothelial cell S1P1 receptors to inhibit lymphocyte migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT6yH1S8NBXbVg90H21EOLACvtfcHk0lgru7ECzzJZpw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlShur3E&md5=1e8e381a3808c9231937e05a0c010b73</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fni1269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1269%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DS.%2BH.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMatheu%26aufirst%3DM.%2BP.%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DS.-K.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DC.-H.%26aulast%3DParker%26aufirst%3DI.%26aulast%3DCahalan%26aufirst%3DM.%2BD.%26atitle%3DSphingosine%25201-phosphate%2520type%25201%2520receptor%2520agonism%2520inhibits%2520transendothelial%2520migration%2520of%2520medullary%2520T%2520cells%2520to%2520lymphatic%2520sinuses%26jtitle%3DNat.%2520Immunol.%26date%3D2005%26volume%3D6%26spage%3D1228%26epage%3D1235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Choi, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yung, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span> </span><span class="NLM_article-title">FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">â</span> <span class="NLM_lpage">756</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=751-756&author=J.+W.+Choiauthor=S.+E.+Gardellauthor=D.+R.+Herrauthor=R.+Riveraauthor=C.-W.+Leeauthor=K.+Noguchiauthor=S.+T.+Teoauthor=Y.+C.+Yungauthor=M.+Luauthor=G.+Kennedyauthor=J.+Chun&title=FTY720+%28fingolimod%29+efficacy+in+an+animal+model+of+multiple+sclerosis+requires+astrocyte+sphingosine+1-phosphate+receptor+1+%28S1P1%29+modulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%2BW.%26aulast%3DGardell%26aufirst%3DS.%2BE.%26aulast%3DHerr%26aufirst%3DD.%2BR.%26aulast%3DRivera%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.-W.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DTeo%26aufirst%3DS.%2BT.%26aulast%3DYung%26aufirst%3DY.%2BC.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DKennedy%26aufirst%3DG.%26aulast%3DChun%26aufirst%3DJ.%26atitle%3DFTY720%2520%2528fingolimod%2529%2520efficacy%2520in%2520an%2520animal%2520model%2520of%2520multiple%2520sclerosis%2520requires%2520astrocyte%2520sphingosine%25201-phosphate%2520receptor%25201%2520%2528S1P1%2529%2520modulation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D751%26epage%3D756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Cohen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span> </span><span class="NLM_article-title">Mechanisms of fingolimodâs efficacy and adverse effects in multiple sclerosis</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">759</span><span class="NLM_x">â</span> <span class="NLM_lpage">777</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1002%2Fana.22426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21520239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltVyhtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2011&pages=759-777&author=J.+A.+Cohenauthor=J.+Chun&title=Mechanisms+of+fingolimod%E2%80%99s+efficacy+and+adverse+effects+in+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis</span></div><div class="casAuthors">Cohen, Jeffrey A.; Chun, Jerold</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">759-777</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Until recently, all approved multiple sclerosis (MS) disease treatments were administered parenterally.  Oral fingolimod was approved in Sept. 2010 by the US Food and Drug Administration to reduce relapses and disability progression in relapsing forms of MS.  In the clin. trials that led to approval, fingolimod reduced not only acute relapses and magnetic resonance imaging lesion activity but also disability progression and brain vol. loss, suggesting preservation of tissue.  Fingolimod's mechanism of action in MS is not known with certainty.  Its active form, fingolimod-phosphate (fingolimod-P), is a sphingosine 1-phosphate receptor (S1PR) modulator that inhibits egress of lymphocytes from lymph nodes and their recirculation, potentially reducing trafficking of pathogenic cells into the central nervous system (CNS).  Fingolimod also readily penetrates the CNS, and fingolimod-P formed in situ may have direct effects on neural cells.  Fingolimod potently inhibits the MS animal model, exptl. autoimmune encephalomyelitis, but is ineffective in mice with selective deficiency of the S1P1 S1PR subtype on astrocytes despite normal expression in the immune compartment.  These findings suggest that S1PR modulation by fingolimod in both the immune system and CNS, producing a combination of beneficial anti-inflammatory and possibly neuroprotective/reparative effects, may contribute to its efficacy in MS.  In clin. trials, fingolimod was generally safe and well tolerated.  Its interaction with S1PRs in a variety of tissues largely accounts for the reported adverse effects, which were seen more frequently with doses 2.5 to 10Ã the approved 0.5mg dose.  Fingolimod's unique mechanism of action distinguishes it from all other currently approved MS therapies.  Ann Neurol 2011;69:759-777.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQ9gv8GATt7Vg90H21EOLACvtfcHk0lgru7ECzzJZpw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltVyhtLo%253D&md5=8444099f3b8b40bf8fd529e374eaf294</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fana.22426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.22426%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DJ.%2BA.%26aulast%3DChun%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520fingolimod%25E2%2580%2599s%2520efficacy%2520and%2520adverse%2520effects%2520in%2520multiple%2520sclerosis%26jtitle%3DAnn.%2520Neurol.%26date%3D2011%26volume%3D69%26spage%3D759%26epage%3D777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">758</span><span class="NLM_x">â</span> <span class="NLM_lpage">768</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1124%2Fjpet.103.062828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=14747617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2004&pages=758-768&author=M.+Forrestauthor=S.-Y.+Sunauthor=R.+Hajduauthor=J.+Bergstromauthor=D.+Cardauthor=G.+Dohertyauthor=J.+Haleauthor=C.+Keohaneauthor=C.+Meyersauthor=J.+Milliganauthor=S.+Millsauthor=N.+Nomuraauthor=H.+Rosenauthor=M.+Rosenbachauthor=G.-J.+Sheiauthor=I.+I.+Singerauthor=M.+Tianauthor=S.+Westauthor=V.+Whiteauthor=J.+Xieauthor=R.+L.+Proiaauthor=S.+Mandala&title=Immune+Cell+Regulation+and+Cardiovascular+Effects+of+Sphingosine+1-Phosphate+Receptor+Agonists+in+Rodents+Are+Mediated+via+Distinct+Receptor+Subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes</span></div><div class="casAuthors">Forrest, M.; Sun, S.-Y.; Hajdu, R.; Bergstrom, J.; Card, D.; Doherty, G.; Hale, J.; Keohane, C.; Meyers, C.; Milligan, J.; Mills, S.; Nomura, N.; Rosen, H.; Rosenbach, M.; Shei, G.-J.; Singer, I. I.; Tian, M.; West, S.; White, V.; Xie, J.; Proia, R. L.; Mandala, S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">758-768</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a bioactive lysolipid with pleiotropic functions mediated through a family of G protein-coupled receptors, S1P1,2,3,4,5.  Physiol. effects of S1P receptor agonists include regulation of cardiovascular function and immunosuppression via redistribution of lymphocytes from blood to secondary lymphoid organs.  The phosphorylated metabolite of the immunosuppressant agent FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol) and other phosphonate analogs with differential receptor selectivity were investigated.  No significant species differences in compd. potency or rank order of activity on receptors cloned from human, murine, and rat sources were obsd.  All synthetic analogs were high-affinity agonists on S1P1, with IC50 values for ligand binding between 0.3 and 14 nM.  The correlation between S1P1 receptor activation and the ED50 for lymphocyte redn. was highly significant (p < 0.001) and lower for the other receptors.  In contrast to S1P1-mediated effects on lymphocyte recirculation, three lines of evidence link S1P3 receptor activity with acute toxicity and cardiovascular regulation: compd. potency on S1P3 correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia vs. bradycardia and hypertension was consistent with affinity for S1P1 relative to S1P3; and toxicity, bradycardia, and hypertension were absent in S1P3-/- mice.  Blood pressure effects of agonists in anesthetized rats were complex, whereas hypertension was the predominant effect in conscious rats and mice.  Immunolocalization of S1P3 in rodent heart revealed abundant expression on myocytes and perivascular smooth muscle cells consistent with regulation of bradycardia and hypertension, whereas S1P1 expression was restricted to the vascular endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKo2vpih4eoLVg90H21EOLACvtfcHk0lgru7ECzzJZpw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D&md5=27183d4991bffbc5d2b88174b1386d5a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.062828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.062828%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DS.-Y.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DDoherty%26aufirst%3DG.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DKeohane%26aufirst%3DC.%26aulast%3DMeyers%26aufirst%3DC.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DMills%26aufirst%3DS.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DSinger%26aufirst%3DI.%2BI.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DProia%26aufirst%3DR.%2BL.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DImmune%2520Cell%2520Regulation%2520and%2520Cardiovascular%2520Effects%2520of%2520Sphingosine%25201-Phosphate%2520Receptor%2520Agonists%2520in%2520Rodents%2520Are%2520Mediated%2520via%2520Distinct%2520Receptor%2520Subtypes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D309%26spage%3D758%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">13839</span><span class="NLM_x">â</span> <span class="NLM_lpage">13848</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=13839-13848&author=M.+G.+Sannaauthor=J.+Liaoauthor=E.+Joauthor=C.+Alfonsoauthor=M.-Y.+Ahnauthor=M.+S.+Petersonauthor=B.+Webbauthor=S.+Lefebvreauthor=J.+Chunauthor=N.+Grayauthor=H.+Rosen&title=Sphingosine+1-Phosphate+%28S1P%29+Receptor+Subtypes+S1P1+and+S1P3%2C+Respectively%2C+Regulate+Lymphocyte+Recirculation+and+Heart+Rate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DAlfonso%26aufirst%3DC.%26aulast%3DAhn%26aufirst%3DM.-Y.%26aulast%3DPeterson%26aufirst%3DM.%2BS.%26aulast%3DWebb%26aufirst%3DB.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DSphingosine%25201-Phosphate%2520%2528S1P%2529%2520Receptor%2520Subtypes%2520S1P1%2520and%2520S1P3%252C%2520Respectively%252C%2520Regulate%2520Lymphocyte%2520Recirculation%2520and%2520Heart%2520Rate%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D13839%26epage%3D13848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Gergely, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">WallstrÃ¶m, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuesslein-Hildesheim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ZÃ©cri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traebert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltzman, M.</span><span> </span><span class="NLM_article-title">Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans</span> <span class="citation_source-journal">Mult. Scler.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">S235</span><span class="NLM_x">â</span> <span class="NLM_lpage">S236</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=S235-S236&author=P.+Gergelyauthor=E.+Wallstr%C3%B6mauthor=B.+Nuesslein-Hildesheimauthor=C.+Brunsauthor=F.+Z%C3%A9criauthor=N.+Cookeauthor=M.+Traebertauthor=T.+Tuntlandauthor=M.+Rosenbergauthor=M.+Saltzman&title=Phase+I+study+with+the+selective+S1P1%2FS1P5+receptor+modulator+BAF312+indicates+that+S1P1+rather+than+S1P3+mediates+transient+heart+rate+reduction+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGergely%26aufirst%3DP.%26aulast%3DWallstr%25C3%25B6m%26aufirst%3DE.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DZ%25C3%25A9cri%26aufirst%3DF.%26aulast%3DCooke%26aufirst%3DN.%26aulast%3DTraebert%26aufirst%3DM.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DRosenberg%26aufirst%3DM.%26aulast%3DSaltzman%26aufirst%3DM.%26atitle%3DPhase%2520I%2520study%2520with%2520the%2520selective%2520S1P1%252FS1P5%2520receptor%2520modulator%2520BAF312%2520indicates%2520that%2520S1P1%2520rather%2520than%2520S1P3%2520mediates%2520transient%2520heart%2520rate%2520reduction%2520in%2520humans%26jtitle%3DMult.%2520Scler.%26date%3D2009%26volume%3D15%26spage%3DS235%26epage%3DS236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Bolli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lescop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span> </span><span class="NLM_article-title">Synthetic Sphingosine 1-Phosphate Receptor Modulators - Opportunities and Potential Pitfalls</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">726</span><span class="NLM_x">â</span> <span class="NLM_lpage">757</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.2174%2F1568026611109060726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21261590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSmsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=726-757&author=M.+Bolliauthor=C.+Lescopauthor=O.+Nayler&title=Synthetic+Sphingosine+1-Phosphate+Receptor+Modulators+-+Opportunities+and+Potential+Pitfalls"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic sphingosine 1-phosphate receptor modulators - opportunities and potential pitfalls</span></div><div class="casAuthors">Bolli, Martin H.; Lescop, Cyrille; Nayler, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">726-757</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) evokes a plethora of physiol. responses by stimulating members of a G protein-coupled receptor family, known as S1P receptors.  Currently five different mammalian S1P receptor subtypes, S1P1-5, each with a different cellular expression pattern, were identified.  The S1P1 receptor in particular has attracted major interest throughout the pharmaceutical industry following the breakthrough discovery that this S1P receptor subtype is critically involved in the regulation of lymphocyte trafficking through secondary lymphoid organs.  Since then, examples of synthetic S1P1 agonists with lymphocyte reducing and immunomodulating activity demonstrated efficacy in numerous preclin. models of autoimmune disease and transplantation.  Notably FTY720 (fingolimod), a pro-drug that is phosphorylated in vivo and converted into a non-selective S1P1,3,4,5 receptor agonist, has been widely used to increase the understanding of S1P1 receptor biol.  Results from recently completed phase III clin. trials using FTY720 paved the way for this non-selective S1P1 receptor agonist to become the first oral therapy in multiple sclerosis, with potential expansion into many other autoimmune diseases.  This review briefly outlines the field of S1P1 receptor biol. and summarizes recent approaches in medicinal chem. to discover potent and selective S1P1 receptor agonists.  In particular, the complexity of discovering a mol. akin to FTY720 but with an improved side-effect profile will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTTZ2jfUXEtrVg90H21EOLACvtfcHk0ljzw0s8A2RY6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSmsro%253D&md5=9f6d05909fb5615126ea642f4cc19271</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F1568026611109060726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611109060726%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%26aulast%3DLescop%26aufirst%3DC.%26aulast%3DNayler%26aufirst%3DO.%26atitle%3DSynthetic%2520Sphingosine%25201-Phosphate%2520Receptor%2520Modulators%2520-%2520Opportunities%2520and%2520Potential%2520Pitfalls%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D726%26epage%3D757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Evindar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernier, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavarana, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satz, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchette, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saha, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span> </span><span class="NLM_article-title">Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2520</span><span class="NLM_x">â</span> <span class="NLM_lpage">2524</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2520-2524&author=G.+Evindarauthor=S.+G.+Bernierauthor=E.+Doyleauthor=M.+J.+Kavaranaauthor=A.+L.+Satzauthor=J.+Lorussoauthor=H.+S.+Blanchetteauthor=A.+K.+Sahaauthor=G.+Hannigauthor=B.+A.+Morganauthor=W.+F.+Westlin&title=Exploration+of+amino+alcohol+derivatives+as+novel%2C+potent%2C+and+highly+selective+sphingosine-1-phosphate+receptor+subtype-1+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEvindar%26aufirst%3DG.%26aulast%3DBernier%26aufirst%3DS.%2BG.%26aulast%3DDoyle%26aufirst%3DE.%26aulast%3DKavarana%26aufirst%3DM.%2BJ.%26aulast%3DSatz%26aufirst%3DA.%2BL.%26aulast%3DLorusso%26aufirst%3DJ.%26aulast%3DBlanchette%26aufirst%3DH.%2BS.%26aulast%3DSaha%26aufirst%3DA.%2BK.%26aulast%3DHannig%26aufirst%3DG.%26aulast%3DMorgan%26aufirst%3DB.%2BA.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DExploration%2520of%2520amino%2520alcohol%2520derivatives%2520as%2520novel%252C%2520potent%252C%2520and%2520highly%2520selective%2520sphingosine-1-phosphate%2520receptor%2520subtype-1%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2520%26epage%3D2524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Vachal, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3684</span><span class="NLM_x">â</span> <span class="NLM_lpage">3687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3684-3687&author=P.+Vachalauthor=L.+M.+Tothauthor=J.+J.+Haleauthor=L.+Yanauthor=S.+G.+Millsauthor=G.+L.+Chrebetauthor=C.+A.+Koehaneauthor=R.+Hajduauthor=J.+A.+Milliganauthor=M.+J.+Rosenbachauthor=S.+Mandala&title=Highly+selective+and+potent+agonists+of+sphingosine-1-phosphate+1+%28S1P1%29+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVachal%26aufirst%3DP.%26aulast%3DToth%26aufirst%3DL.%2BM.%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DChrebet%26aufirst%3DG.%2BL.%26aulast%3DKoehane%26aufirst%3DC.%2BA.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DHighly%2520selective%2520and%2520potent%2520agonists%2520of%2520sphingosine-1-phosphate%25201%2520%2528S1P1%2529%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3684%26epage%3D3687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neway, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parent, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strulovici, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6662</span><span class="NLM_x">â</span> <span class="NLM_lpage">6665</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0492507" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6662-6665&author=J.+J.+Haleauthor=C.+L.+Lynchauthor=W.+Newayauthor=S.+G.+Millsauthor=R.+Hajduauthor=C.+A.+Keohaneauthor=M.+J.+Rosenbachauthor=J.+A.+Milliganauthor=G.-J.+Sheiauthor=S.+A.+Parentauthor=G.+Chrebetauthor=J.+Bergstromauthor=D.+Cardauthor=M.+Ferrerauthor=P.+Hodderauthor=B.+Struloviciauthor=H.+Rosenauthor=S.+Mandala&title=A+Rational+Utilization+of+High-Throughput+Screening+Affords+Selective%2C+Orally+Bioavailable+1-Benzyl-3-carboxyazetidine+Sphingosine-1-phosphate-1+Receptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm0492507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0492507%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DNeway%26aufirst%3DW.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DParent%26aufirst%3DS.%2BA.%26aulast%3DChrebet%26aufirst%3DG.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DStrulovici%26aufirst%3DB.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DA%2520Rational%2520Utilization%2520of%2520High-Throughput%2520Screening%2520Affords%2520Selective%252C%2520Orally%2520Bioavailable%25201-Benzyl-3-carboxyazetidine%2520Sphingosine-1-phosphate-1%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6662%26epage%3D6665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Piali, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froidevaux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span> </span><span class="NLM_article-title">The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">â</span> <span class="NLM_lpage">556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1124%2Fjpet.110.176487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21345969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Kquro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=547-556&author=L.+Pialiauthor=S.+Froidevauxauthor=P.+Hessauthor=O.+Naylerauthor=M.+H.+Bolliauthor=E.+Schlosserauthor=C.+Kohlauthor=B.+Steinerauthor=M.+Clozel&title=The+Selective+Sphingosine+1-Phosphate+Receptor+1+Agonist+Ponesimod+Protects+against+Lymphocyte-Mediated+Tissue+Inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation</span></div><div class="casAuthors">Piali, Luca; Froidevaux, Sylvie; Hess, Patrick; Nayler, Oliver; Bolli, Martin H.; Schlosser, Eva; Kohl, Christopher; Steiner, Beat; Clozel, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">547-556</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Lymphocyte exit from lymph nodes and their recirculation into blood is controlled by the sphingolipid sphingosine 1-phosphate (S1P).  The cellular receptor mediating lymphocyte exit is S1P1, one of five S1P receptors.  Nonselective agonists for S1P receptors lead to blood lymphocyte count redn.  The effects of selective S1P1 agonists on blood lymphocyte count and their impact in models of lymphocyte-mediated tissue inflammation have been less investigated.  We describe here the general pharmacol. of ponesimod, (Z,Z)-5-[3-chloro-4-((2R)-2,3-dihydroxy-propoxy)-benzylidene]-2-propylimino-3-o-tolylthiazolidin-4-one, a new, potent, and orally active selective S1P1 agonist.  Ponesimod activated S1P1-mediated signal transduction with high potency (EC50 of 5.7 nM) and selectivity.  Oral administration of ponesimod to rats led to a dose-dependent decrease of blood lymphocyte count.  After discontinuation of dosing, blood lymphocyte count returned to baseline within 48 h.  Ponesimod prevented edema formation, inflammatory cell accumulation, and cytokine release in the skin of mice with delayed-type hypersensitivity.  Ponesimod also prevented the increase in paw vol. and joint inflammation in rats with adjuvant-induced arthritis.  These data show that selective activation of S1P1 using ponesimod leads to blood lymphocyte count redn. and efficacy in models of lymphocyte-mediated tissue inflammation.  Immunomodulation with a rapidly reversible S1P1-selective agonist may represent a new therapeutic approach in lymphocyte-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsVGy9rlbA3LVg90H21EOLACvtfcHk0lise2QNckNCLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Kquro%253D&md5=d8e8c32a6860fde1eb07621d3cddb15d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.176487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.176487%26sid%3Dliteratum%253Aachs%26aulast%3DPiali%26aufirst%3DL.%26aulast%3DFroidevaux%26aufirst%3DS.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DSchlosser%26aufirst%3DE.%26aulast%3DKohl%26aufirst%3DC.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DThe%2520Selective%2520Sphingosine%25201-Phosphate%2520Receptor%25201%2520Agonist%2520Ponesimod%2520Protects%2520against%2520Lymphocyte-Mediated%2520Tissue%2520Inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D547%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Pelletier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafler, D. A.</span><span> </span><span class="NLM_article-title">Fingolimod for Multiple Sclerosis</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">â</span> <span class="NLM_lpage">347</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1056%2FNEJMct1101691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=22276823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1artLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=339-347&author=D.+Pelletierauthor=D.+A.+Hafler&title=Fingolimod+for+Multiple+Sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Fingolimod for multiple sclerosis</span></div><div class="casAuthors">Pelletier, Daniel; Hafler, David A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">339-347</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A 37-yr-old man with multiple sclerosis was evaluated for consideration of oral immunotherapy. Six years earlier, he had reported acute monocular visual disturbance.  The diagnosis of multiple sclerosis was subsequently confirmed by means of examn. of cerebrospinal fluid, which revealed an increased IgG index and oligoclonal banding, and by abnormal results on magnetic resonance imaging (MRI).  There was no family history of multiple sclerosis.  Daily injections of glatiramer acetate were initiated at the time of diagnosis, but two consecutive annual brain MRI scans revealed substantial disease activity.  He was then switched to interferon beta therapy, but this treatment was discontinued after the patient had two episodes of acute neurol. worsening.  Monthly natalizumab therapy was then considered, but a test for JC virus antibodies was pos.  Neurol. examn. showed disk pallor and visual acuity of 20/40 in the right eye, partial internuclear ophthalmoplegia, wide-based gait, and posterior column deficits in both legs.  The patient was referred to a specialist in multiple sclerosis for consideration of oral fingolimod therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7E7D-NWq_7LVg90H21EOLACvtfcHk0lise2QNckNCLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1artLc%253D&md5=6e217009d6b857582cab89b7629ba4e5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMct1101691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMct1101691%26sid%3Dliteratum%253Aachs%26aulast%3DPelletier%26aufirst%3DD.%26aulast%3DHafler%26aufirst%3DD.%2BA.%26atitle%3DFingolimod%2520for%2520Multiple%2520Sclerosis%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D339%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">David, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovarik, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmouder, R. L.</span><span> </span><span class="NLM_article-title">Clinical Pharmacokinetics of Fingolimod</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">â</span> <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.2165%2F11596550-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=22149256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=15-28&author=O.+J.+Davidauthor=J.+M.+Kovarikauthor=R.+L.+Schmouder&title=Clinical+Pharmacokinetics+of+Fingolimod"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of fingolimod</span></div><div class="casAuthors">David, Olivier J.; Kovarik, John M.; Schmouder, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-28</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review.  Fingolimod (FTY720), a sphingosine 1-phosphate receptor modulator, is the first in a new class of therapeutic compds. and is the first oral therapy approved for the treatment of relapsing forms of multiple sclerosis (MS).  Fingolimod is a structural analog of endogenous sphingosine and undergoes phosphorylation to produce fingolimod phosphate, the active moiety.  Fingolimod targets MS via effects on the immune system, and evidence from animal models indicates that it may also have actions in the central nervous system.  In phase III studies in patients with relapsing-remitting MS, fingolimod has demonstrated efficacy superior to that of an approved first-line therapy, i.m. interferon-Î²-1a, as well as placebo, with benefits extending across clin. and magnetic resonance imaging measures.  The pharmacokinetic profiles of fingolimod and fingolimod phosphate have been extensively investigated in studies in healthy volunteers, renal transplant recipients (the indication for which fingolimod was initially under clin. development, but the development was subsequently discontinued) and MS patients.  Results from these studies have demonstrated that fingolimod is efficiently absorbed, with an oral bioavailability of >90%, and its absorption is unaffected by dietary intake, therefore it can be taken without regard to meals.  Fingolimod and fingolimod phosphate have a half-life of 6-9 days, and steady-state pharmacokinetics are reached after 1-2 mo of daily dosing.  The long half-life of fingolimod, together with its slow absorption, means that fingolimod has a fiat concn. profile over time with once-daily dosing.  Fingolimod and fingolimod phosphate show dose-proportional exposure in single- and multiple-dose studies over a range of 0.125-5 mg; hence, there is a predictable relationship between dose and systemic exposure.  Furthermore, fingolimod and fingolimod phosphate exhibit low to moderate intersubject pharmacokinetic variability.  Fingolimod is extensively metabolized, with biotransformation occurring via three main pathways: (i) reversible phosphorylation to fingolimod phosphate; (ii) hydroxylation and oxidn. to yield a series of inactive carboxylic acid metabolites; and (iii) formation of non-polar ceramides.  Fingolimod is largely cleared through metab. by cytochrome P 450 (CYP) 4F2.  Since few drugs are metabolized by CYP4F2, fingolimod would be expected to have a relatively low potential for drug-drug interactions.  This is supported by data from in vitro studies indicating that fingolimod and fingolimod phosphate have little or no capacity to inhibit and no capacity to induce other major drug-metabolizing CYP enzymes at therapeutically relevant steady-state blood concns.  Population pharmacokinetic evaluations indicate that CYP3A inhibitors and CYP3A inducers have no effect or only a weak effect on the pharmacokinetics of fingolimod and fingolimod phosphate.  However, blood concns. of fingolimod and fingolimod phosphate are increased moderately when fingolimod is coadministered with ketoconazole, an inhibitor of CYP4F2.  The pharmacokinetics of fingolimod are unaffected by renal impairment or mild-to-moderate hepatic impairment.  However, exposure to fingolimod is increased in patients with severe hepatic impairment.  No clin. relevant effects of age, sex or ethnicity on the pharmacokinetics of fingolimod have been obsd.  Fingolimod is thus a promising new therapy for eligible patients with MS, with a predictable pharmacokinetic profile that allows effective once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoxIUshcr8m7Vg90H21EOLACvtfcHk0liEEU9AOsGiJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D&md5=a1a6d271470f6c297892ef00f0fe6ec6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2165%2F11596550-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596550-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DDavid%26aufirst%3DO.%2BJ.%26aulast%3DKovarik%26aufirst%3DJ.%2BM.%26aulast%3DSchmouder%26aufirst%3DR.%2BL.%26atitle%3DClinical%2520Pharmacokinetics%2520of%2520Fingolimod%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2012%26volume%3D51%26spage%3D15%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Montanari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarparin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleeson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braggio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longhi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, T.</span><span> </span><span class="NLM_article-title">Application of drug efficiency index in drug discovery: a strategy towards low therapeutic dose</span> <span class="citation_source-journal">Exp. Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">â</span> <span class="NLM_lpage">920</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1517%2F17460441.2011.602968" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=913-920&author=D.+Montanariauthor=E.+Chiarparinauthor=M.+P.+Gleesonauthor=S.+Braggioauthor=R.+Longhiauthor=K.+Valkoauthor=T.+Rossi&title=Application+of+drug+efficiency+index+in+drug+discovery%3A+a+strategy+towards+low+therapeutic+dose"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1517%2F17460441.2011.602968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2011.602968%26sid%3Dliteratum%253Aachs%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DChiarparin%26aufirst%3DE.%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DLonghi%26aufirst%3DR.%26aulast%3DValko%26aufirst%3DK.%26aulast%3DRossi%26aufirst%3DT.%26atitle%3DApplication%2520of%2520drug%2520efficiency%2520index%2520in%2520drug%2520discovery%253A%2520a%2520strategy%2520towards%2520low%2520therapeutic%2520dose%26jtitle%3DExp.%2520Opin.%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D913%26epage%3D920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St-Gallay, S. A.</span><span> </span><span class="NLM_article-title">The influence of the âorganizational factorâ on compound quality in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">â</span> <span class="NLM_lpage">765</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=749-765&author=P.+D.+Leesonauthor=S.+A.+St-Gallay&title=The+influence+of+the+%E2%80%98organizational+factor%E2%80%99+on+compound+quality+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSt-Gallay%26aufirst%3DS.%2BA.%26atitle%3DThe%2520influence%2520of%2520the%2520%25E2%2580%2598organizational%2520factor%25E2%2580%2599%2520on%2520compound%2520quality%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D749%26epage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Hughes, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellsworth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fobian, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilles, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger-Burke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wager, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span> </span><span class="NLM_article-title">Physiochemical drug properties associated with in vivo toxicological outcomes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4872</span><span class="NLM_x">â</span> <span class="NLM_lpage">4875</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0liEEU9AOsGiJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4872%26epage%3D4875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">McKeown, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giblin, G. M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorthioir, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blunt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewell, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdhury, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessell, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pipe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span> </span><span class="NLM_article-title">Identification of novel pyrazole acid antagonists for the EP1 receptor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4767</span><span class="NLM_x">â</span> <span class="NLM_lpage">4771</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4767-4771&author=S.+C.+McKeownauthor=A.+Hallauthor=G.+M.+P.+Giblinauthor=O.+Lorthioirauthor=R.+Bluntauthor=X.+Q.+Lewellauthor=R.+J.+Wilsonauthor=S.+H.+Brownauthor=A.+Chowdhuryauthor=T.+Colemanauthor=S.+P.+Watsonauthor=I.+P.+Chessellauthor=A.+Pipeauthor=N.+Claytonauthor=P.+Goldsmith&title=Identification+of+novel+pyrazole+acid+antagonists+for+the+EP1+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeown%26aufirst%3DS.%2BC.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DGiblin%26aufirst%3DG.%2BM.%2BP.%26aulast%3DLorthioir%26aufirst%3DO.%26aulast%3DBlunt%26aufirst%3DR.%26aulast%3DLewell%26aufirst%3DX.%2BQ.%26aulast%3DWilson%26aufirst%3DR.%2BJ.%26aulast%3DBrown%26aufirst%3DS.%2BH.%26aulast%3DChowdhury%26aufirst%3DA.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DWatson%26aufirst%3DS.%2BP.%26aulast%3DChessell%26aufirst%3DI.%2BP.%26aulast%3DPipe%26aufirst%3DA.%26aulast%3DClayton%26aufirst%3DN.%26aulast%3DGoldsmith%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520pyrazole%2520acid%2520antagonists%2520for%2520the%2520EP1%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4767%26epage%3D4771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parent, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickham, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P1) Receptor Agonists with Exceptional Selectivity against S1P2 and S1P3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6169</span><span class="NLM_x">â</span> <span class="NLM_lpage">6173</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0503244" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6169-6173&author=Z.+Liauthor=W.+Chenauthor=J.+J.+Haleauthor=C.+L.+Lynchauthor=S.+G.+Millsauthor=R.+Hajduauthor=C.+A.+Keohaneauthor=M.+J.+Rosenbachauthor=J.+A.+Milliganauthor=G.-J.+Sheiauthor=G.+Chrebetauthor=S.+A.+Parentauthor=J.+Bergstromauthor=D.+Cardauthor=M.+Forrestauthor=E.+J.+Quackenbushauthor=L.+A.+Wickhamauthor=H.+Vargasauthor=R.+M.+Evansauthor=H.+Rosenauthor=S.+Mandala&title=Discovery+of+Potent+3%2C5-Diphenyl-1%2C2%2C4-oxadiazole+Sphingosine-1-phosphate-1+%28S1P1%29+Receptor+Agonists+with+Exceptional+Selectivity+against+S1P2+and+S1P3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm0503244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0503244%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DChrebet%26aufirst%3DG.%26aulast%3DParent%26aufirst%3DS.%2BA.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DQuackenbush%26aufirst%3DE.%2BJ.%26aulast%3DWickham%26aufirst%3DL.%2BA.%26aulast%3DVargas%26aufirst%3DH.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Potent%25203%252C5-Diphenyl-1%252C2%252C4-oxadiazole%2520Sphingosine-1-phosphate-1%2520%2528S1P1%2529%2520Receptor%2520Agonists%2520with%2520Exceptional%2520Selectivity%2520against%2520S1P2%2520and%2520S1P3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6169%26epage%3D6173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Demont, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arpino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bit, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deeks, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heightman, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panchal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witherington, J.</span><span> </span><span class="NLM_article-title">Discovery of a Brain-Penetrant S1P3-Sparing Direct Agonist of the S1P1 and S1P5 Receptors Efficacious at Low Oral Dose</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6724</span><span class="NLM_x">â</span> <span class="NLM_lpage">6733</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200609t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6724-6733&author=E.+H.+Demontauthor=S.+Arpinoauthor=R.+A.+Bitauthor=C.+A.+Campbellauthor=N.+Deeksauthor=S.+Desaiauthor=S.+J.+Dowellauthor=P.+Gaskinauthor=J.+R.+J.+Grayauthor=L.+A.+Harrisonauthor=A.+Haynesauthor=T.+D.+Heightmanauthor=D.+S.+Holmesauthor=P.+G.+Humphreysauthor=U.+Kumarauthor=M.+A.+Morseauthor=G.+J.+Osborneauthor=T.+Panchalauthor=K.+L.+Philpottauthor=S.+Taylorauthor=R.+Watsonauthor=R.+Willisauthor=J.+Witherington&title=Discovery+of+a+Brain-Penetrant+S1P3-Sparing+Direct+Agonist+of+the+S1P1+and+S1P5+Receptors+Efficacious+at+Low+Oral+Dose"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm200609t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200609t%26sid%3Dliteratum%253Aachs%26aulast%3DDemont%26aufirst%3DE.%2BH.%26aulast%3DArpino%26aufirst%3DS.%26aulast%3DBit%26aufirst%3DR.%2BA.%26aulast%3DCampbell%26aufirst%3DC.%2BA.%26aulast%3DDeeks%26aufirst%3DN.%26aulast%3DDesai%26aufirst%3DS.%26aulast%3DDowell%26aufirst%3DS.%2BJ.%26aulast%3DGaskin%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DHarrison%26aufirst%3DL.%2BA.%26aulast%3DHaynes%26aufirst%3DA.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DHumphreys%26aufirst%3DP.%2BG.%26aulast%3DKumar%26aufirst%3DU.%26aulast%3DMorse%26aufirst%3DM.%2BA.%26aulast%3DOsborne%26aufirst%3DG.%2BJ.%26aulast%3DPanchal%26aufirst%3DT.%26aulast%3DPhilpott%26aufirst%3DK.%2BL.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DWillis%26aufirst%3DR.%26aulast%3DWitherington%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520Brain-Penetrant%2520S1P3-Sparing%2520Direct%2520Agonist%2520of%2520the%2520S1P1%2520and%2520S1P5%2520Receptors%2520Efficacious%2520at%2520Low%2520Oral%2520Dose%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6724%26epage%3D6733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Beaudry, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N. K.</span><span> </span><span class="NLM_article-title">Determination of drugâplasma protein binding using human serum albumin chromatographic column and multiple linear regression model</span> <span class="citation_source-journal">Biomed. Chromatogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">â</span> <span class="NLM_lpage">406</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1002%2F%28SICI%291099-0801%28199910%2913%3A6%3C401%3A%3AAID-BMC899%3E3.0.CO%3B2-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=10477897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADyaK1MXms1Wktb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=401-406&author=F.+Beaudryauthor=M.+Coutuauthor=N.+K.+Brown&title=Determination+of+drug%E2%80%93plasma+protein+binding+using+human+serum+albumin+chromatographic+column+and+multiple+linear+regression+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of drug-plasma protein binding using human serum albumin chromatographic column and multiple linear regression model</span></div><div class="casAuthors">Beaudry, Francis; Coutu, Michel; Brown, Nigel K.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedical Chromatography</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">401-406</span>CODEN:
                <span class="NLM_cas:coden">BICHE2</span>;
        ISSN:<span class="NLM_cas:issn">0269-3879</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Reversible attachment to serum proteins plays a significant role in pharmacokinetics and pharmacodynamics, and a clear understanding of this process is fundamental in the development of the rational use of many therapeutics agents.  Over the last few years, it has been demonstrated that immobilized human serum albumin (HSA) could be used to est. plasma protein binding.  A series of 40 structurally unrelated pharmaceutical compds. were chromatographed on an immobilized HSA column in order to construct a protein binding "calibration curve" and multiple linear regression system.  When studying the relationship between the chromatog. retention and the percentage of binding detd. in vitro, a good correlation can be obsd. (r2 = 0.799) using a wide variety of compds. with different binding affinities (from 0 to 99% binding).  Using a quant. structure-retention relationships (QSRR) approach to analyzing chromatog. data, the correlation was improved compared to the traditional approach (r2=0.824).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmRO3uzmkjX7Vg90H21EOLACvtfcHk0lj9LPUFbZGp9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXms1Wktb4%253D&md5=172b4ea614105afcfb9e3b0a63eb3177</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291099-0801%28199910%2913%3A6%3C401%3A%3AAID-BMC899%3E3.0.CO%3B2-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291099-0801%2528199910%252913%253A6%253C401%253A%253AAID-BMC899%253E3.0.CO%253B2-C%26sid%3Dliteratum%253Aachs%26aulast%3DBeaudry%26aufirst%3DF.%26aulast%3DCoutu%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DN.%2BK.%26atitle%3DDetermination%2520of%2520drug%25E2%2580%2593plasma%2520protein%2520binding%2520using%2520human%2520serum%2520albumin%2520chromatographic%2520column%2520and%2520multiple%2520linear%2520regression%2520model%26jtitle%3DBiomed.%2520Chromatogr.%26date%3D1999%26volume%3D13%26spage%3D401%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Roberts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnusson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burczynski, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M.</span><span> </span><span class="NLM_article-title">Enterohepatic Circulation</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">â</span> <span class="NLM_lpage">790</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.2165%2F00003088-200241100-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=12162761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFyru78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=751-790&author=M.+Robertsauthor=B.+Magnussonauthor=F.+Burczynskiauthor=M.+Weiss&title=Enterohepatic+Circulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Enterohepatic circulation: physiological, pharmacokinetic and clinical implications</span></div><div class="casAuthors">Roberts, Michael S.; Magnusson, Beatrice M.; Burczynski, Frank J.; Weiss, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">751-790</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Enterohepatic recycling occurs by biliary excretion and intestinal reabsorption of a solute, sometimes with hepatic conjugation and intestinal deconjugation.  Cycling is often assocd. with multiple peaks and a longer apparent half-life in a plasma concn.-time profile.  Factors affecting biliary excretion include drug characteristics (chem. structure, polarity and mol. size), transport across sinusoidal plasma membrane and canniculae membranes, biotransformation and possible reabsorption from intrahepatic bile ductules.  Intestinal reabsorption to complete the enterohepatic cycle may depend on hydrolysis of a drug conjugate by gut bacteria.  Bioavailability is also affected by the extent of intestinal absorption, gut-wall P-glycoprotein efflux and gut-wall metab.  Recently, there has been a considerable increase in our understanding of the role of transporters, of gene expression of intestinal and hepatic enzymes, and of hepatic zonation.  Drugs, disease and genetics may result in induced or inhibited activity of transporters and metabolizing enzymes.  Reduced expression of one transporter, for example hepatic canalicular multidrug resistance-assocd. protein (MRP) 2, is often assocd. with enhanced expression of others, for example the usually quiescent basolateral efflux MRP3, to limit hepatic toxicity.  In addn., physiol. relevant pharmacokinetic models, which describe enterohepatic recirculation in terms of its determinants (such as sporadic gall bladder emptying), have been developed.  In general, enterohepatic recirculation may prolong the pharmacol. effect of certain drugs and drug metabolites.  Of particular importance is the potential amplifying effect of enterohepatic variability in defining differences in the bioavailability, apparent vol. of distribution and clearance of a given compd.  Genetic abnormalities, disease states, orally administered adsorbents and certain co-administered drugs all affect enterohepatic recycling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDmTzuEhf7QLVg90H21EOLACvtfcHk0lj9LPUFbZGp9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFyru78%253D&md5=514a6ffb4ee275ccd2a7082fe2fe3d87</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2165%2F00003088-200241100-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200241100-00005%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DM.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DBurczynski%26aufirst%3DF.%26aulast%3DWeiss%26aufirst%3DM.%26atitle%3DEnterohepatic%2520Circulation%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2002%26volume%3D41%26spage%3D751%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S. M.</span><span> </span><span class="NLM_article-title">Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3679</span><span class="NLM_x">â</span> <span class="NLM_lpage">3683</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3679-3683&author=L.+Yanauthor=P.+Huoauthor=G.+Dohertyauthor=L.+Tothauthor=J.+J.+Haleauthor=S.+G.+Millsauthor=R.+Hajduauthor=C.+A.+Keohaneauthor=M.+J.+Rosenbachauthor=J.+A.+Milliganauthor=G.-J.+Sheiauthor=G.+Chrebetauthor=J.+Bergstromauthor=D.+Cardauthor=E.+Quackenbushauthor=A.+Wickhamauthor=S.+M.+Mandala&title=Discovery+of+3-arylpropionic+acids+as+potent+agonists+of+sphingosine-1-phosphate+receptor-1+%28S1P1%29+with+high+selectivity+against+all+other+known+S1P+receptor+subtypes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%26aulast%3DHuo%26aufirst%3DP.%26aulast%3DDoherty%26aufirst%3DG.%26aulast%3DToth%26aufirst%3DL.%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DChrebet%26aufirst%3DG.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DQuackenbush%26aufirst%3DE.%26aulast%3DWickham%26aufirst%3DA.%26aulast%3DMandala%26aufirst%3DS.%2BM.%26atitle%3DDiscovery%2520of%25203-arylpropionic%2520acids%2520as%2520potent%2520agonists%2520of%2520sphingosine-1-phosphate%2520receptor-1%2520%2528S1P1%2529%2520with%2520high%2520selectivity%2520against%2520all%2520other%2520known%2520S1P%2520receptor%2520subtypes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3679%26epage%3D3683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Cahalan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Cabrera, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisyan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, M.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeager, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemons, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">â</span> <span class="NLM_lpage">256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1038%2Fnchembio.547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21445057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVOhsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=254-256&author=S.+M.+Cahalanauthor=P.+J.+Gonzalez-Cabreraauthor=G.+Sarkisyanauthor=N.+Nguyenauthor=M.-T.+Schaefferauthor=L.+Huangauthor=A.+Yeagerauthor=B.+Clemonsauthor=F.+Scottauthor=H.+Rosen&title=Actions+of+a+picomolar+short-acting+S1P1+agonist+in+S1P1-eGFP+knock-in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice</span></div><div class="casAuthors">Cahalan, Stuart M.; Gonzalez-Cabrera, Pedro J.; Sarkisyan, Gor; Nguyen, Nhan; Schaeffer, Marie-Therese; Huang, Liming; Yeager, Adam; Clemons, Bryan; Scott, Fiona; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">254-256</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate receptor 1 (S1P1) is crit. for lymphocyte recirculation and is a clin. target for treatment of multiple sclerosis.  By generating a short-duration S1P1 agonist and mice in which fluorescently tagged S1P1 replaces wild-type receptor, the authors elucidate physiol. and agonist-perturbed changes in expression of S1P1 at a subcellular level in vivo.  The authors demonstrate differential downregulation of S1P1 on lymphocytes and endothelia after agonist treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNs3fjYUWAVrVg90H21EOLACvtfcHk0lhJoIQ2h5kX2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVOhsb0%253D&md5=667724613ca1aef5478cb3b9cd6f215c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.547%26sid%3Dliteratum%253Aachs%26aulast%3DCahalan%26aufirst%3DS.%2BM.%26aulast%3DGonzalez-Cabrera%26aufirst%3DP.%2BJ.%26aulast%3DSarkisyan%26aufirst%3DG.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DSchaeffer%26aufirst%3DM.-T.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DYeager%26aufirst%3DA.%26aulast%3DClemons%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DF.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DActions%2520of%2520a%2520picomolar%2520short-acting%2520S1P1%2520agonist%2520in%2520S1P1-eGFP%2520knock-in%2520mice%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D254%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Nicolaides, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efthymiopoulos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reppas, C.</span><span> </span><span class="NLM_article-title">Forecasting the In Vivo Performance of Four Low Solubility Drugs from Their In Vitro Dissolution Data</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1876</span><span class="NLM_x">â</span> <span class="NLM_lpage">1882</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1999&pages=1876-1882&author=E.+Nicolaidesauthor=E.+Galiaauthor=C.+Efthymiopoulosauthor=J.+B.+Dressmanauthor=C.+Reppas&title=Forecasting+the+In+Vivo+Performance+of+Four+Low+Solubility+Drugs+from+Their+In+Vitro+Dissolution+Data"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNicolaides%26aufirst%3DE.%26aulast%3DGalia%26aufirst%3DE.%26aulast%3DEfthymiopoulos%26aufirst%3DC.%26aulast%3DDressman%26aufirst%3DJ.%2BB.%26aulast%3DReppas%26aufirst%3DC.%26atitle%3DForecasting%2520the%2520In%2520Vivo%2520Performance%2520of%2520Four%2520Low%2520Solubility%2520Drugs%2520from%2520Their%2520In%2520Vitro%2520Dissolution%2520Data%26jtitle%3DPharm.%2520Res.%26date%3D1999%26volume%3D16%26spage%3D1876%26epage%3D1882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deeks, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavens, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demont, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cryan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garden, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witherington, J.</span><span> </span><span class="NLM_article-title">The utility of pharmacokineticâpharmacodynamic modeling in the discovery and optimization of selective S1P1 agonists</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=671&author=S.+Taylorauthor=J.+R.+J.+Grayauthor=R.+Willisauthor=N.+Deeksauthor=A.+Haynesauthor=C.+Campbellauthor=P.+Gaskinauthor=K.+Leavensauthor=E.+Demontauthor=S.+Dowellauthor=J.+Cryanauthor=M.+Morseauthor=A.+Patelauthor=H.+Gardenauthor=J.+Witherington&title=The+utility+of+pharmacokinetic%E2%80%93pharmacodynamic+modeling+in+the+discovery+and+optimization+of+selective+S1P1+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DWillis%26aufirst%3DR.%26aulast%3DDeeks%26aufirst%3DN.%26aulast%3DHaynes%26aufirst%3DA.%26aulast%3DCampbell%26aufirst%3DC.%26aulast%3DGaskin%26aufirst%3DP.%26aulast%3DLeavens%26aufirst%3DK.%26aulast%3DDemont%26aufirst%3DE.%26aulast%3DDowell%26aufirst%3DS.%26aulast%3DCryan%26aufirst%3DJ.%26aulast%3DMorse%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DGarden%26aufirst%3DH.%26aulast%3DWitherington%26aufirst%3DJ.%26atitle%3DThe%2520utility%2520of%2520pharmacokinetic%25E2%2580%2593pharmacodynamic%2520modeling%2520in%2520the%2520discovery%2520and%2520optimization%2520of%2520selective%2520S1P1%2520agonists%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26spage%3D671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Gleeson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J.</span><span> </span><span class="NLM_article-title">Probing the links between in vitro potency, ADMET and physicochemical parameters</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1038%2Fnrd3367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21358739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=197-208&author=M.+P.+Gleesonauthor=A.+Herseyauthor=D.+Montanariauthor=J.+Overington&title=Probing+the+links+between+in+vitro+potency%2C+ADMET+and+physicochemical+parameters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the links between in vitro potency, ADMET and physicochemical parameters</span></div><div class="casAuthors">Gleeson, M. Paul; Hersey, Anne; Montanari, Dino; Overington, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-208</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A common underlying assumption in current drug discovery strategies is that compds. with higher in vitro potency at their target(s) have greater potential to translate into successful, low-dose therapeutics.  This has led to the development of screening cascades with in vitro potency embedded as an early filter.  However, this approach is beginning to be questioned, given the bias in physicochem. properties that it can introduce early in lead generation and optimization, which is due to the often diametrically opposed relationship between physicochem. parameters assocd. with high in vitro potency and those assocd. with desirable absorption, distribution, metab., excretion and toxicity (ADMET) characteristics.  Here, we describe analyses that probe these issues further using the ChEMBL database, which includes more than 500,000 drug discovery and marketed oral drug compds.  Key findings include: first, that oral drugs seldom possess nanomolar potency (50 nM on av.); second, that many oral drugs have considerable off-target activity; and third, that in vitro potency does not correlate strongly with the therapeutic dose.  These findings suggest that the perceived benefit of high in vitro potency may be negated by poorer ADMET properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovOslFSgIkUbVg90H21EOLACvtfcHk0liIzTXiq1RVfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D&md5=e275044516e9b0245b71c9603477ef74</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd3367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3367%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DOverington%26aufirst%3DJ.%26atitle%3DProbing%2520the%2520links%2520between%2520in%2520vitro%2520potency%252C%2520ADMET%2520and%2520physicochemical%2520parameters%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D197%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summerhill, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, J. E.</span><span> </span><span class="NLM_article-title">Aromatic chloride to nitrile transformation: medicinal and synthetic chemistry</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">â</span> <span class="NLM_lpage">318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1039%2FC0MD00135J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeku7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=309-318&author=L.+H.+Jonesauthor=N.+W.+Summerhillauthor=N.+A.+Swainauthor=J.+E.+Mills&title=Aromatic+chloride+to+nitrile+transformation%3A+medicinal+and+synthetic+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatic chloride to nitrile transformation: medicinal and synthetic chemistry</span></div><div class="casAuthors">Jones, Lyn H.; Summerhill, Nicholas W.; Swain, Nigel A.; Mills, James E.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">309-318</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review highlights the medicinal and synthetic chem. relevance of replacing an arom. chloride motif with an arom. nitrile.  Desirable features that this transformation can bring in a drug design are explored as are recent synthetic chem. advances that effect this replacement in a single step.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJt7anfomBpLVg90H21EOLACvtfcHk0liIzTXiq1RVfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeku7zO&md5=e0b1cbf19a7bc117e9a8a83af9e19322</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2FC0MD00135J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0MD00135J%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DSummerhill%26aufirst%3DN.%2BW.%26aulast%3DSwain%26aufirst%3DN.%2BA.%26aulast%3DMills%26aufirst%3DJ.%2BE.%26atitle%3DAromatic%2520chloride%2520to%2520nitrile%2520transformation%253A%2520medicinal%2520and%2520synthetic%2520chemistry%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2010%26volume%3D1%26spage%3D309%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Fleming, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravikumar, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shook, B. C.</span><span> </span><span class="NLM_article-title">Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7902</span><span class="NLM_x">â</span> <span class="NLM_lpage">7917</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100762r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7902-7917&author=F.+F.+Flemingauthor=L.+Yaoauthor=P.+C.+Ravikumarauthor=L.+Funkauthor=B.+C.+Shook&title=Nitrile-Containing+Pharmaceuticals%3A+Efficacious+Roles+of+the+Nitrile+Pharmacophore"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore</span></div><div class="casAuthors">Fleming, Fraser F.; Yao, Lihua; Ravikumar, P. C.; Funk, Lee; Shook, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7902-7917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review is structured according to the nature of the nitrile-bearing substituent.  As the no. of nitrile-contg. drug leads is vast, the review has focused on launched nitrile-contg. pharmaceuticals and currently active clin. candidates.  Most nitrile-contg. pharmaceuticals are aroms. with aliph.-, alkene-, and nitrogen-bearing nitriles being progressively less frequent.  Within each class, the bioactive nitriles are collated according to common structural elements and mode of action.  The hope is that this survey will allow greater deployment of this versatile functionality within drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR6kPPdWVuvLVg90H21EOLACvtfcHk0liIzTXiq1RVfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP&md5=040bbaebd9e8c9999d195b9a22221fea</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm100762r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100762r%26sid%3Dliteratum%253Aachs%26aulast%3DFleming%26aufirst%3DF.%2BF.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DRavikumar%26aufirst%3DP.%2BC.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DShook%26aufirst%3DB.%2BC.%26atitle%3DNitrile-Containing%2520Pharmaceuticals%253A%2520Efficacious%2520Roles%2520of%2520the%2520Nitrile%2520Pharmacophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7902%26epage%3D7917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">â</span> <span class="NLM_lpage">6756</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+Flatland%3A+Increasing+Saturation+as+an+Approach+to+Improving+Clinical+Success"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0liIzTXiq1RVfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520Flatland%253A%2520Increasing%2520Saturation%2520as%2520an%2520Approach%2520to%2520Improving%2520Clinical%2520Success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">SchÃ¼rer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Cabrera, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, M.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Ligand-Binding Pocket Shape Differences between Sphingosine 1-Phosphate (S1P) Receptors S1P1 and S1P3 Determine Efficiency of Chemical Probe Identification by Ultrahigh-Throughput Screening</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">â</span> <span class="NLM_lpage">498</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb800051m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=486-498&author=S.+C.+Sch%C3%BCrerauthor=S.+J.+Brownauthor=P.+J.+Gonzalez-Cabreraauthor=M.-T.+Schaefferauthor=J.+Chapmanauthor=E.+Joauthor=P.+Chaseauthor=T.+Spicerauthor=P.+Hodderauthor=H.+Rosen&title=Ligand-Binding+Pocket+Shape+Differences+between+Sphingosine+1-Phosphate+%28S1P%29+Receptors+S1P1+and+S1P3+Determine+Efficiency+of+Chemical+Probe+Identification+by+Ultrahigh-Throughput+Screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fcb800051m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb800051m%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%2BC.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DGonzalez-Cabrera%26aufirst%3DP.%2BJ.%26aulast%3DSchaeffer%26aufirst%3DM.-T.%26aulast%3DChapman%26aufirst%3DJ.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DChase%26aufirst%3DP.%26aulast%3DSpicer%26aufirst%3DT.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DLigand-Binding%2520Pocket%2520Shape%2520Differences%2520between%2520Sphingosine%25201-Phosphate%2520%2528S1P%2529%2520Receptors%2520S1P1%2520and%2520S1P3%2520Determine%2520Efficiency%2520of%2520Chemical%2520Probe%2520Identification%2520by%2520Ultrahigh-Throughput%2520Screening%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2008%26volume%3D3%26spage%3D486%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">ValkÃ³, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D.</span><span> </span><span class="NLM_article-title">Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC: A High-Throughput Alternative to log P/log D</span> <span class="citation_source-journal">Anal. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">2022</span><span class="NLM_x">â</span> <span class="NLM_lpage">2029</span></span><div class="citationLinks">[<a href="/doi/10.1021/ac961242d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1997&pages=2022-2029&author=K.+Valk%C3%B3author=C.+Bevanauthor=D.+Reynolds&title=Chromatographic+Hydrophobicity+Index+by+Fast-Gradient+RP-HPLC%3A+A+High-Throughput+Alternative+to+log+P%2Flog+D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fac961242d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac961242d%26sid%3Dliteratum%253Aachs%26aulast%3DValk%25C3%25B3%26aufirst%3DK.%26aulast%3DBevan%26aufirst%3DC.%26aulast%3DReynolds%26aufirst%3DD.%26atitle%3DChromatographic%2520Hydrophobicity%2520Index%2520by%2520Fast-Gradient%2520RP-HPLC%253A%2520A%2520High-Throughput%2520Alternative%2520to%2520log%2520P%252Flog%2520D%26jtitle%3DAnal.%2520Chem.%26date%3D1997%26volume%3D69%26spage%3D2022%26epage%3D2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Skidmore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atcha, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boucherat, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelletti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coppo, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunsdon, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchings, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maskell, E. S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redshaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sehmi, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scoccitti, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theobald, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span> </span><span class="NLM_article-title">The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1,3,4-oxadiazol-2-yl)phenyl) benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3531</span><span class="NLM_x">â</span> <span class="NLM_lpage">3534</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3531-3534&author=J.+Skidmoreauthor=Z.+Atchaauthor=E.+Boucheratauthor=L.+Castellettiauthor=D.+W.+Chenauthor=F.+T.+Coppoauthor=L.+Cutlerauthor=R.+M.+Dunsdonauthor=B.+M.+Heathauthor=R.+Hutchingsauthor=D.+N.+Hurstauthor=S.+Javedauthor=S.+Martinauthor=E.+S.+L.+Maskellauthor=D.+Nortonauthor=D.+J.+Pembertonauthor=S.+Redshawauthor=R.+Rutterauthor=S.+S.+Sehmiauthor=T.+Scoccittiauthor=H.+E.+Templeauthor=P.+Theobaldauthor=R.+W.+Wardauthor=D.+M.+Wilson&title=The+discovery+of+2-fluoro-N-%283-fluoro-4-%285-%28%284-morpholinobutyl%29amino%29-1%2C3%2C4-oxadiazol-2-yl%29phenyl%29+benzamide%2C+a+full+agonist+of+the+alpha-7+nicotinic+acetylcholine+receptor+showing+efficacy+in+the+novel+object+recognition+model+of+cognition+enhancement"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSkidmore%26aufirst%3DJ.%26aulast%3DAtcha%26aufirst%3DZ.%26aulast%3DBoucherat%26aufirst%3DE.%26aulast%3DCastelletti%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DD.%2BW.%26aulast%3DCoppo%26aufirst%3DF.%2BT.%26aulast%3DCutler%26aufirst%3DL.%26aulast%3DDunsdon%26aufirst%3DR.%2BM.%26aulast%3DHeath%26aufirst%3DB.%2BM.%26aulast%3DHutchings%26aufirst%3DR.%26aulast%3DHurst%26aufirst%3DD.%2BN.%26aulast%3DJaved%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMaskell%26aufirst%3DE.%2BS.%2BL.%26aulast%3DNorton%26aufirst%3DD.%26aulast%3DPemberton%26aufirst%3DD.%2BJ.%26aulast%3DRedshaw%26aufirst%3DS.%26aulast%3DRutter%26aufirst%3DR.%26aulast%3DSehmi%26aufirst%3DS.%2BS.%26aulast%3DScoccitti%26aufirst%3DT.%26aulast%3DTemple%26aufirst%3DH.%2BE.%26aulast%3DTheobald%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BW.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DThe%2520discovery%2520of%25202-fluoro-N-%25283-fluoro-4-%25285-%2528%25284-morpholinobutyl%2529amino%2529-1%252C3%252C4-oxadiazol-2-yl%2529phenyl%2529%2520benzamide%252C%2520a%2520full%2520agonist%2520of%2520the%2520alpha-7%2520nicotinic%2520acetylcholine%2520receptor%2520showing%2520efficacy%2520in%2520the%2520novel%2520object%2520recognition%2520model%2520of%2520cognition%2520enhancement%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3531%26epage%3D3534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rager, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardos, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobson, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, I. J.</span><span> </span><span class="NLM_article-title">Evaluation of the MDR-MDCK cell line as a permeability screen for the bloodâbrain barrier</span> <span class="citation_source-journal">Int. J. Pharmaceut.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">â</span> <span class="NLM_lpage">359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1016%2Fj.ijpharm.2004.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=15620875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFGhurvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2005&pages=349-359&author=Q.+Wangauthor=J.+D.+Ragerauthor=K.+Weinsteinauthor=P.+S.+Kardosauthor=G.+L.+Dobsonauthor=J.+Liauthor=I.+J.+Hidalgo&title=Evaluation+of+the+MDR-MDCK+cell+line+as+a+permeability+screen+for+the+blood%E2%80%93brain+barrier"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier</span></div><div class="casAuthors">Wang, Qing; Rager, Joseph D.; Weinstein, Kathryn; Kardos, Paula S.; Dobson, Glenn L.; Li, Jibin; Hidalgo, Ismael J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">349-359</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The objectives of this study were to (1) characterize MDR-MDCK monolayers as an in vitro model to predict brain uptake potential; (2) examine the ability of MDR-MDCK monolayers to identify the brain uptake potential of compds. that interact with P-glycoprotein (P-gp).  The study measured the bi-directional transport of 28 compds. across MDR-MDCK monolayers.  The brain uptake of a subset of the compds. was detd. in the rat brain perfusion model.  Drug concns. were analyzed by LC-MS-MS.  CNS-pos. drugs exhibited absorptive permeability coeffs. (Papp, A-B) values ranging from 3.4 Ã 10-6 to 20.2 Ã 10-6 cm/s; whereas CNS-neg. drugs showed Papp (A-B) ranging from 0.03 Ã 10-6 to 0.83 Ã 10-6 cm/s.  Inhibition of P-gp by cyclosporin A (CsA) significantly reduced secretory flux of compds. known to be P-pg substrates, but only enhanced the absorptive flux of compds. with high efflux ratio (>100).  In vitro results were confirmed by brain perfusion studies on selected compds.  MDR-MDCK monolayers can be used to classify compds. into CNS-pos. or CNS-neg. based on the permeability coeffs. (Papp, A-B).  Under the authors' exptl. conditions, compds. with Papp (A-B) >3 Ã 10-6 cm/s have high brain uptake potential; compds. with Papp (A-B) < 1 Ã 10-6 cm/s are unable to penetrate the blood-brain barrier (BBB); the brain uptake of compds. with Papp (A-B) < 1 Ã 10-6 cm/s and a P-gp-mediated efflux ratio of >100 may be enhanced by inhibiting P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvF-zoLte8trVg90H21EOLACvtfcHk0lik_0Xs5TCihA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFGhurvE&md5=7d2cb9e13b2767b337bf808e73141ae1</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2004.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2004.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DRager%26aufirst%3DJ.%2BD.%26aulast%3DWeinstein%26aufirst%3DK.%26aulast%3DKardos%26aufirst%3DP.%2BS.%26aulast%3DDobson%26aufirst%3DG.%2BL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHidalgo%26aufirst%3DI.%2BJ.%26atitle%3DEvaluation%2520of%2520the%2520MDR-MDCK%2520cell%2520line%2520as%2520a%2520permeability%2520screen%2520for%2520the%2520blood%25E2%2580%2593brain%2520barrier%26jtitle%3DInt.%2520J.%2520Pharmaceut.%26date%3D2005%26volume%3D288%26spage%3D349%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="note"><p class="first last">Further analysis showed that one of the four rats used in the 1 mg/kg study for compound <b>31a</b> had a significantly prolonged lymphopenia compared with the other three rats, hence the average prolonged effect. See <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Bonanomi, G.; Cardullo, F.; Damiani, F.; Gentile, G.; Hamprecht, D.; Micheli, F.; Tarsi, L.</span> (Glaxo Group Limited, U.K.) <span> </span><span class="NLM_article-title">Preparation of fused benzazepines having affinity for the dopamine D3 receptor</span>. Int. Patent Appl. WO2006002928, 12 Jan<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=G.+Bonanomi&author=F.+Cardullo&author=F.+Damiani&author=G.+Gentile&author=D.+Hamprecht&author=F.+Micheli&author=L.+Tarsi&title=Preparation+of+fused+benzazepines+having+affinity+for+the+dopamine+D3+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBonanomi%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520fused%2520benzazepines%2520having%2520affinity%2520for%2520the%2520dopamine%2520D3%2520receptor%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':[],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chandan Kumar  Shahi</span>, <span class="hlFld-ContribAuthor ">Aditya  Bhattacharyya</span>, <span class="hlFld-ContribAuthor ">Yerramsetti  Nanaji</span>, and <span class="hlFld-ContribAuthor ">Manas K.  Ghorai</span>  . </span><span class="cited-content_cbyCitation_article-title">A Stereoselective Route to Tetrahydrobenzoxazepines and Tetrahydrobenzodiazepines via Ring-Opening and Aza-Michael Addition of Activated Aziridines with 2-Hydroxyphenyl and 2-Aminophenyl Acrylates. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>82 </em>
                                    (1)
                                     , 37-47. <a href="https://doi.org/10.1021/acs.joc.6b01919" title="DOI URL">https://doi.org/10.1021/acs.joc.6b01919</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b01919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b01919%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DA%252BStereoselective%252BRoute%252Bto%252BTetrahydrobenzoxazepines%252Band%252BTetrahydrobenzodiazepines%252Bvia%252BRing-Opening%252Band%252BAza-Michael%252BAddition%252Bof%252BActivated%252BAziridines%252Bwith%252B2-Hydroxyphenyl%252Band%252B2-Aminophenyl%252BAcrylates%26aulast%3DShahi%26aufirst%3DChandan%2BKumar%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D05082016%26date%3D17102016%26date%3D06012017%26date%3D05102016%26volume%3D82%26issue%3D1%26spage%3D37%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-Yun  Xiao</span>, <span class="hlFld-ContribAuthor ">Scott H.  Watterson</span>, <span class="hlFld-ContribAuthor ">Charles M.  Langevine</span>, <span class="hlFld-ContribAuthor ">Anurag S.  Srivastava</span>, <span class="hlFld-ContribAuthor ">Soo S.  Ko</span>, <span class="hlFld-ContribAuthor ">Yanlei  Zhang</span>, <span class="hlFld-ContribAuthor ">Robert J.  Cherney</span>, <span class="hlFld-ContribAuthor ">Wei-Wei  Guo</span>, <span class="hlFld-ContribAuthor ">John L.  Gilmore</span>, <span class="hlFld-ContribAuthor ">James E.  Sheppeck, II</span>, <span class="hlFld-ContribAuthor ">Dauh-Rurng  Wu</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Duraisamy  Ramasamy</span>, <span class="hlFld-ContribAuthor ">Piramanayagam  Arunachalam</span>, <span class="hlFld-ContribAuthor ">Arvind  Mathur</span>, <span class="hlFld-ContribAuthor ">Tracy L.  Taylor</span>, <span class="hlFld-ContribAuthor ">David J.  Shuster</span>, <span class="hlFld-ContribAuthor ">Kim W.  McIntyre</span>, <span class="hlFld-ContribAuthor ">Ding-Ren  Shen</span>, <span class="hlFld-ContribAuthor ">Melissa  Yarde</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Cvijic</span>, <span class="hlFld-ContribAuthor ">Anthony M.  Marino</span>, <span class="hlFld-ContribAuthor ">Praveen V.  Balimane</span>, <span class="hlFld-ContribAuthor ">Zheng  Yang</span>, <span class="hlFld-ContribAuthor ">Dana M.  Banas</span>, <span class="hlFld-ContribAuthor ">Georgia  Cornelius</span>, <span class="hlFld-ContribAuthor ">Celia J.  DâArienzo</span>, <span class="hlFld-ContribAuthor ">Bethanne M.  Warrack</span>, <span class="hlFld-ContribAuthor ">Lois  Lehman-McKeeman</span>, <span class="hlFld-ContribAuthor ">Luisa M.  Salter-Cid</span>, <span class="hlFld-ContribAuthor ">Jenny  Xie</span>, <span class="hlFld-ContribAuthor ">Joel C.  Barrish</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">Alaric J.  Dyckman</span>, and <span class="hlFld-ContribAuthor ">T. G. Murali  Dhar</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of Tricyclic Agonists of Sphingosine-1-phosphate Receptor 1 (S1P1) Employing Ligand-Based Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (21)
                                     , 9837-9854. <a href="https://doi.org/10.1021/acs.jmedchem.6b01099" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01099</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01099%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BTricyclic%252BAgonists%252Bof%252BSphingosine-1-phosphate%252BReceptor%252B1%252B%252528S1P1%252529%252BEmploying%252BLigand-Based%252BDrug%252BDesign%26aulast%3DXiao%26aufirst%3DHai-Yun%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D25072016%26date%3D20102016%26date%3D10112016%26date%3D11102016%26volume%3D59%26issue%3D21%26spage%3D9837%26epage%3D9854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maxime  Giardinetti</span>, <span class="hlFld-ContribAuthor ">JÃ©rÃ´me  Marrot</span>, <span class="hlFld-ContribAuthor ">Xavier  Moreau</span>, <span class="hlFld-ContribAuthor ">Vincent  Coeffard</span>, and <span class="hlFld-ContribAuthor ">Christine  Greck</span>  . </span><span class="cited-content_cbyCitation_article-title">Asymmetric Synthesis of Fused Polycyclic Indazoles through Aminocatalyzed Aza-Michael Addition/Intramolecular Cyclization. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (15)
                                     , 6855-6861. <a href="https://doi.org/10.1021/acs.joc.6b01201" title="DOI URL">https://doi.org/10.1021/acs.joc.6b01201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b01201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b01201%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAsymmetric%252BSynthesis%252Bof%252BFused%252BPolycyclic%252BIndazoles%252Bthrough%252BAminocatalyzed%252BAza-Michael%252BAddition%25252FIntramolecular%252BCyclization%26aulast%3DGiardinetti%26aufirst%3DMaxime%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D20052016%26date%3D13072016%26date%3D05082016%26date%3D05072016%26volume%3D81%26issue%3D15%26spage%3D6855%26epage%3D6861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John L.  Gilmore</span>, <span class="hlFld-ContribAuthor ">James E.  Sheppeck, II</span>, <span class="hlFld-ContribAuthor ">Scott H.  Watterson</span>, <span class="hlFld-ContribAuthor ">Lauren  Haque</span>, <span class="hlFld-ContribAuthor ">Parag  Mukhopadhyay</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Tebben</span>, <span class="hlFld-ContribAuthor ">Michael A.  Galella</span>, <span class="hlFld-ContribAuthor ">Ding Ren  Shen</span>, <span class="hlFld-ContribAuthor ">Melissa  Yarde</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Cvijic</span>, <span class="hlFld-ContribAuthor ">Virna  Borowski</span>, <span class="hlFld-ContribAuthor ">Kathleen  Gillooly</span>, <span class="hlFld-ContribAuthor ">Tracy  Taylor</span>, <span class="hlFld-ContribAuthor ">Kim W.  McIntyre</span>, <span class="hlFld-ContribAuthor ">Bethanne  Warrack</span>, <span class="hlFld-ContribAuthor ">Paul C.  Levesque</span>, <span class="hlFld-ContribAuthor ">Julia P.  Li</span>, <span class="hlFld-ContribAuthor ">Georgia  Cornelius</span>, <span class="hlFld-ContribAuthor ">Celia  DâArienzo</span>, <span class="hlFld-ContribAuthor ">Anthony  Marino</span>, <span class="hlFld-ContribAuthor ">Praveen  Balimane</span>, <span class="hlFld-ContribAuthor ">Luisa  Salter-Cid</span>, <span class="hlFld-ContribAuthor ">Joel C.  Barrish</span>, <span class="hlFld-ContribAuthor ">William J.  Pitts</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">Jenny  Xie</span>, and <span class="hlFld-ContribAuthor ">Alaric J.  Dyckman</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and StructureâActivity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (13)
                                     , 6248-6264. <a href="https://doi.org/10.1021/acs.jmedchem.6b00373" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00373%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationship%252B%252528SAR%252529%252Bof%252Ba%252BSeries%252Bof%252BEthanolamine-Based%252BDirect-Acting%252BAgonists%252Bof%252BSphingosine-1-phosphate%252B%252528S1P1%252529%26aulast%3DGilmore%26aufirst%3DJohn%2BL.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D29032016%26date%3D01072016%26date%3D14072016%26date%3D16062016%26volume%3D59%26issue%3D13%26spage%3D6248%26epage%3D6264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott H.  Watterson</span>, <span class="hlFld-ContribAuthor ">Junqing  Guo</span>, <span class="hlFld-ContribAuthor ">Steve H.  Spergel</span>, <span class="hlFld-ContribAuthor ">Charles M.  Langevine</span>, <span class="hlFld-ContribAuthor ">Robert V.  Moquin</span>, <span class="hlFld-ContribAuthor ">Ding Ren  Shen</span>, <span class="hlFld-ContribAuthor ">Melissa  Yarde</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Cvijic</span>, <span class="hlFld-ContribAuthor ">Dana  Banas</span>, <span class="hlFld-ContribAuthor ">Richard  Liu</span>, <span class="hlFld-ContribAuthor ">Suzanne J.  Suchard</span>, <span class="hlFld-ContribAuthor ">Kathleen  Gillooly</span>, <span class="hlFld-ContribAuthor ">Tracy  Taylor</span>, <span class="hlFld-ContribAuthor ">Sandra  Rex-Rabe</span>, <span class="hlFld-ContribAuthor ">David J.  Shuster</span>, <span class="hlFld-ContribAuthor ">Kim W.  McIntyre</span>, <span class="hlFld-ContribAuthor ">Georgia  Cornelius</span>, <span class="hlFld-ContribAuthor ">Celia  DâArienzo</span>, <span class="hlFld-ContribAuthor ">Anthony  Marino</span>, <span class="hlFld-ContribAuthor ">Praveen  Balimane</span>, <span class="hlFld-ContribAuthor ">Bethanne  Warrack</span>, <span class="hlFld-ContribAuthor ">Luisa  Salter-Cid</span>, <span class="hlFld-ContribAuthor ">Murray  McKinnon</span>, <span class="hlFld-ContribAuthor ">Joel C.  Barrish</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">William J.  Pitts</span>, <span class="hlFld-ContribAuthor ">Jenny  Xie</span>, and <span class="hlFld-ContribAuthor ">Alaric J.  Dyckman</span>  . </span><span class="cited-content_cbyCitation_article-title">Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (6)
                                     , 2820-2840. <a href="https://doi.org/10.1021/acs.jmedchem.6b00089" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00089</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00089%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252Band%252BSelective%252BAgonists%252Bof%252BSphingosine%252B1-Phosphate%252B1%252B%252528S1P1%252529%25253A%252BDiscovery%252Band%252BSAR%252Bof%252Ba%252BNovel%252BIsoxazole%252BBased%252BSeries%26aulast%3DWatterson%26aufirst%3DScott%2BH.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D19012016%26date%3D10032016%26date%3D24032016%26date%3D28022016%26volume%3D59%26issue%3D6%26spage%3D2820%26epage%3D2840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emmanuel H.  Demont</span>, <span class="hlFld-ContribAuthor ">James M.  Bailey</span>, <span class="hlFld-ContribAuthor ">Rino A.  Bit</span>, <span class="hlFld-ContribAuthor ">Jack A.  Brown</span>, <span class="hlFld-ContribAuthor ">Colin A.  Campbell</span>, <span class="hlFld-ContribAuthor ">Nigel  Deeks</span>, <span class="hlFld-ContribAuthor ">Simon J.  Dowell</span>, <span class="hlFld-ContribAuthor ">Colin  Eldred</span>, <span class="hlFld-ContribAuthor ">Pam  Gaskin</span>, <span class="hlFld-ContribAuthor ">James R. J.  Gray</span>, <span class="hlFld-ContribAuthor ">Andrea  Haynes</span>, <span class="hlFld-ContribAuthor ">David J.  Hirst</span>, <span class="hlFld-ContribAuthor ">Duncan S.  Holmes</span>, <span class="hlFld-ContribAuthor ">Umesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Mary A.  Morse</span>, <span class="hlFld-ContribAuthor ">Greg J.  Osborne</span>, <span class="hlFld-ContribAuthor ">Jessica F.  Renaux</span>, <span class="hlFld-ContribAuthor ">Gail A. L.  Seal</span>, <span class="hlFld-ContribAuthor ">Chris A.  Smethurst</span>, <span class="hlFld-ContribAuthor ">Simon  Taylor</span>, <span class="hlFld-ContribAuthor ">Robert  Watson</span>, <span class="hlFld-ContribAuthor ">Robert  Willis</span>, and <span class="hlFld-ContribAuthor ">Jason  Witherington</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (3)
                                     , 1003-1020. <a href="https://doi.org/10.1021/acs.jmedchem.5b01512" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01512</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01512%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BTetrahydropyrazolopyridine%252Bas%252BSphingosine%252B1-Phosphate%252BReceptor%252B3%252B%252528S1P3%252529-Sparing%252BS1P1%252BAgonists%252BActive%252Bat%252BLow%252BOral%252BDoses%26aulast%3DDemont%26aufirst%3DEmmanuel%2BH.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D29092015%26date%3D22012016%26date%3D11022016%26date%3D11012016%26volume%3D59%26issue%3D3%26spage%3D1003%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon J.  Taylor</span>, <span class="hlFld-ContribAuthor ">Emmanuel H.  Demont</span>, <span class="hlFld-ContribAuthor ">James  Gray</span>, <span class="hlFld-ContribAuthor ">Nigel  Deeks</span>, <span class="hlFld-ContribAuthor ">Aarti  Patel</span>, <span class="hlFld-ContribAuthor ">Dung  Nguyen</span>, <span class="hlFld-ContribAuthor ">Maxine  Taylor</span>, <span class="hlFld-ContribAuthor ">Steve  Hood</span>, <span class="hlFld-ContribAuthor ">Robert J.  Watson</span>, <span class="hlFld-ContribAuthor ">Rino A.  Bit</span>, <span class="hlFld-ContribAuthor ">Fiona  McClure</span>, <span class="hlFld-ContribAuthor ">Holly  Ashall</span>, and <span class="hlFld-ContribAuthor ">Jason  Witherington</span>  . </span><span class="cited-content_cbyCitation_article-title">Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P1 Agonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (20)
                                     , 8236-8256. <a href="https://doi.org/10.1021/acs.jmedchem.5b01102" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01102%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNavigating%252BCYP1A%252BInduction%252Band%252BArylhydrocarbon%252BReceptor%252BAgonism%252Bin%252BDrug%252BDiscovery.%252BA%252BCase%252BHistory%252Bwith%252BS1P1%252BAgonists%26aulast%3DTaylor%26aufirst%3DSimon%2BJ.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D14072015%26date%3D01102015%26date%3D22102015%26date%3D22092015%26volume%3D58%26issue%3D20%26spage%3D8236%26epage%3D8256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikita P.  Burlutskiy</span>, <span class="hlFld-ContribAuthor ">Andrei S.  Potapov</span>. </span><span class="cited-content_cbyCitation_article-title">Approaches to the Synthesis of Dicarboxylic Derivatives of Bis(pyrazol-1-yl)alkanes. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (2)
                                     , 413. <a href="https://doi.org/10.3390/molecules26020413" title="DOI URL">https://doi.org/10.3390/molecules26020413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26020413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26020413%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DApproaches%252Bto%252Bthe%252BSynthesis%252Bof%252BDicarboxylic%252BDerivatives%252Bof%252BBis%252528pyrazol-1-yl%252529alkanes%26aulast%3DBurlutskiy%26aufirst%3DNikita%2BP.%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D2%26spage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Taylor</span>. </span><span class="cited-content_cbyCitation_article-title">The Integrated Optimization of Safety and DMPK Properties Enabling Preclinical Development: A Case History with S1P
              1
              Agonists. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 603-630. <a href="https://doi.org/10.1002/9783527801756.ch22" title="DOI URL">https://doi.org/10.1002/9783527801756.ch22</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527801756.ch22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527801756.ch22%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BIntegrated%252BOptimization%252Bof%252BSafety%252Band%252BDMPK%252BProperties%252BEnabling%252BPreclinical%252BDevelopment%25253A%252BA%252BCase%252BHistory%252Bwith%252BS1P%252B1%252BAgonists%26aulast%3DTaylor%26aufirst%3DSimon%26date%3D2018%26date%3D2018%26spage%3D603%26epage%3D630%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DEarly%252BDrug%252BDevelopment%26aulast%3DGiordanetto%26aufirst%3DFabrizio%2BGiordanetto%26date%3D2018%26volume%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dominik  Vogt</span>, <span class="hlFld-ContribAuthor ">Holger  Stark</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2017,</strong> <em>37 </em>
                                    (1)
                                     , 3-51. <a href="https://doi.org/10.1002/med.21402" title="DOI URL">https://doi.org/10.1002/med.21402</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21402%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTherapeutic%252BStrategies%252Band%252BPharmacological%252BTools%252BInfluencing%252BS1P%252BSignaling%252Band%252BMetabolism%26aulast%3DVogt%26aufirst%3DDominik%26date%3D2017%26date%3D2016%26volume%3D37%26issue%3D1%26spage%3D3%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junqing  Guo</span>, <span class="hlFld-ContribAuthor ">Scott H.  Watterson</span>, <span class="hlFld-ContribAuthor ">Steven H.  Spergel</span>, <span class="hlFld-ContribAuthor ">James  Kempson</span>, <span class="hlFld-ContribAuthor ">Charles M.  Langevine</span>, <span class="hlFld-ContribAuthor ">Ding Ren  Shen</span>, <span class="hlFld-ContribAuthor ">Melissa  Yarde</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Cvijic</span>, <span class="hlFld-ContribAuthor ">Dana  Banas</span>, <span class="hlFld-ContribAuthor ">Richard  Liu</span>, <span class="hlFld-ContribAuthor ">Suzanne J.  Suchard</span>, <span class="hlFld-ContribAuthor ">Kathleen  Gillooly</span>, <span class="hlFld-ContribAuthor ">Tracy  Taylor</span>, <span class="hlFld-ContribAuthor ">Sandra  Rex-Rabe</span>, <span class="hlFld-ContribAuthor ">David J.  Shuster</span>, <span class="hlFld-ContribAuthor ">Kim W.  McIntyre</span>, <span class="hlFld-ContribAuthor ">Georgia  Cornelius</span>, <span class="hlFld-ContribAuthor ">Celia  DâArienzo</span>, <span class="hlFld-ContribAuthor ">Anthony  Marino</span>, <span class="hlFld-ContribAuthor ">Praveen  Balimane</span>, <span class="hlFld-ContribAuthor ">Luisa  Salter-Cid</span>, <span class="hlFld-ContribAuthor ">Murray  McKinnon</span>, <span class="hlFld-ContribAuthor ">Joel C.  Barrish</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">William J.  Pitts</span>, <span class="hlFld-ContribAuthor ">Jenny  Xie</span>, <span class="hlFld-ContribAuthor ">Alaric J.  Dyckman</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (10)
                                     , 2470-2474. <a href="https://doi.org/10.1016/j.bmcl.2016.03.105" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.03.105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.03.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.03.105%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Band%252Bsynthesis%252Bof%252Bpotent%252Band%252Bselective%252Bpyridyl-isoxazole%252Bbased%252Bagonists%252Bof%252Bsphingosine-1-phosphate%252B1%252B%252528S1P1%252529%26aulast%3DGuo%26aufirst%3DJunqing%26date%3D2016%26volume%3D26%26issue%3D10%26spage%3D2470%26epage%3D2474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pol  SanllehÃ­</span>, <span class="hlFld-ContribAuthor ">JosÃ©-Luis  Abad</span>, <span class="hlFld-ContribAuthor ">Josefina  Casas</span>, <span class="hlFld-ContribAuthor ">Antonio  Delgado</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of sphingosine-1-phosphate metabolism (sphingosine kinases and sphingosine-1-phosphate lyase). </span><span class="cited-content_cbyCitation_journal-name">Chemistry and Physics of Lipids</span><span> <strong>2016,</strong> <em>197 </em>, 69-81. <a href="https://doi.org/10.1016/j.chemphyslip.2015.07.007" title="DOI URL">https://doi.org/10.1016/j.chemphyslip.2015.07.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chemphyslip.2015.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chemphyslip.2015.07.007%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520and%2520Physics%2520of%2520Lipids%26atitle%3DInhibitors%252Bof%252Bsphingosine-1-phosphate%252Bmetabolism%252B%252528sphingosine%252Bkinases%252Band%252Bsphingosine-1-phosphate%252Blyase%252529%26aulast%3DSanlleh%25C3%25AD%26aufirst%3DPol%26date%3D2016%26volume%3D197%26spage%3D69%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John H.  Ryan</span>, <span class="hlFld-ContribAuthor ">Jason A.  Smith</span>, <span class="hlFld-ContribAuthor ">Christopher  Hyland</span>, <span class="hlFld-ContribAuthor ">Adam G.  Meyer</span>, <span class="hlFld-ContribAuthor ">Charlotte C.  Williams</span>, <span class="hlFld-ContribAuthor ">Alex C.  Bissember</span>, <span class="hlFld-ContribAuthor ">Jeremy  Just</span>. </span><span class="cited-content_cbyCitation_article-title">Seven-Membered Rings. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 531-573. <a href="https://doi.org/10.1016/B978-0-08-100024-3.00016-7" title="DOI URL">https://doi.org/10.1016/B978-0-08-100024-3.00016-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-100024-3.00016-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-100024-3.00016-7%26sid%3Dliteratum%253Aachs%26atitle%3DSeven-Membered%252BRings%26aulast%3DRyan%26aufirst%3DJohn%2BH.%26date%3D2015%26spage%3D531%26epage%3D573%26pub%3DElsevier%26date%3D2015%26volume%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0002.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected examples of published S1P<sub>1</sub> receptor agonists or prodrugs thereof.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0003.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of indazole propionic acid <b>10</b> on circulating lymphocyte levels in rats after (a) single dose in the range 0.1â3 mg/kg or (b) 7-day repeat dosing at 0.3 and 1 mg/kg, showing reversal within 24 h after the final dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0004.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Three-dimensional rendering highlighting difference in overall shape of different templates represented by benzoxazepines <b>29b</b> (âlinearâ) and <b>30a</b> (âsteppedâ).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0005.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CD3+ lymphocyte counts in rat blood after oral dose with benzoxazepine <b>26a</b> (0.1â3 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0006.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of benzoxazepine <b>26a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0007.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of a range of doses of compound <b>27c</b> on CD3+ lymphocyte counts in rat blood.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0008.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of single oral doses of compounds <b>31a</b> and <b>31b</b> on CD3+ lymphocyte counts in rat blood.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Compound <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PPh<sub>3</sub>, NBS, THF, 0 Â°C; (b) H<sub>2</sub>SO<sub>4</sub>, EtOH, reflux, 97%; (c) KO<sup>t</sup>Bu, EtOH, 60 Â°C, 63% (2 steps); (d) LiOH, H<sub>2</sub>O, EtOH, 40 Â°C, 62%.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Compound <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BrCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Et, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 Â°C, 66%; (b) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 50 Â°C, 87%; (c) EDC, HOBt, DMF, 120 Â°C, 58%; (d) NaOH, EtOH, room temperature, 55%.</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) Ac<sub>2</sub>O, AcOK, isoamyl nitrite, CHCl<sub>3</sub>, 0â60 Â°C; (ii) conc. HCl then NaOH, 0â30 Â°C, 91%; (b) ethyl acrylate, DBU, CH<sub>3</sub>CN, 70 Â°C, 78%; (c) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 1,4-dioxane, reflux, 78%; (d) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, reflux, 80%; (e) (i) acid, (COCl<sub>2</sub>)<sub>2</sub>, DMF cat., CH<sub>2</sub>Cl<sub>2</sub>, room temperature; (ii) hydroxyimidate, DMF, room temperature to 120 Â°C, 78%; (f) NaOH, EtOH/H<sub>2</sub>O, 60 Â°C, 99%.</p></p></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Compounds <b>11a</b>,<b>b</b> and <b>21a</b>â<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NBS, (PhCO<sub>2</sub>)<sub>2</sub>, CCl<sub>4</sub>, 80 Â°C; (b) PhCH<sub>2</sub>NH<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, MeCN, 80 Â°C, 25% (2 steps); (c) ClCH<sub>2</sub>CH<sub>2</sub>OCOCl, 4 Ã sieves, PhCl, 90 Â°C, 79%; (d) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, 34%; (e) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 50 Â°C, 58%; (f) EDC, HOBt, DMF, room temperature to 120 Â°C, 28% (<b>11a</b>), 11% (<b>11b</b>); (g) TFA, DCM, room temperature, 96% (<b>11a</b>), 88% (<b>11b</b>) ; (h) Br(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Et, EtN(iPr)<sub>2</sub>, MeCN, 80 Â°C, 93% (<b>21a</b>); (i) NaOH, EtOH/water, room temperature, 41% (<b>21a</b>); (j) Br(CH<sub>2</sub>)<sub>3</sub>CO<sub>2</sub>Et, EtN(iPr)<sub>2</sub>, MeCN, 80 Â°C, 92% (<b>21b</b>), 83% (<b>21c</b>); (k) NaOH, EtOH/water, room temperature, 33% (<b>21b</b>), 16% (<b>21c</b>).</p></p></figure><figure data-id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Compounds <b>12a</b>,<b>b</b> and <b>22a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Tf<sub>2</sub>O, Et<sub>3</sub>N, DCM, â10 Â°C, 51%; (b) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 150 Â°C, 99%; (c) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 50 Â°C, 39%; (d) NaH, 3-Cl-4-<sup>i</sup>PrO-PhCO<sub>2</sub>Me or 3-CN-4-<sup>i</sup>PrO-PhCO<sub>2</sub>Me, THF, reflux, 96% (<b>12a</b>), 86% (<b>12b</b>); (e) TFA, DCM, reflux (100%, <b>12a</b>,<b>b</b>); (f) Br(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>tBu, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 Â°C, 25% (<b>22a</b>); (g) HCl, 1,4-dioxane, room temperature, 54% (<b>22a</b>); (h) BrCH<sub>2</sub>CO<sub>2</sub>tBu, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 Â°C, 92% (<b>22b</b>); (i) HCl, 1,4-dioxane, room temperature, 94% (<b>22b</b>).</p></p></figure><figure data-id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0014.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Compounds <b>14a</b>,<b>b</b>, <b>25</b>, and <b>28a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Boc<sub>2</sub>O, DCM, room temperature, 66%; (b) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 65 Â°C, 91%; (c) NaH, 3-Cl-4-<sup>i</sup>PrO-PhCO<sub>2</sub>Me, THF, reflux, 80% (<b>14a</b>) or 3-CN-4-<sup>i</sup>PrO-PhCOCl, DIPEA, DMAP, DMF, 95 Â°C, 31% (<b>14b</b>); (d) HCl, 1,4-dioxane, room temperature, 90% (<b>14a</b>), 76% (<b>14b</b>); (e) BrCH<sub>2</sub>CO<sub>2</sub>Et, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 60 Â°C, 32%; (f) LiOH, THF/MeOH/water, 100 Â°C, 85%; (g) NBS, DCM, microwave, 100 Â°C for (<b>28a</b>), or NBS, DCM, reflux for (<b>28b)</b>, 45%; (h) <b>28a</b>, tBuO<sub>2</sub>CCH<sub>2</sub>CO<sub>2</sub>H, K<sub>2</sub>CO<sub>3</sub>, MeCN, microwave 100 Â°C, 51% (2 steps) followed by HCl, 1,4-dioxane, room temperature, 92%; <b>28b</b>, EtO<sub>2</sub>CCH<sub>2</sub>CO<sub>2</sub>H, K<sub>2</sub>CO<sub>3</sub>, THF, microwave 100 Â°C followed by LiOH, MeOH/THF/water, microwave 100 Â°C, 21% (2 steps).</p></p></figure><figure data-id="sch7" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0015.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Compounds <b>15a</b> and <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) 3-Cl-4-<sup>i</sup>PrO-PhCO<sub>2</sub>Cl, (COCl<sub>2</sub>)<sub>2</sub>, DMF cat., DCM, room temperature; (ii) amidoxime, DMF, room temperature to 120 Â°C, 82% (2 steps); (b) HCl, 1,4-dioxane, room temperature, 99%; (c) Br(CH<sub>2</sub>)<sub>3</sub>COOC<sub>2</sub>H<sub>5</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 Â°C, 70%; (d) NaOH, EtOH/H<sub>2</sub>O, room temperature, 79%.</p></p></figure><figure data-id="sch8" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0016.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Compounds <b>16a</b>,<b>b</b> and <b>23a</b>â<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DIAD, PPh<sub>3</sub>, THF, room temperature, 55%; (b) TFA, DCM, room temperature; then Et<sub>3</sub>N, toluene, 100 Â°C, 59%; (c) BH<sub>3</sub>.THF, THF, room temperature to 65 Â°C, 97%; (d) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, room temperature, 89%; (e) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 Â°C, 90%; (f) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 60 Â°C, 78%; (g) 4-Cl-3-iPrOPhCO<sub>2</sub>H or 4-CN-3-iPrOPhCO<sub>2</sub>H, EDC, HOBt, DMF, room temperature to 120 Â°C, 31% (<b>16a</b>,<b>b</b>); (h) HCl, 1,4-dioxane, room temperature, 71% (<b>16a</b>), 73% (<b>16b</b>); (i) Br(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Et, EtN(iPr)<sub>2</sub>, MeCN, 80 Â°C, 97% (<b>23a</b>), 72% (<b>23b</b>); (j) NaOH, EtOH/water, room temperature, 47% (<b>23a</b>), 10% (<b>23b</b>); (k) Br(CH<sub>2</sub>)<sub>3</sub>CO<sub>2</sub>Et, EtN(iPr)<sub>2</sub>, MeCN, 80 Â°C, 62%; (l) NaOH, EtOH/water, room temperature, 28%.</p></p></figure><figure data-id="sch9" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0017.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Compounds <b>17a</b>,<b>b</b> and <b>27a</b>â<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 60 Â°C, 93%; (b) 4-Cl-3-iPrOPhCO<sub>2</sub>H, EDC, HOBt, DMF, room temperature to 120 Â°C, 29% (<b>17a</b>) or (i) 4-CN-3-iPrOPhCO<sub>2</sub>H, (COCl<sub>2</sub>)<sub>2</sub>, DMF cat., CH<sub>2</sub>Cl<sub>2</sub>, room temperature; (ii) hydroxyimidate, toluene/pyridine, room temperature to reflux, 78%, (<b>17b</b>); (b) HCl, 1,4-dioxane, room temperature, 82% (<b>17a</b>), 95% (<b>17b</b>); (c) BrCH<sub>2</sub>CO<sub>2</sub>Et, Cs<sub>2</sub>CO<sub>3</sub>, DMF, room temperature to 60 Â°C, 62%; (d) NaOH, EtOH/H<sub>2</sub>O, 40 Â°C, 89%; (e) <i>t</i>-butyl acrylate, EtN(iPr)<sub>2</sub>, MeOH, 90 Â°C; (f) HCl, 1,4-dioxane, room temperature, 46% (2 steps); (g) Br(CH<sub>2</sub>)<sub>3</sub>COOC<sub>2</sub>H<sub>5</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, 90 Â°C, 90%; (h) NaOH, EtOH/H<sub>2</sub>O, room temperature, 63%.</p></p></figure><figure data-id="sch10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0018.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Compounds <b>18a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DIAD, PPh<sub>3</sub>, THF, 0 Â°C to room temperature; (b) TFA, DCM; then Et<sub>3</sub>N, toluene, 100 Â°C, 44% (2 steps); (c) HBr, 110 Â°C; (d) BnBr, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 Â°C, 75% (2 steps); (e) LiAlH<sub>4</sub>, THF, 0â60 Â°C, 95%; (f) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, room temperature, 70%; (g) H<sub>2</sub>/Pd/C, THF/EtOH, room temperature, 100%; (h) Tf<sub>2</sub>O, Py, 0 Â°C, 100%; (i) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 Â°C, 72%; (j) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 60 Â°C, 96%; (k) 4-Cl-3-iPrOPhCO<sub>2</sub>H or 4-CN-3-iPrOPhCO<sub>2</sub>H, EDC, HOBt, DMF, room temperature to 120 Â°C, 56% (<b>18a</b>), 92% (<b>18b</b>); (l) HCl, 1,4-dioxane, room temperature, 76% (<b>18a</b>), 90% (<b>18b</b>).</p></p></figure><figure data-id="sch11" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0019.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Compounds <b>19a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CHI<sub>3</sub>, tBuONO, THF, room temperature to 50 Â°C, 68%; (b) BH<sub>3</sub>Â·THF, THF, reflux, 76%; (c) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, room temperature, 100%; (d) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 Â°C, 74%; (e) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 55 Â°C, 82%; (f) 4-Cl-3-iPrOPhCO<sub>2</sub>H or 4-CN-3-iPrOPhCO<sub>2</sub>H, EDC, HOBt, DMF, room temperature to 90 Â°C, 16% (<b>19a</b>), 46% (<b>19b</b>); (g) HCl, 1,4-dioxane, room temperature, 69% (<b>19a</b>), 86% (<b>19b</b>).</p></p></figure><figure data-id="sch12" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0020.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Compound <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 60 Â°C, 51%; (b) NaH, 4-Cl-3-iPrOPhCO<sub>2</sub>Me, THF, room temperature to reflux, 90%; (c) LDA, THF, AllBr, â78 Â°C, 60%; (d) O<sub>3</sub>, DCM, â78 Â°C; then THF, BH<sub>3</sub>Â·DMS, room temperature to 40 Â°C, 19%; (e) DIAD, PPh<sub>3</sub>, DCM, room temperature, 13%.</p></p></figure><figure data-id="sch13" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0021.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Compounds <b>29a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DIAD, PPh<sub>3</sub>, toluene, 80 Â°C, 57%; (b) p-TsOH, MeOH, room temperature, 81%; (c) TFA, DCM, room temperature; then Et<sub>3</sub>N, toluene, 100 Â°C, 73%; (d) BH<sub>3</sub>Â·THF, THF, room temperature to 65 Â°C, 86%; (e) Boc<sub>2</sub>O, aqueous Na<sub>2</sub>CO<sub>3</sub>, THF, room temperature, 88%; (f) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 Â°C, 82%; (g) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, EtOH, 50 Â°C, 95%; (h) 4-Cl-3-iPrOPhCO<sub>2</sub>H, EDC, HOBt, DMF, room temperature to 100 Â°C, 28%; (i) CrO<sub>3</sub>, H<sub>2</sub>SO<sub>4</sub>, acetone, 0 Â°C, 68%; (j) HCl, 1,4-dioxane, room temperature, 64%; (k) DessâMartin, DCM, room temperature, 88%; (l) Ph<sub>3</sub>PCHCO<sub>2</sub>Et, THF, 40 Â°C, 71%; (m) H<sub>2</sub>/Pd/C, EtOH, room temperature, 54%; (n) aq NaOH, EtOH, room temperature, 98%; (o) HCl, 1,4-dioxane, room temperature, 61%.</p></p></figure><figure data-id="sch14" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/medium/jm-2014-010336_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0022.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Compounds <b>30a</b>,<b>b</b> and <b>31a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-24/jm5010336/20141218/images/large/jm-2014-010336_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5010336&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Ph<sub>3</sub>PâCHCOOC<sub>2</sub>H<sub>5</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 Â°C, 95%; (b) BocNH(CH<sub>2</sub>)<sub>2</sub>OH, PPh<sub>3</sub>, DIAD, THF, 0 Â°C, 94%; (c), CF<sub>3</sub>COOH, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 100%; (d) DBU, THF, 60 Â°C, 97%; (e) Boc<sub>2</sub>O, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 92%; (f) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 96 Â°C, 92%; (g) LiBH<sub>4</sub>, EtOH/Et<sub>2</sub>O, room temperature, 96%; (h) DMSO, DIPEA, then Py.SO<sub>3</sub>, Py, 0 Â°C, 100%; (i) Ph<sub>2</sub>POCH<sub>2</sub>OMe, LDA, THF, â78 Â°C to room temperature, then NaH, THF, room temperature, 42% (2 steps); (j) PCC, DCM, room temperature, 56% ; (k) NH<sub>2</sub>OHÂ·HCl, NaHCO<sub>3</sub>, MeOH, reflux, 100%; (l) 4-Cl-3-iPrOPhCO<sub>2</sub>Cl, Et<sub>3</sub>N, MeCN, room temperature to 100 Â°C, 10%; (m) aqueous NaOH, EtOH, 60 Â°C, 85%; (n) HCl, 1,4-dioxane, room temperature, 35%; (o) Ph<sub>3</sub>PâCHCOOC<sub>2</sub>H<sub>5</sub>, 0 Â°C to room temperature, 94%; (p) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, Pd/C, H<sub>2</sub> (1 atm), EtOH, room temperature, 100%; (q) aqueous NH<sub>2</sub>OH, EtOH, reflux, 96%; (r) 4-Cl-3-iPrOPhCO<sub>2</sub>Cl, Et<sub>3</sub>N, MeCN, room temperature to 100 Â°C, 12%; (s) aqueous NaOH, EtOH, 50 Â°C, 94%; (t) HCl, 1,4-dioxane, room temperature, 17%; (u) (i) acid, (COCl<sub>2</sub>)<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temperature; (ii) hydroxyimidate, NEt<sub>3</sub>, DMF, room temperature to 120 Â°C, 60%; (v) Separation of enantiomers by chiral chromatography, 95%; (w) NaOH, EtOH/H<sub>2</sub>O, 50 Â°C, 93%; (x) HCl, 1,4-dioxane, room temperature, 76%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56513" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56513" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Singer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobias, K.</span><span> </span><span class="NLM_article-title">Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis</span> <span class="citation_source-journal">Int. J. Clin. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">887</span><span class="NLM_x">â</span> <span class="NLM_lpage">895</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1111%2Fj.1742-1241.2011.02721.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21679286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2011&pages=887-895&author=B.+Singerauthor=A.+P.+Rossauthor=K.+Tobias&title=Oral+fingolimod+for+the+treatment+of+patients+with+relapsing+forms+of+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis</span></div><div class="casAuthors">Singer, B.; Ross, A. P.; Tobias, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">887-895</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1742-1241</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Fingolimod, a sphingosine 1-phosphate receptor modulator, is the first oral treatment approved by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (MS).  The aim of this review was to provide a concise, comprehensive overview of the clin. relevant mechanism of action, efficacy and safety information available for fingolimod.  Key data were derived from two international, Phase III, double-blind, randomised trials (TRANSFORMS and FREEDOMS) performed over 12 and 24 mo, resp., which evaluated fingolimod 0.5 and 1.25 mg daily in 1703 patients with relapsing forms of MS.  In TRANSFORMS, there was a 52% redn. in the annualised relapse rate (ARR) with fingolimod 0.5 mg vs. 30 Î¼g i.m. interferon beta-1a (0.16 vs. 0.33; p < 0.001) at 1 yr.  In FREEDOMS, there was a 55% decrease in ARR at 2 years with fingolimod 0.5 mg vs. placebo (0.18 vs. 0.40; p < 0.001).  Risk of disability progression, confirmed at 3 mo, was also reduced by 30% over the 2-yr study period with fingolimod vs. placebo (p = 0.02).  Significantly fewer new or enlarged lesions on T2-weighted images were seen in both studies (TRANSFORMS, p = 0.002 vs. interferon beta-1a at 1 yr; FREEDOMS, p < 0.001 vs. placebo at 2 years).  Overall, fingolimod 0.5 mg was well tolerated by patients.  Transient, generally asymptomatic bradycardia and infrequent atrioventricular block were seen with the administration of the first dose.  Macular edema and serious infections occurred infrequently.  Reversible, asymptomatic elevations of liver enzymes could also occur.  As the first approved oral disease-modifying treatment, fingolimod offers patients a convenient alternative to regular self-injection for the treatment of relapsing forms of MS.  In addn. to high efficacy with a relatively acceptable safety profile, fingolimod provides a therapy with a new mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVKs1Biiz177Vg90H21EOLACvtfcHk0ljqgS8I7UJtaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D&md5=8be8ad56fc253ddccb59597c041b9ff8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2011.02721.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2011.02721.x%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DA.%2BP.%26aulast%3DTobias%26aufirst%3DK.%26atitle%3DOral%2520fingolimod%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520relapsing%2520forms%2520of%2520multiple%2520sclerosis%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2011%26volume%3D65%26spage%3D887%26epage%3D895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Fujino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funeshima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitazawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amemiya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.-K.</span><span> </span><span class="NLM_article-title">Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">â</span> <span class="NLM_lpage">77</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1124%2Fjpet.102.045658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=12649354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1antb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2003&pages=70-77&author=M.+Fujinoauthor=N.+Funeshimaauthor=Y.+Kitazawaauthor=H.+Kimuraauthor=H.+Amemiyaauthor=S.+Suzukiauthor=X.-K.+Li&title=Amelioration+of+Experimental+Autoimmune+Encephalomyelitis+in+Lewis+Rats+by+FTY720+Treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment</span></div><div class="casAuthors">Fujino, Masayuki; Funeshima, Naoko; Kitazawa, Yusuke; Kimura, Hiromitsu; Amemiya, Hiroshi; Suzuki, Seiichi; Li, Xiao-Kang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-77</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Exptl. autoimmune encephalomyelitis (EAE) is a T-cell-dependent autoimmune disease that reproduces the inflammatory demyelinating pathol. of multiple sclerosis (MS).  We investigated the efficacy and mechanism of immunosuppression against EAE by administering 2-amino-[2-(4-octylphenyl) ethyl]-1,3-propanediol hydrochloride (FTY720) in Lewis rats immunized with myelin basic protein together with complete Freund's adjuvant.  FTY720 treatment almost completely protected the rats against disease.  The protection by FTY720 was assocd. with a dramatic redn. in the no. of lymphocytes staining for T-cell receptors in the spinal cord as examd. by immunohistochem.  The mRNA expression of Th1 cytokines interleukin (IL)-2, IL-6, and interferon-Î³ in the spinal cord was also reduced dramatically as assessed by reverse-transcription polymerase chain reaction.  Furthermore, lymphocytes isolated from the spleen of FTY720-treated rats were transferred into naive recipient rats against EAE manifestation by reducing both disease incidence and clin. score.  These results suggested that the protective anti-inflammatory effect of treatment with FTY720 was, to a large extent, due to the inhibition of encephalitogenic T-cell responses and/or their migration into the central nervous system and may be a potential candidate for use in treating patients with MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzq_-OyLLfCrVg90H21EOLACvtfcHk0lj05WJE1DO05A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1antb4%253D&md5=fa8fd35f8ce313790e3776a7ab820b0f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.045658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.045658%26sid%3Dliteratum%253Aachs%26aulast%3DFujino%26aufirst%3DM.%26aulast%3DFuneshima%26aufirst%3DN.%26aulast%3DKitazawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DAmemiya%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.-K.%26atitle%3DAmelioration%2520of%2520Experimental%2520Autoimmune%2520Encephalomyelitis%2520in%2520Lewis%2520Rats%2520by%2520FTY720%2520Treatment%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D305%26spage%3D70%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Comi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalban, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radue, E.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohlmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aradhye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FTY720D2201 Study Group</span><span> </span><span class="NLM_article-title">Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results</span> <span class="citation_source-journal">Mult. Scler.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1177%2F1352458509357065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=20028707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFCqu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=197-207&author=G.+Comiauthor=P.+O%E2%80%99Connorauthor=X.+Montalbanauthor=J.+Antelauthor=E.-W.+Radueauthor=G.+Karlssonauthor=H.+Pohlmannauthor=S.+Aradhyeauthor=L.+Kapposauthor=FTY720D2201+Study+Group&title=Phase+II+study+of+oral+fingolimod+%28FTY720%29+in+multiple+sclerosis%3A+3-year+results"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results</span></div><div class="casAuthors">Comi, G.; O'Connor, P.; Montalban, X.; Antel, J.; Radue, E.-W.; Karlsson, G.; Pohlmann, H.; Aradhye, S.; Kappos, L.</div><div class="citationInfo"><span class="NLM_cas:title">Multiple Sclerosis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">MUSCFZ</span>;
        ISSN:<span class="NLM_cas:issn">1352-4585</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">In a 6-mo, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized relapse rate compared with placebo in patients with relapsing multiple sclerosis (MS).  The objectives were to monitor the 36-mo, interim efficacy and safety results of the ongoing extension of this study.  In the extension (months 7-36), placebo-treated patients were re-randomized to either dose of fingolimod; fingolimod-treated patients continued at the same dose.  During months 15-24, all patients receiving fingolimod 5.0 mg switched to 1.25 mg.  Of the 250 patients who entered the extension study, 173 (69%) continued to month 36.  Most patients were free from gadolinium-enhanced lesions (88-89%) or new T2 lesions (70-78%) at month 36.  Patients receiving continuous fingolimod treatment had sustained low annualized relapse rates of 0.20-0.21, and 68-73% remained relapse-free at month 36.  Over 36 mo, nasopharyngitis (34%), headache (30%), fatigue (19%) and influenza (18%) were the most commonly reported adverse events.  Pulmonary function remained stable and blood pressure was stable after an initial increase (3-5 mmHg) during the first 6 mo of fingolimod treatment; serious adverse events included infections and skin cancer.  The low MRI and clin. disease activity at 6 mo were maintained at 36 mo with fingolimod, which was generally well tolerated by most patients.  The efficacy and safety of oral fingolimod are being further evaluated in a large phase III MS study program.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlZ0UpJLK0DrVg90H21EOLACvtfcHk0lj05WJE1DO05A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFCqu7c%253D&md5=7509750f7c949e59b23eca7027fa0d47</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1177%2F1352458509357065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1352458509357065%26sid%3Dliteratum%253Aachs%26aulast%3DComi%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DAntel%26aufirst%3DJ.%26aulast%3DRadue%26aufirst%3DE.-W.%26aulast%3DKarlsson%26aufirst%3DG.%26aulast%3DPohlmann%26aufirst%3DH.%26aulast%3DAradhye%26aufirst%3DS.%26aulast%3DKappos%26aufirst%3DL.%26aulast%3D%26atitle%3DPhase%2520II%2520study%2520of%2520oral%2520fingolimod%2520%2528FTY720%2529%2520in%2520multiple%2520sclerosis%253A%25203-year%2520results%26jtitle%3DMult.%2520Scler.%26date%3D2010%26volume%3D16%26spage%3D197%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Billich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornancin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DÃ©vay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechtcheriakova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urtz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumruker, T.</span><span> </span><span class="NLM_article-title">Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">47408</span><span class="NLM_x">â</span> <span class="NLM_lpage">47415</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1074%2Fjbc.M307687200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=13129923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=47408-47415&author=A.+Billichauthor=F.+Bornancinauthor=P.+D%C3%A9vayauthor=D.+Mechtcheriakovaauthor=N.+Urtzauthor=T.+Baumruker&title=Phosphorylation+of+the+Immunomodulatory+Drug+FTY720+by+Sphingosine+Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases</span></div><div class="casAuthors">Billich, Andreas; Bornancin, Frederic; Devay, Piroska; Mechtcheriakova, Diana; Urtz, Nicole; Baumruker, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">47408-47415</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The immunomodulatory drug FTY720 is phosphorylated in vivo, and the resulting FTY720 phosphate as a ligand for sphingosine-1-phosphate receptors is responsible for the unique biol. effects of the compd.  So far, phosphorylation of FTY720 by murine sphingosine kinase (SPHK) 1a had been documented.  We found that, while FTY720 is also phosphorylated by human SPHK1, the human type 2 isoform phosphorylates the drug 30-fold more efficiently, because of a lower Km of FTY720 for SPHK2.  Similarly, murine SPHK2 was more efficient than SPHK1a.  Among splice variants of the human SPHKs, an N-terminally extended SPHK2 isoform was even more active than SPHK2 itself.  Further SPHK superfamily members, namely ceramide kinase and a "SPHK-like" protein, failed to phosphorylate sphingosine and FTY720.  Thus, only SPHK1 and 2 appear to be capable of phosphorylating FTY720.  Using selective assay conditions, SPHK1 and 2 activities in murine tissues were measured.  While activity of SPHK2 toward sphingosine was generally lower than of SPHK1, FTY720 phosphorylation was higher under conditions favoring SPHK2.  In human endothelial cells, while activity of SPHK1 toward sphingosine was 2-fold higher than of SPHK2, FTY720 phosphorylation was 7-fold faster under SPHK2 assay conditions.  Finally, FTY720 was poorly phosphorylated in human blood as compared with rodent blood, in line with the low activity of SPHK1 and in particular of SPHK2 in human blood.  To conclude, both SPHK1 and 2 are capable of phosphorylating FTY720, but SPHK2 is quant. more important than SPHK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR5e-dVWnBT7Vg90H21EOLACvtfcHk0lj05WJE1DO05A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D&md5=26820503680682863dc76a69ea02fc7e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307687200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307687200%26sid%3Dliteratum%253Aachs%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBornancin%26aufirst%3DF.%26aulast%3DD%25C3%25A9vay%26aufirst%3DP.%26aulast%3DMechtcheriakova%26aufirst%3DD.%26aulast%3DUrtz%26aufirst%3DN.%26aulast%3DBaumruker%26aufirst%3DT.%26atitle%3DPhosphorylation%2520of%2520the%2520Immunomodulatory%2520Drug%2520FTY720%2520by%2520Sphingosine%2520Kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D47408%26epage%3D47415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Albert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¼ller-Hartwieg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knecht, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streiff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welzenbach, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ZÃ©cri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zollinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francotte, E.</span><span> </span><span class="NLM_article-title">Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5373</span><span class="NLM_x">â</span> <span class="NLM_lpage">5377</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050242f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5373-5377&author=R.+Albertauthor=K.+Hinterdingauthor=V.+Brinkmannauthor=D.+Gueriniauthor=C.+M%C3%BCller-Hartwiegauthor=H.+Knechtauthor=C.+Simeonauthor=M.+Streiffauthor=T.+Wagnerauthor=K.+Welzenbachauthor=F.+Z%C3%A9criauthor=M.+Zollingerauthor=N.+Cookeauthor=E.+Francotte&title=Novel+Immunomodulator+FTY720+Is+Phosphorylated+in+Rats+and+Humans+To+Form+a+Single+Stereoisomer.+Identification%2C+Chemical+Proof%2C+and+Biological+Characterization+of+the+Biologically+Active+Species+and+Its+Enantiomer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm050242f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050242f%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DM%25C3%25BCller-Hartwieg%26aufirst%3DC.%26aulast%3DKnecht%26aufirst%3DH.%26aulast%3DSimeon%26aufirst%3DC.%26aulast%3DStreiff%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWelzenbach%26aufirst%3DK.%26aulast%3DZ%25C3%25A9cri%26aufirst%3DF.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DN.%26aulast%3DFrancotte%26aufirst%3DE.%26atitle%3DNovel%2520Immunomodulator%2520FTY720%2520Is%2520Phosphorylated%2520in%2520Rats%2520and%2520Humans%2520To%2520Form%2520a%2520Single%2520Stereoisomer.%2520Identification%252C%2520Chemical%2520Proof%252C%2520and%2520Biological%2520Characterization%2520of%2520the%2520Biologically%2520Active%2520Species%2520and%2520Its%2520Enantiomer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5373%26epage%3D5377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Adachi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, K.</span><span> </span><span class="NLM_article-title">FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology</span> <span class="citation_source-journal">Perspect. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=19812733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A280%3ADC%252BD1MnnslSgsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=11&author=K.+Adachiauthor=K.+Chiba&title=FTY720+Story.+Its+Discovery+and+the+Following+Accelerated+Development+of+Sphingosine+1-Phosphate+Receptor+Agonists+as+Immunomodulators+Based+on+Reverse+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology</span></div><div class="casAuthors">Adachi Kunitomo; Chiba Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Perspectives in medicinal chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fingolimod (FTY720) is the first of a novel class: sphingosine 1-phosphate (S1P) receptor modulator and is currently in phase 3 clinical trials for multiple sclerosis (MS).  FTY720 was first synthesized in 1992 by chemical modification of an immunosuppressive natural product, ISP-I (myriocin).  ISP-I was isolated from the culture broth of Isaria sinclairii, a type of vegetative wasp that was an 'eternal youth' nostrum in traditional Chinese medicine.  ISP-I is an amino acid having three successive asymmetric centers and some functionalities.  We simplified the structure drastically to find a nonchiral symmetric 2-substitued-2-aminopropane-1,3-diol framework for an in vivo immunosuppressive activity (inhibition of rat skin allograft rejection test or prolonging effect on rat skin allograft survival) and finally discovered FTY720.  During the course of the lead optimization process, we encountered an unexpected dramatic change of the mechanism of action with an in vivo output unchanged.  Since it proved that FTY720 did not inhibit serine palmitoyltransferase that is the target enzyme of ISP-I, reverse pharmacological approaches have been preformed to elucidate that FTY720 is mainly phosphorylated by sphingosine kinease 2 in vivo and the phosphorylated drug acts as a potent agonist of four of the five G protein coupled receptors for S1P: S1P(1), S1P(3), S1P(4) and S1P(5).  Evidence has accumulated that immunomodulation by FTY720-P is based on agonism at the S1P(1) receptor.  Medicinal chemistry targeting S1P(1) receptor agonists is currently in progress.  The FTY720 story provides a methodology where in vivo screens rather than in vitro screens play important roles in the lead optimization.  Unlike recent drug discovery methodologies, such a strategy as adopted by the FTY720 program would more likely meet serendipity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXM2ChGVrbaBgd2Wuil24tfW6udTcc2eYM6-zvmup8N7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MnnslSgsQ%253D%253D&md5=b07a533e402ebff342a228bcad1ad452</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DK.%26aulast%3DChiba%26aufirst%3DK.%26atitle%3DFTY720%2520Story.%2520Its%2520Discovery%2520and%2520the%2520Following%2520Accelerated%2520Development%2520of%2520Sphingosine%25201-Phosphate%2520Receptor%2520Agonists%2520as%2520Immunomodulators%2520Based%2520on%2520Reverse%2520Pharmacology%26jtitle%3DPerspect.%2520Med.%2520Chem.%26date%3D2007%26volume%3D1%26spage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Matloubian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cinamon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesneski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allende, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyster, J. G.</span><span> </span><span class="NLM_article-title">Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">427</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">â</span> <span class="NLM_lpage">360</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=427&publication_year=2004&pages=355-360&author=M.+Matloubianauthor=C.+G.+Loauthor=G.+Cinamonauthor=M.+J.+Lesneskiauthor=Y.+Xuauthor=V.+Brinkmannauthor=M.+L.+Allendeauthor=R.+L.+Proiaauthor=J.+G.+Cyster&title=Lymphocyte+egress+from+thymus+and+peripheral+lymphoid+organs+is+dependent+on+S1P+receptor+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatloubian%26aufirst%3DM.%26aulast%3DLo%26aufirst%3DC.%2BG.%26aulast%3DCinamon%26aufirst%3DG.%26aulast%3DLesneski%26aufirst%3DM.%2BJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DAllende%26aufirst%3DM.%2BL.%26aulast%3DProia%26aufirst%3DR.%2BL.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26atitle%3DLymphocyte%2520egress%2520from%2520thymus%2520and%2520peripheral%2520lymphoid%2520organs%2520is%2520dependent%2520on%2520S1P%2520receptor%25201%26jtitle%3DNature%26date%3D2004%26volume%3D427%26spage%3D355%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Wei, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheu, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalan, M. D.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1228</span><span class="NLM_x">â</span> <span class="NLM_lpage">1235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1038%2Fni1269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=16273098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlShur3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=1228-1235&author=S.+H.+Weiauthor=H.+Rosenauthor=M.+P.+Matheuauthor=M.+G.+Sannaauthor=S.-K.+Wangauthor=E.+Joauthor=C.-H.+Wongauthor=I.+Parkerauthor=M.+D.+Cahalan&title=Sphingosine+1-phosphate+type+1+receptor+agonism+inhibits+transendothelial+migration+of+medullary+T+cells+to+lymphatic+sinuses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses</span></div><div class="casAuthors">Wei, Sindy H.; Rosen, Hugh; Matheu, Melanie P.; Sanna, M. Germana; Wang, Sheng-Kai; Jo, Euijung; Wong, Chi-Huey; Parker, Ian; Cahalan, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1228-1235</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate type 1 (S1P1) receptor agonists cause sequestration of lymphocytes in secondary lymphoid organs by a mechanism that is not well understood.  One hypothesis proposes that agonists act as "functional antagonists" by binding and internalizing S1P1 receptors on lymphocytes; a second hypothesis proposes instead that S1P1 agonists act on endothelial cells to prevent lymphocyte egress from lymph nodes.  Here, 2-photon imaging of living T cells in explanted lymph nodes after treatment with S1P1 agonists or antagonists has provided insight into the mechanism by which S1P1 agonists function.  The selective S1P1 agonist SEW2871 caused reversible slowing and "log-jamming" of T cells between filled medullary cords and empty sinuses, whereas motility was unaltered in diffuse cortex.  Removal or antagonist competition of SEW2871 permitted recovery of T cell motility in the parenchyma of the medulla and resumption of migration across the stromal endothelial barrier, leading to refilling of sinuses.  The authors' results provide visualization of transendothelial migration of T cells into lymphatic sinuses and suggest that S1P1 agonists act mainly on endothelial cell S1P1 receptors to inhibit lymphocyte migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT6yH1S8NBXbVg90H21EOLACvtfcHk0lgCNgOM4uub6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlShur3E&md5=1e8e381a3808c9231937e05a0c010b73</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fni1269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1269%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DS.%2BH.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMatheu%26aufirst%3DM.%2BP.%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DS.-K.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DC.-H.%26aulast%3DParker%26aufirst%3DI.%26aulast%3DCahalan%26aufirst%3DM.%2BD.%26atitle%3DSphingosine%25201-phosphate%2520type%25201%2520receptor%2520agonism%2520inhibits%2520transendothelial%2520migration%2520of%2520medullary%2520T%2520cells%2520to%2520lymphatic%2520sinuses%26jtitle%3DNat.%2520Immunol.%26date%3D2005%26volume%3D6%26spage%3D1228%26epage%3D1235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Choi, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardell, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yung, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span> </span><span class="NLM_article-title">FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">â</span> <span class="NLM_lpage">756</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=751-756&author=J.+W.+Choiauthor=S.+E.+Gardellauthor=D.+R.+Herrauthor=R.+Riveraauthor=C.-W.+Leeauthor=K.+Noguchiauthor=S.+T.+Teoauthor=Y.+C.+Yungauthor=M.+Luauthor=G.+Kennedyauthor=J.+Chun&title=FTY720+%28fingolimod%29+efficacy+in+an+animal+model+of+multiple+sclerosis+requires+astrocyte+sphingosine+1-phosphate+receptor+1+%28S1P1%29+modulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%2BW.%26aulast%3DGardell%26aufirst%3DS.%2BE.%26aulast%3DHerr%26aufirst%3DD.%2BR.%26aulast%3DRivera%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.-W.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DTeo%26aufirst%3DS.%2BT.%26aulast%3DYung%26aufirst%3DY.%2BC.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DKennedy%26aufirst%3DG.%26aulast%3DChun%26aufirst%3DJ.%26atitle%3DFTY720%2520%2528fingolimod%2529%2520efficacy%2520in%2520an%2520animal%2520model%2520of%2520multiple%2520sclerosis%2520requires%2520astrocyte%2520sphingosine%25201-phosphate%2520receptor%25201%2520%2528S1P1%2529%2520modulation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D751%26epage%3D756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Cohen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span> </span><span class="NLM_article-title">Mechanisms of fingolimodâs efficacy and adverse effects in multiple sclerosis</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">759</span><span class="NLM_x">â</span> <span class="NLM_lpage">777</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1002%2Fana.22426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21520239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltVyhtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2011&pages=759-777&author=J.+A.+Cohenauthor=J.+Chun&title=Mechanisms+of+fingolimod%E2%80%99s+efficacy+and+adverse+effects+in+multiple+sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis</span></div><div class="casAuthors">Cohen, Jeffrey A.; Chun, Jerold</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">759-777</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Until recently, all approved multiple sclerosis (MS) disease treatments were administered parenterally.  Oral fingolimod was approved in Sept. 2010 by the US Food and Drug Administration to reduce relapses and disability progression in relapsing forms of MS.  In the clin. trials that led to approval, fingolimod reduced not only acute relapses and magnetic resonance imaging lesion activity but also disability progression and brain vol. loss, suggesting preservation of tissue.  Fingolimod's mechanism of action in MS is not known with certainty.  Its active form, fingolimod-phosphate (fingolimod-P), is a sphingosine 1-phosphate receptor (S1PR) modulator that inhibits egress of lymphocytes from lymph nodes and their recirculation, potentially reducing trafficking of pathogenic cells into the central nervous system (CNS).  Fingolimod also readily penetrates the CNS, and fingolimod-P formed in situ may have direct effects on neural cells.  Fingolimod potently inhibits the MS animal model, exptl. autoimmune encephalomyelitis, but is ineffective in mice with selective deficiency of the S1P1 S1PR subtype on astrocytes despite normal expression in the immune compartment.  These findings suggest that S1PR modulation by fingolimod in both the immune system and CNS, producing a combination of beneficial anti-inflammatory and possibly neuroprotective/reparative effects, may contribute to its efficacy in MS.  In clin. trials, fingolimod was generally safe and well tolerated.  Its interaction with S1PRs in a variety of tissues largely accounts for the reported adverse effects, which were seen more frequently with doses 2.5 to 10Ã the approved 0.5mg dose.  Fingolimod's unique mechanism of action distinguishes it from all other currently approved MS therapies.  Ann Neurol 2011;69:759-777.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQ9gv8GATt7Vg90H21EOLACvtfcHk0lhVB-BqwbDxlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltVyhtLo%253D&md5=8444099f3b8b40bf8fd529e374eaf294</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fana.22426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.22426%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DJ.%2BA.%26aulast%3DChun%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520fingolimod%25E2%2580%2599s%2520efficacy%2520and%2520adverse%2520effects%2520in%2520multiple%2520sclerosis%26jtitle%3DAnn.%2520Neurol.%26date%3D2011%26volume%3D69%26spage%3D759%26epage%3D777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">758</span><span class="NLM_x">â</span> <span class="NLM_lpage">768</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1124%2Fjpet.103.062828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=14747617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2004&pages=758-768&author=M.+Forrestauthor=S.-Y.+Sunauthor=R.+Hajduauthor=J.+Bergstromauthor=D.+Cardauthor=G.+Dohertyauthor=J.+Haleauthor=C.+Keohaneauthor=C.+Meyersauthor=J.+Milliganauthor=S.+Millsauthor=N.+Nomuraauthor=H.+Rosenauthor=M.+Rosenbachauthor=G.-J.+Sheiauthor=I.+I.+Singerauthor=M.+Tianauthor=S.+Westauthor=V.+Whiteauthor=J.+Xieauthor=R.+L.+Proiaauthor=S.+Mandala&title=Immune+Cell+Regulation+and+Cardiovascular+Effects+of+Sphingosine+1-Phosphate+Receptor+Agonists+in+Rodents+Are+Mediated+via+Distinct+Receptor+Subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes</span></div><div class="casAuthors">Forrest, M.; Sun, S.-Y.; Hajdu, R.; Bergstrom, J.; Card, D.; Doherty, G.; Hale, J.; Keohane, C.; Meyers, C.; Milligan, J.; Mills, S.; Nomura, N.; Rosen, H.; Rosenbach, M.; Shei, G.-J.; Singer, I. I.; Tian, M.; West, S.; White, V.; Xie, J.; Proia, R. L.; Mandala, S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">758-768</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a bioactive lysolipid with pleiotropic functions mediated through a family of G protein-coupled receptors, S1P1,2,3,4,5.  Physiol. effects of S1P receptor agonists include regulation of cardiovascular function and immunosuppression via redistribution of lymphocytes from blood to secondary lymphoid organs.  The phosphorylated metabolite of the immunosuppressant agent FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol) and other phosphonate analogs with differential receptor selectivity were investigated.  No significant species differences in compd. potency or rank order of activity on receptors cloned from human, murine, and rat sources were obsd.  All synthetic analogs were high-affinity agonists on S1P1, with IC50 values for ligand binding between 0.3 and 14 nM.  The correlation between S1P1 receptor activation and the ED50 for lymphocyte redn. was highly significant (p < 0.001) and lower for the other receptors.  In contrast to S1P1-mediated effects on lymphocyte recirculation, three lines of evidence link S1P3 receptor activity with acute toxicity and cardiovascular regulation: compd. potency on S1P3 correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia vs. bradycardia and hypertension was consistent with affinity for S1P1 relative to S1P3; and toxicity, bradycardia, and hypertension were absent in S1P3-/- mice.  Blood pressure effects of agonists in anesthetized rats were complex, whereas hypertension was the predominant effect in conscious rats and mice.  Immunolocalization of S1P3 in rodent heart revealed abundant expression on myocytes and perivascular smooth muscle cells consistent with regulation of bradycardia and hypertension, whereas S1P1 expression was restricted to the vascular endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKo2vpih4eoLVg90H21EOLACvtfcHk0lhVB-BqwbDxlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D&md5=27183d4991bffbc5d2b88174b1386d5a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.062828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.062828%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DS.-Y.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DDoherty%26aufirst%3DG.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DKeohane%26aufirst%3DC.%26aulast%3DMeyers%26aufirst%3DC.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DMills%26aufirst%3DS.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DSinger%26aufirst%3DI.%2BI.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DProia%26aufirst%3DR.%2BL.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DImmune%2520Cell%2520Regulation%2520and%2520Cardiovascular%2520Effects%2520of%2520Sphingosine%25201-Phosphate%2520Receptor%2520Agonists%2520in%2520Rodents%2520Are%2520Mediated%2520via%2520Distinct%2520Receptor%2520Subtypes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D309%26spage%3D758%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">13839</span><span class="NLM_x">â</span> <span class="NLM_lpage">13848</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=13839-13848&author=M.+G.+Sannaauthor=J.+Liaoauthor=E.+Joauthor=C.+Alfonsoauthor=M.-Y.+Ahnauthor=M.+S.+Petersonauthor=B.+Webbauthor=S.+Lefebvreauthor=J.+Chunauthor=N.+Grayauthor=H.+Rosen&title=Sphingosine+1-Phosphate+%28S1P%29+Receptor+Subtypes+S1P1+and+S1P3%2C+Respectively%2C+Regulate+Lymphocyte+Recirculation+and+Heart+Rate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DAlfonso%26aufirst%3DC.%26aulast%3DAhn%26aufirst%3DM.-Y.%26aulast%3DPeterson%26aufirst%3DM.%2BS.%26aulast%3DWebb%26aufirst%3DB.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DSphingosine%25201-Phosphate%2520%2528S1P%2529%2520Receptor%2520Subtypes%2520S1P1%2520and%2520S1P3%252C%2520Respectively%252C%2520Regulate%2520Lymphocyte%2520Recirculation%2520and%2520Heart%2520Rate%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D13839%26epage%3D13848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Gergely, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">WallstrÃ¶m, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuesslein-Hildesheim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ZÃ©cri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traebert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltzman, M.</span><span> </span><span class="NLM_article-title">Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans</span> <span class="citation_source-journal">Mult. Scler.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">S235</span><span class="NLM_x">â</span> <span class="NLM_lpage">S236</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=S235-S236&author=P.+Gergelyauthor=E.+Wallstr%C3%B6mauthor=B.+Nuesslein-Hildesheimauthor=C.+Brunsauthor=F.+Z%C3%A9criauthor=N.+Cookeauthor=M.+Traebertauthor=T.+Tuntlandauthor=M.+Rosenbergauthor=M.+Saltzman&title=Phase+I+study+with+the+selective+S1P1%2FS1P5+receptor+modulator+BAF312+indicates+that+S1P1+rather+than+S1P3+mediates+transient+heart+rate+reduction+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGergely%26aufirst%3DP.%26aulast%3DWallstr%25C3%25B6m%26aufirst%3DE.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DZ%25C3%25A9cri%26aufirst%3DF.%26aulast%3DCooke%26aufirst%3DN.%26aulast%3DTraebert%26aufirst%3DM.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DRosenberg%26aufirst%3DM.%26aulast%3DSaltzman%26aufirst%3DM.%26atitle%3DPhase%2520I%2520study%2520with%2520the%2520selective%2520S1P1%252FS1P5%2520receptor%2520modulator%2520BAF312%2520indicates%2520that%2520S1P1%2520rather%2520than%2520S1P3%2520mediates%2520transient%2520heart%2520rate%2520reduction%2520in%2520humans%26jtitle%3DMult.%2520Scler.%26date%3D2009%26volume%3D15%26spage%3DS235%26epage%3DS236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Bolli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lescop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span> </span><span class="NLM_article-title">Synthetic Sphingosine 1-Phosphate Receptor Modulators - Opportunities and Potential Pitfalls</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">726</span><span class="NLM_x">â</span> <span class="NLM_lpage">757</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.2174%2F1568026611109060726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21261590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSmsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=726-757&author=M.+Bolliauthor=C.+Lescopauthor=O.+Nayler&title=Synthetic+Sphingosine+1-Phosphate+Receptor+Modulators+-+Opportunities+and+Potential+Pitfalls"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic sphingosine 1-phosphate receptor modulators - opportunities and potential pitfalls</span></div><div class="casAuthors">Bolli, Martin H.; Lescop, Cyrille; Nayler, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">726-757</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) evokes a plethora of physiol. responses by stimulating members of a G protein-coupled receptor family, known as S1P receptors.  Currently five different mammalian S1P receptor subtypes, S1P1-5, each with a different cellular expression pattern, were identified.  The S1P1 receptor in particular has attracted major interest throughout the pharmaceutical industry following the breakthrough discovery that this S1P receptor subtype is critically involved in the regulation of lymphocyte trafficking through secondary lymphoid organs.  Since then, examples of synthetic S1P1 agonists with lymphocyte reducing and immunomodulating activity demonstrated efficacy in numerous preclin. models of autoimmune disease and transplantation.  Notably FTY720 (fingolimod), a pro-drug that is phosphorylated in vivo and converted into a non-selective S1P1,3,4,5 receptor agonist, has been widely used to increase the understanding of S1P1 receptor biol.  Results from recently completed phase III clin. trials using FTY720 paved the way for this non-selective S1P1 receptor agonist to become the first oral therapy in multiple sclerosis, with potential expansion into many other autoimmune diseases.  This review briefly outlines the field of S1P1 receptor biol. and summarizes recent approaches in medicinal chem. to discover potent and selective S1P1 receptor agonists.  In particular, the complexity of discovering a mol. akin to FTY720 but with an improved side-effect profile will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTTZ2jfUXEtrVg90H21EOLACvtfcHk0lg0kYGm2dKDGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSmsro%253D&md5=9f6d05909fb5615126ea642f4cc19271</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F1568026611109060726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611109060726%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%26aulast%3DLescop%26aufirst%3DC.%26aulast%3DNayler%26aufirst%3DO.%26atitle%3DSynthetic%2520Sphingosine%25201-Phosphate%2520Receptor%2520Modulators%2520-%2520Opportunities%2520and%2520Potential%2520Pitfalls%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D726%26epage%3D757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Evindar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernier, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavarana, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satz, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchette, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saha, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span> </span><span class="NLM_article-title">Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2520</span><span class="NLM_x">â</span> <span class="NLM_lpage">2524</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2520-2524&author=G.+Evindarauthor=S.+G.+Bernierauthor=E.+Doyleauthor=M.+J.+Kavaranaauthor=A.+L.+Satzauthor=J.+Lorussoauthor=H.+S.+Blanchetteauthor=A.+K.+Sahaauthor=G.+Hannigauthor=B.+A.+Morganauthor=W.+F.+Westlin&title=Exploration+of+amino+alcohol+derivatives+as+novel%2C+potent%2C+and+highly+selective+sphingosine-1-phosphate+receptor+subtype-1+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEvindar%26aufirst%3DG.%26aulast%3DBernier%26aufirst%3DS.%2BG.%26aulast%3DDoyle%26aufirst%3DE.%26aulast%3DKavarana%26aufirst%3DM.%2BJ.%26aulast%3DSatz%26aufirst%3DA.%2BL.%26aulast%3DLorusso%26aufirst%3DJ.%26aulast%3DBlanchette%26aufirst%3DH.%2BS.%26aulast%3DSaha%26aufirst%3DA.%2BK.%26aulast%3DHannig%26aufirst%3DG.%26aulast%3DMorgan%26aufirst%3DB.%2BA.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DExploration%2520of%2520amino%2520alcohol%2520derivatives%2520as%2520novel%252C%2520potent%252C%2520and%2520highly%2520selective%2520sphingosine-1-phosphate%2520receptor%2520subtype-1%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2520%26epage%3D2524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Vachal, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3684</span><span class="NLM_x">â</span> <span class="NLM_lpage">3687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3684-3687&author=P.+Vachalauthor=L.+M.+Tothauthor=J.+J.+Haleauthor=L.+Yanauthor=S.+G.+Millsauthor=G.+L.+Chrebetauthor=C.+A.+Koehaneauthor=R.+Hajduauthor=J.+A.+Milliganauthor=M.+J.+Rosenbachauthor=S.+Mandala&title=Highly+selective+and+potent+agonists+of+sphingosine-1-phosphate+1+%28S1P1%29+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVachal%26aufirst%3DP.%26aulast%3DToth%26aufirst%3DL.%2BM.%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DChrebet%26aufirst%3DG.%2BL.%26aulast%3DKoehane%26aufirst%3DC.%2BA.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DHighly%2520selective%2520and%2520potent%2520agonists%2520of%2520sphingosine-1-phosphate%25201%2520%2528S1P1%2529%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3684%26epage%3D3687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neway, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parent, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strulovici, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6662</span><span class="NLM_x">â</span> <span class="NLM_lpage">6665</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0492507" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6662-6665&author=J.+J.+Haleauthor=C.+L.+Lynchauthor=W.+Newayauthor=S.+G.+Millsauthor=R.+Hajduauthor=C.+A.+Keohaneauthor=M.+J.+Rosenbachauthor=J.+A.+Milliganauthor=G.-J.+Sheiauthor=S.+A.+Parentauthor=G.+Chrebetauthor=J.+Bergstromauthor=D.+Cardauthor=M.+Ferrerauthor=P.+Hodderauthor=B.+Struloviciauthor=H.+Rosenauthor=S.+Mandala&title=A+Rational+Utilization+of+High-Throughput+Screening+Affords+Selective%2C+Orally+Bioavailable+1-Benzyl-3-carboxyazetidine+Sphingosine-1-phosphate-1+Receptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm0492507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0492507%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DNeway%26aufirst%3DW.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DParent%26aufirst%3DS.%2BA.%26aulast%3DChrebet%26aufirst%3DG.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DStrulovici%26aufirst%3DB.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DA%2520Rational%2520Utilization%2520of%2520High-Throughput%2520Screening%2520Affords%2520Selective%252C%2520Orally%2520Bioavailable%25201-Benzyl-3-carboxyazetidine%2520Sphingosine-1-phosphate-1%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6662%26epage%3D6665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Piali, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froidevaux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span> </span><span class="NLM_article-title">The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">â</span> <span class="NLM_lpage">556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1124%2Fjpet.110.176487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21345969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Kquro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=547-556&author=L.+Pialiauthor=S.+Froidevauxauthor=P.+Hessauthor=O.+Naylerauthor=M.+H.+Bolliauthor=E.+Schlosserauthor=C.+Kohlauthor=B.+Steinerauthor=M.+Clozel&title=The+Selective+Sphingosine+1-Phosphate+Receptor+1+Agonist+Ponesimod+Protects+against+Lymphocyte-Mediated+Tissue+Inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation</span></div><div class="casAuthors">Piali, Luca; Froidevaux, Sylvie; Hess, Patrick; Nayler, Oliver; Bolli, Martin H.; Schlosser, Eva; Kohl, Christopher; Steiner, Beat; Clozel, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">547-556</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Lymphocyte exit from lymph nodes and their recirculation into blood is controlled by the sphingolipid sphingosine 1-phosphate (S1P).  The cellular receptor mediating lymphocyte exit is S1P1, one of five S1P receptors.  Nonselective agonists for S1P receptors lead to blood lymphocyte count redn.  The effects of selective S1P1 agonists on blood lymphocyte count and their impact in models of lymphocyte-mediated tissue inflammation have been less investigated.  We describe here the general pharmacol. of ponesimod, (Z,Z)-5-[3-chloro-4-((2R)-2,3-dihydroxy-propoxy)-benzylidene]-2-propylimino-3-o-tolylthiazolidin-4-one, a new, potent, and orally active selective S1P1 agonist.  Ponesimod activated S1P1-mediated signal transduction with high potency (EC50 of 5.7 nM) and selectivity.  Oral administration of ponesimod to rats led to a dose-dependent decrease of blood lymphocyte count.  After discontinuation of dosing, blood lymphocyte count returned to baseline within 48 h.  Ponesimod prevented edema formation, inflammatory cell accumulation, and cytokine release in the skin of mice with delayed-type hypersensitivity.  Ponesimod also prevented the increase in paw vol. and joint inflammation in rats with adjuvant-induced arthritis.  These data show that selective activation of S1P1 using ponesimod leads to blood lymphocyte count redn. and efficacy in models of lymphocyte-mediated tissue inflammation.  Immunomodulation with a rapidly reversible S1P1-selective agonist may represent a new therapeutic approach in lymphocyte-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsVGy9rlbA3LVg90H21EOLACvtfcHk0ljv26JEKRGwdQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Kquro%253D&md5=d8e8c32a6860fde1eb07621d3cddb15d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.176487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.176487%26sid%3Dliteratum%253Aachs%26aulast%3DPiali%26aufirst%3DL.%26aulast%3DFroidevaux%26aufirst%3DS.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DSchlosser%26aufirst%3DE.%26aulast%3DKohl%26aufirst%3DC.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DThe%2520Selective%2520Sphingosine%25201-Phosphate%2520Receptor%25201%2520Agonist%2520Ponesimod%2520Protects%2520against%2520Lymphocyte-Mediated%2520Tissue%2520Inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D547%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Pelletier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafler, D. A.</span><span> </span><span class="NLM_article-title">Fingolimod for Multiple Sclerosis</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">â</span> <span class="NLM_lpage">347</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1056%2FNEJMct1101691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=22276823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1artLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=339-347&author=D.+Pelletierauthor=D.+A.+Hafler&title=Fingolimod+for+Multiple+Sclerosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Fingolimod for multiple sclerosis</span></div><div class="casAuthors">Pelletier, Daniel; Hafler, David A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">339-347</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A 37-yr-old man with multiple sclerosis was evaluated for consideration of oral immunotherapy. Six years earlier, he had reported acute monocular visual disturbance.  The diagnosis of multiple sclerosis was subsequently confirmed by means of examn. of cerebrospinal fluid, which revealed an increased IgG index and oligoclonal banding, and by abnormal results on magnetic resonance imaging (MRI).  There was no family history of multiple sclerosis.  Daily injections of glatiramer acetate were initiated at the time of diagnosis, but two consecutive annual brain MRI scans revealed substantial disease activity.  He was then switched to interferon beta therapy, but this treatment was discontinued after the patient had two episodes of acute neurol. worsening.  Monthly natalizumab therapy was then considered, but a test for JC virus antibodies was pos.  Neurol. examn. showed disk pallor and visual acuity of 20/40 in the right eye, partial internuclear ophthalmoplegia, wide-based gait, and posterior column deficits in both legs.  The patient was referred to a specialist in multiple sclerosis for consideration of oral fingolimod therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7E7D-NWq_7LVg90H21EOLACvtfcHk0ljv26JEKRGwdQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1artLc%253D&md5=6e217009d6b857582cab89b7629ba4e5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMct1101691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMct1101691%26sid%3Dliteratum%253Aachs%26aulast%3DPelletier%26aufirst%3DD.%26aulast%3DHafler%26aufirst%3DD.%2BA.%26atitle%3DFingolimod%2520for%2520Multiple%2520Sclerosis%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D339%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">David, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovarik, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmouder, R. L.</span><span> </span><span class="NLM_article-title">Clinical Pharmacokinetics of Fingolimod</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">â</span> <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.2165%2F11596550-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=22149256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=15-28&author=O.+J.+Davidauthor=J.+M.+Kovarikauthor=R.+L.+Schmouder&title=Clinical+Pharmacokinetics+of+Fingolimod"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of fingolimod</span></div><div class="casAuthors">David, Olivier J.; Kovarik, John M.; Schmouder, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-28</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review.  Fingolimod (FTY720), a sphingosine 1-phosphate receptor modulator, is the first in a new class of therapeutic compds. and is the first oral therapy approved for the treatment of relapsing forms of multiple sclerosis (MS).  Fingolimod is a structural analog of endogenous sphingosine and undergoes phosphorylation to produce fingolimod phosphate, the active moiety.  Fingolimod targets MS via effects on the immune system, and evidence from animal models indicates that it may also have actions in the central nervous system.  In phase III studies in patients with relapsing-remitting MS, fingolimod has demonstrated efficacy superior to that of an approved first-line therapy, i.m. interferon-Î²-1a, as well as placebo, with benefits extending across clin. and magnetic resonance imaging measures.  The pharmacokinetic profiles of fingolimod and fingolimod phosphate have been extensively investigated in studies in healthy volunteers, renal transplant recipients (the indication for which fingolimod was initially under clin. development, but the development was subsequently discontinued) and MS patients.  Results from these studies have demonstrated that fingolimod is efficiently absorbed, with an oral bioavailability of >90%, and its absorption is unaffected by dietary intake, therefore it can be taken without regard to meals.  Fingolimod and fingolimod phosphate have a half-life of 6-9 days, and steady-state pharmacokinetics are reached after 1-2 mo of daily dosing.  The long half-life of fingolimod, together with its slow absorption, means that fingolimod has a fiat concn. profile over time with once-daily dosing.  Fingolimod and fingolimod phosphate show dose-proportional exposure in single- and multiple-dose studies over a range of 0.125-5 mg; hence, there is a predictable relationship between dose and systemic exposure.  Furthermore, fingolimod and fingolimod phosphate exhibit low to moderate intersubject pharmacokinetic variability.  Fingolimod is extensively metabolized, with biotransformation occurring via three main pathways: (i) reversible phosphorylation to fingolimod phosphate; (ii) hydroxylation and oxidn. to yield a series of inactive carboxylic acid metabolites; and (iii) formation of non-polar ceramides.  Fingolimod is largely cleared through metab. by cytochrome P 450 (CYP) 4F2.  Since few drugs are metabolized by CYP4F2, fingolimod would be expected to have a relatively low potential for drug-drug interactions.  This is supported by data from in vitro studies indicating that fingolimod and fingolimod phosphate have little or no capacity to inhibit and no capacity to induce other major drug-metabolizing CYP enzymes at therapeutically relevant steady-state blood concns.  Population pharmacokinetic evaluations indicate that CYP3A inhibitors and CYP3A inducers have no effect or only a weak effect on the pharmacokinetics of fingolimod and fingolimod phosphate.  However, blood concns. of fingolimod and fingolimod phosphate are increased moderately when fingolimod is coadministered with ketoconazole, an inhibitor of CYP4F2.  The pharmacokinetics of fingolimod are unaffected by renal impairment or mild-to-moderate hepatic impairment.  However, exposure to fingolimod is increased in patients with severe hepatic impairment.  No clin. relevant effects of age, sex or ethnicity on the pharmacokinetics of fingolimod have been obsd.  Fingolimod is thus a promising new therapy for eligible patients with MS, with a predictable pharmacokinetic profile that allows effective once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoxIUshcr8m7Vg90H21EOLACvtfcHk0liDgTtzixnBDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D&md5=a1a6d271470f6c297892ef00f0fe6ec6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2165%2F11596550-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596550-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DDavid%26aufirst%3DO.%2BJ.%26aulast%3DKovarik%26aufirst%3DJ.%2BM.%26aulast%3DSchmouder%26aufirst%3DR.%2BL.%26atitle%3DClinical%2520Pharmacokinetics%2520of%2520Fingolimod%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2012%26volume%3D51%26spage%3D15%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Montanari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarparin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleeson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braggio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longhi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, T.</span><span> </span><span class="NLM_article-title">Application of drug efficiency index in drug discovery: a strategy towards low therapeutic dose</span> <span class="citation_source-journal">Exp. Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">â</span> <span class="NLM_lpage">920</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1517%2F17460441.2011.602968" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=913-920&author=D.+Montanariauthor=E.+Chiarparinauthor=M.+P.+Gleesonauthor=S.+Braggioauthor=R.+Longhiauthor=K.+Valkoauthor=T.+Rossi&title=Application+of+drug+efficiency+index+in+drug+discovery%3A+a+strategy+towards+low+therapeutic+dose"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1517%2F17460441.2011.602968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2011.602968%26sid%3Dliteratum%253Aachs%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DChiarparin%26aufirst%3DE.%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DLonghi%26aufirst%3DR.%26aulast%3DValko%26aufirst%3DK.%26aulast%3DRossi%26aufirst%3DT.%26atitle%3DApplication%2520of%2520drug%2520efficiency%2520index%2520in%2520drug%2520discovery%253A%2520a%2520strategy%2520towards%2520low%2520therapeutic%2520dose%26jtitle%3DExp.%2520Opin.%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D913%26epage%3D920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St-Gallay, S. A.</span><span> </span><span class="NLM_article-title">The influence of the âorganizational factorâ on compound quality in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">â</span> <span class="NLM_lpage">765</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=749-765&author=P.+D.+Leesonauthor=S.+A.+St-Gallay&title=The+influence+of+the+%E2%80%98organizational+factor%E2%80%99+on+compound+quality+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSt-Gallay%26aufirst%3DS.%2BA.%26atitle%3DThe%2520influence%2520of%2520the%2520%25E2%2580%2598organizational%2520factor%25E2%2580%2599%2520on%2520compound%2520quality%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D749%26epage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Hughes, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellsworth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fobian, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilles, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger-Burke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wager, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span> </span><span class="NLM_article-title">Physiochemical drug properties associated with in vivo toxicological outcomes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4872</span><span class="NLM_x">â</span> <span class="NLM_lpage">4875</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0liDgTtzixnBDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4872%26epage%3D4875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">McKeown, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giblin, G. M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorthioir, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blunt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewell, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdhury, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessell, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pipe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span> </span><span class="NLM_article-title">Identification of novel pyrazole acid antagonists for the EP1 receptor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4767</span><span class="NLM_x">â</span> <span class="NLM_lpage">4771</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4767-4771&author=S.+C.+McKeownauthor=A.+Hallauthor=G.+M.+P.+Giblinauthor=O.+Lorthioirauthor=R.+Bluntauthor=X.+Q.+Lewellauthor=R.+J.+Wilsonauthor=S.+H.+Brownauthor=A.+Chowdhuryauthor=T.+Colemanauthor=S.+P.+Watsonauthor=I.+P.+Chessellauthor=A.+Pipeauthor=N.+Claytonauthor=P.+Goldsmith&title=Identification+of+novel+pyrazole+acid+antagonists+for+the+EP1+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeown%26aufirst%3DS.%2BC.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DGiblin%26aufirst%3DG.%2BM.%2BP.%26aulast%3DLorthioir%26aufirst%3DO.%26aulast%3DBlunt%26aufirst%3DR.%26aulast%3DLewell%26aufirst%3DX.%2BQ.%26aulast%3DWilson%26aufirst%3DR.%2BJ.%26aulast%3DBrown%26aufirst%3DS.%2BH.%26aulast%3DChowdhury%26aufirst%3DA.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DWatson%26aufirst%3DS.%2BP.%26aulast%3DChessell%26aufirst%3DI.%2BP.%26aulast%3DPipe%26aufirst%3DA.%26aulast%3DClayton%26aufirst%3DN.%26aulast%3DGoldsmith%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520pyrazole%2520acid%2520antagonists%2520for%2520the%2520EP1%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4767%26epage%3D4771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parent, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickham, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P1) Receptor Agonists with Exceptional Selectivity against S1P2 and S1P3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6169</span><span class="NLM_x">â</span> <span class="NLM_lpage">6173</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0503244" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6169-6173&author=Z.+Liauthor=W.+Chenauthor=J.+J.+Haleauthor=C.+L.+Lynchauthor=S.+G.+Millsauthor=R.+Hajduauthor=C.+A.+Keohaneauthor=M.+J.+Rosenbachauthor=J.+A.+Milliganauthor=G.-J.+Sheiauthor=G.+Chrebetauthor=S.+A.+Parentauthor=J.+Bergstromauthor=D.+Cardauthor=M.+Forrestauthor=E.+J.+Quackenbushauthor=L.+A.+Wickhamauthor=H.+Vargasauthor=R.+M.+Evansauthor=H.+Rosenauthor=S.+Mandala&title=Discovery+of+Potent+3%2C5-Diphenyl-1%2C2%2C4-oxadiazole+Sphingosine-1-phosphate-1+%28S1P1%29+Receptor+Agonists+with+Exceptional+Selectivity+against+S1P2+and+S1P3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm0503244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0503244%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DChrebet%26aufirst%3DG.%26aulast%3DParent%26aufirst%3DS.%2BA.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DQuackenbush%26aufirst%3DE.%2BJ.%26aulast%3DWickham%26aufirst%3DL.%2BA.%26aulast%3DVargas%26aufirst%3DH.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Potent%25203%252C5-Diphenyl-1%252C2%252C4-oxadiazole%2520Sphingosine-1-phosphate-1%2520%2528S1P1%2529%2520Receptor%2520Agonists%2520with%2520Exceptional%2520Selectivity%2520against%2520S1P2%2520and%2520S1P3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6169%26epage%3D6173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Demont, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arpino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bit, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deeks, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heightman, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panchal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witherington, J.</span><span> </span><span class="NLM_article-title">Discovery of a Brain-Penetrant S1P3-Sparing Direct Agonist of the S1P1 and S1P5 Receptors Efficacious at Low Oral Dose</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6724</span><span class="NLM_x">â</span> <span class="NLM_lpage">6733</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200609t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6724-6733&author=E.+H.+Demontauthor=S.+Arpinoauthor=R.+A.+Bitauthor=C.+A.+Campbellauthor=N.+Deeksauthor=S.+Desaiauthor=S.+J.+Dowellauthor=P.+Gaskinauthor=J.+R.+J.+Grayauthor=L.+A.+Harrisonauthor=A.+Haynesauthor=T.+D.+Heightmanauthor=D.+S.+Holmesauthor=P.+G.+Humphreysauthor=U.+Kumarauthor=M.+A.+Morseauthor=G.+J.+Osborneauthor=T.+Panchalauthor=K.+L.+Philpottauthor=S.+Taylorauthor=R.+Watsonauthor=R.+Willisauthor=J.+Witherington&title=Discovery+of+a+Brain-Penetrant+S1P3-Sparing+Direct+Agonist+of+the+S1P1+and+S1P5+Receptors+Efficacious+at+Low+Oral+Dose"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm200609t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200609t%26sid%3Dliteratum%253Aachs%26aulast%3DDemont%26aufirst%3DE.%2BH.%26aulast%3DArpino%26aufirst%3DS.%26aulast%3DBit%26aufirst%3DR.%2BA.%26aulast%3DCampbell%26aufirst%3DC.%2BA.%26aulast%3DDeeks%26aufirst%3DN.%26aulast%3DDesai%26aufirst%3DS.%26aulast%3DDowell%26aufirst%3DS.%2BJ.%26aulast%3DGaskin%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DHarrison%26aufirst%3DL.%2BA.%26aulast%3DHaynes%26aufirst%3DA.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DHumphreys%26aufirst%3DP.%2BG.%26aulast%3DKumar%26aufirst%3DU.%26aulast%3DMorse%26aufirst%3DM.%2BA.%26aulast%3DOsborne%26aufirst%3DG.%2BJ.%26aulast%3DPanchal%26aufirst%3DT.%26aulast%3DPhilpott%26aufirst%3DK.%2BL.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DWillis%26aufirst%3DR.%26aulast%3DWitherington%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520Brain-Penetrant%2520S1P3-Sparing%2520Direct%2520Agonist%2520of%2520the%2520S1P1%2520and%2520S1P5%2520Receptors%2520Efficacious%2520at%2520Low%2520Oral%2520Dose%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6724%26epage%3D6733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Beaudry, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N. K.</span><span> </span><span class="NLM_article-title">Determination of drugâplasma protein binding using human serum albumin chromatographic column and multiple linear regression model</span> <span class="citation_source-journal">Biomed. Chromatogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">â</span> <span class="NLM_lpage">406</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1002%2F%28SICI%291099-0801%28199910%2913%3A6%3C401%3A%3AAID-BMC899%3E3.0.CO%3B2-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=10477897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADyaK1MXms1Wktb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=401-406&author=F.+Beaudryauthor=M.+Coutuauthor=N.+K.+Brown&title=Determination+of+drug%E2%80%93plasma+protein+binding+using+human+serum+albumin+chromatographic+column+and+multiple+linear+regression+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of drug-plasma protein binding using human serum albumin chromatographic column and multiple linear regression model</span></div><div class="casAuthors">Beaudry, Francis; Coutu, Michel; Brown, Nigel K.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedical Chromatography</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">401-406</span>CODEN:
                <span class="NLM_cas:coden">BICHE2</span>;
        ISSN:<span class="NLM_cas:issn">0269-3879</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Reversible attachment to serum proteins plays a significant role in pharmacokinetics and pharmacodynamics, and a clear understanding of this process is fundamental in the development of the rational use of many therapeutics agents.  Over the last few years, it has been demonstrated that immobilized human serum albumin (HSA) could be used to est. plasma protein binding.  A series of 40 structurally unrelated pharmaceutical compds. were chromatographed on an immobilized HSA column in order to construct a protein binding "calibration curve" and multiple linear regression system.  When studying the relationship between the chromatog. retention and the percentage of binding detd. in vitro, a good correlation can be obsd. (r2 = 0.799) using a wide variety of compds. with different binding affinities (from 0 to 99% binding).  Using a quant. structure-retention relationships (QSRR) approach to analyzing chromatog. data, the correlation was improved compared to the traditional approach (r2=0.824).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmRO3uzmkjX7Vg90H21EOLACvtfcHk0lgtHKgS_IpEiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXms1Wktb4%253D&md5=172b4ea614105afcfb9e3b0a63eb3177</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291099-0801%28199910%2913%3A6%3C401%3A%3AAID-BMC899%3E3.0.CO%3B2-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291099-0801%2528199910%252913%253A6%253C401%253A%253AAID-BMC899%253E3.0.CO%253B2-C%26sid%3Dliteratum%253Aachs%26aulast%3DBeaudry%26aufirst%3DF.%26aulast%3DCoutu%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DN.%2BK.%26atitle%3DDetermination%2520of%2520drug%25E2%2580%2593plasma%2520protein%2520binding%2520using%2520human%2520serum%2520albumin%2520chromatographic%2520column%2520and%2520multiple%2520linear%2520regression%2520model%26jtitle%3DBiomed.%2520Chromatogr.%26date%3D1999%26volume%3D13%26spage%3D401%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Roberts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnusson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burczynski, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M.</span><span> </span><span class="NLM_article-title">Enterohepatic Circulation</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">â</span> <span class="NLM_lpage">790</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.2165%2F00003088-200241100-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=12162761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFyru78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=751-790&author=M.+Robertsauthor=B.+Magnussonauthor=F.+Burczynskiauthor=M.+Weiss&title=Enterohepatic+Circulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Enterohepatic circulation: physiological, pharmacokinetic and clinical implications</span></div><div class="casAuthors">Roberts, Michael S.; Magnusson, Beatrice M.; Burczynski, Frank J.; Weiss, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">751-790</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Enterohepatic recycling occurs by biliary excretion and intestinal reabsorption of a solute, sometimes with hepatic conjugation and intestinal deconjugation.  Cycling is often assocd. with multiple peaks and a longer apparent half-life in a plasma concn.-time profile.  Factors affecting biliary excretion include drug characteristics (chem. structure, polarity and mol. size), transport across sinusoidal plasma membrane and canniculae membranes, biotransformation and possible reabsorption from intrahepatic bile ductules.  Intestinal reabsorption to complete the enterohepatic cycle may depend on hydrolysis of a drug conjugate by gut bacteria.  Bioavailability is also affected by the extent of intestinal absorption, gut-wall P-glycoprotein efflux and gut-wall metab.  Recently, there has been a considerable increase in our understanding of the role of transporters, of gene expression of intestinal and hepatic enzymes, and of hepatic zonation.  Drugs, disease and genetics may result in induced or inhibited activity of transporters and metabolizing enzymes.  Reduced expression of one transporter, for example hepatic canalicular multidrug resistance-assocd. protein (MRP) 2, is often assocd. with enhanced expression of others, for example the usually quiescent basolateral efflux MRP3, to limit hepatic toxicity.  In addn., physiol. relevant pharmacokinetic models, which describe enterohepatic recirculation in terms of its determinants (such as sporadic gall bladder emptying), have been developed.  In general, enterohepatic recirculation may prolong the pharmacol. effect of certain drugs and drug metabolites.  Of particular importance is the potential amplifying effect of enterohepatic variability in defining differences in the bioavailability, apparent vol. of distribution and clearance of a given compd.  Genetic abnormalities, disease states, orally administered adsorbents and certain co-administered drugs all affect enterohepatic recycling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDmTzuEhf7QLVg90H21EOLACvtfcHk0liVGPKoRY4XQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFyru78%253D&md5=514a6ffb4ee275ccd2a7082fe2fe3d87</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2165%2F00003088-200241100-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200241100-00005%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DM.%26aulast%3DMagnusson%26aufirst%3DB.%26aulast%3DBurczynski%26aufirst%3DF.%26aulast%3DWeiss%26aufirst%3DM.%26atitle%3DEnterohepatic%2520Circulation%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2002%26volume%3D41%26spage%3D751%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S. M.</span><span> </span><span class="NLM_article-title">Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3679</span><span class="NLM_x">â</span> <span class="NLM_lpage">3683</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3679-3683&author=L.+Yanauthor=P.+Huoauthor=G.+Dohertyauthor=L.+Tothauthor=J.+J.+Haleauthor=S.+G.+Millsauthor=R.+Hajduauthor=C.+A.+Keohaneauthor=M.+J.+Rosenbachauthor=J.+A.+Milliganauthor=G.-J.+Sheiauthor=G.+Chrebetauthor=J.+Bergstromauthor=D.+Cardauthor=E.+Quackenbushauthor=A.+Wickhamauthor=S.+M.+Mandala&title=Discovery+of+3-arylpropionic+acids+as+potent+agonists+of+sphingosine-1-phosphate+receptor-1+%28S1P1%29+with+high+selectivity+against+all+other+known+S1P+receptor+subtypes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%26aulast%3DHuo%26aufirst%3DP.%26aulast%3DDoherty%26aufirst%3DG.%26aulast%3DToth%26aufirst%3DL.%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DChrebet%26aufirst%3DG.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DQuackenbush%26aufirst%3DE.%26aulast%3DWickham%26aufirst%3DA.%26aulast%3DMandala%26aufirst%3DS.%2BM.%26atitle%3DDiscovery%2520of%25203-arylpropionic%2520acids%2520as%2520potent%2520agonists%2520of%2520sphingosine-1-phosphate%2520receptor-1%2520%2528S1P1%2529%2520with%2520high%2520selectivity%2520against%2520all%2520other%2520known%2520S1P%2520receptor%2520subtypes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3679%26epage%3D3683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Cahalan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Cabrera, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisyan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, M.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeager, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemons, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">â</span> <span class="NLM_lpage">256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1038%2Fnchembio.547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21445057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVOhsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=254-256&author=S.+M.+Cahalanauthor=P.+J.+Gonzalez-Cabreraauthor=G.+Sarkisyanauthor=N.+Nguyenauthor=M.-T.+Schaefferauthor=L.+Huangauthor=A.+Yeagerauthor=B.+Clemonsauthor=F.+Scottauthor=H.+Rosen&title=Actions+of+a+picomolar+short-acting+S1P1+agonist+in+S1P1-eGFP+knock-in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice</span></div><div class="casAuthors">Cahalan, Stuart M.; Gonzalez-Cabrera, Pedro J.; Sarkisyan, Gor; Nguyen, Nhan; Schaeffer, Marie-Therese; Huang, Liming; Yeager, Adam; Clemons, Bryan; Scott, Fiona; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">254-256</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate receptor 1 (S1P1) is crit. for lymphocyte recirculation and is a clin. target for treatment of multiple sclerosis.  By generating a short-duration S1P1 agonist and mice in which fluorescently tagged S1P1 replaces wild-type receptor, the authors elucidate physiol. and agonist-perturbed changes in expression of S1P1 at a subcellular level in vivo.  The authors demonstrate differential downregulation of S1P1 on lymphocytes and endothelia after agonist treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNs3fjYUWAVrVg90H21EOLACvtfcHk0liVGPKoRY4XQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVOhsb0%253D&md5=667724613ca1aef5478cb3b9cd6f215c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.547%26sid%3Dliteratum%253Aachs%26aulast%3DCahalan%26aufirst%3DS.%2BM.%26aulast%3DGonzalez-Cabrera%26aufirst%3DP.%2BJ.%26aulast%3DSarkisyan%26aufirst%3DG.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DSchaeffer%26aufirst%3DM.-T.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DYeager%26aufirst%3DA.%26aulast%3DClemons%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DF.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DActions%2520of%2520a%2520picomolar%2520short-acting%2520S1P1%2520agonist%2520in%2520S1P1-eGFP%2520knock-in%2520mice%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D254%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Nicolaides, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efthymiopoulos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressman, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reppas, C.</span><span> </span><span class="NLM_article-title">Forecasting the In Vivo Performance of Four Low Solubility Drugs from Their In Vitro Dissolution Data</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1876</span><span class="NLM_x">â</span> <span class="NLM_lpage">1882</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1999&pages=1876-1882&author=E.+Nicolaidesauthor=E.+Galiaauthor=C.+Efthymiopoulosauthor=J.+B.+Dressmanauthor=C.+Reppas&title=Forecasting+the+In+Vivo+Performance+of+Four+Low+Solubility+Drugs+from+Their+In+Vitro+Dissolution+Data"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNicolaides%26aufirst%3DE.%26aulast%3DGalia%26aufirst%3DE.%26aulast%3DEfthymiopoulos%26aufirst%3DC.%26aulast%3DDressman%26aufirst%3DJ.%2BB.%26aulast%3DReppas%26aufirst%3DC.%26atitle%3DForecasting%2520the%2520In%2520Vivo%2520Performance%2520of%2520Four%2520Low%2520Solubility%2520Drugs%2520from%2520Their%2520In%2520Vitro%2520Dissolution%2520Data%26jtitle%3DPharm.%2520Res.%26date%3D1999%26volume%3D16%26spage%3D1876%26epage%3D1882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deeks, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavens, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demont, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cryan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garden, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witherington, J.</span><span> </span><span class="NLM_article-title">The utility of pharmacokineticâpharmacodynamic modeling in the discovery and optimization of selective S1P1 agonists</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=671&author=S.+Taylorauthor=J.+R.+J.+Grayauthor=R.+Willisauthor=N.+Deeksauthor=A.+Haynesauthor=C.+Campbellauthor=P.+Gaskinauthor=K.+Leavensauthor=E.+Demontauthor=S.+Dowellauthor=J.+Cryanauthor=M.+Morseauthor=A.+Patelauthor=H.+Gardenauthor=J.+Witherington&title=The+utility+of+pharmacokinetic%E2%80%93pharmacodynamic+modeling+in+the+discovery+and+optimization+of+selective+S1P1+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DWillis%26aufirst%3DR.%26aulast%3DDeeks%26aufirst%3DN.%26aulast%3DHaynes%26aufirst%3DA.%26aulast%3DCampbell%26aufirst%3DC.%26aulast%3DGaskin%26aufirst%3DP.%26aulast%3DLeavens%26aufirst%3DK.%26aulast%3DDemont%26aufirst%3DE.%26aulast%3DDowell%26aufirst%3DS.%26aulast%3DCryan%26aufirst%3DJ.%26aulast%3DMorse%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DGarden%26aufirst%3DH.%26aulast%3DWitherington%26aufirst%3DJ.%26atitle%3DThe%2520utility%2520of%2520pharmacokinetic%25E2%2580%2593pharmacodynamic%2520modeling%2520in%2520the%2520discovery%2520and%2520optimization%2520of%2520selective%2520S1P1%2520agonists%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26spage%3D671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Gleeson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J.</span><span> </span><span class="NLM_article-title">Probing the links between in vitro potency, ADMET and physicochemical parameters</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1038%2Fnrd3367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=21358739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=197-208&author=M.+P.+Gleesonauthor=A.+Herseyauthor=D.+Montanariauthor=J.+Overington&title=Probing+the+links+between+in+vitro+potency%2C+ADMET+and+physicochemical+parameters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the links between in vitro potency, ADMET and physicochemical parameters</span></div><div class="casAuthors">Gleeson, M. Paul; Hersey, Anne; Montanari, Dino; Overington, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-208</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A common underlying assumption in current drug discovery strategies is that compds. with higher in vitro potency at their target(s) have greater potential to translate into successful, low-dose therapeutics.  This has led to the development of screening cascades with in vitro potency embedded as an early filter.  However, this approach is beginning to be questioned, given the bias in physicochem. properties that it can introduce early in lead generation and optimization, which is due to the often diametrically opposed relationship between physicochem. parameters assocd. with high in vitro potency and those assocd. with desirable absorption, distribution, metab., excretion and toxicity (ADMET) characteristics.  Here, we describe analyses that probe these issues further using the ChEMBL database, which includes more than 500,000 drug discovery and marketed oral drug compds.  Key findings include: first, that oral drugs seldom possess nanomolar potency (50 nM on av.); second, that many oral drugs have considerable off-target activity; and third, that in vitro potency does not correlate strongly with the therapeutic dose.  These findings suggest that the perceived benefit of high in vitro potency may be negated by poorer ADMET properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovOslFSgIkUbVg90H21EOLACvtfcHk0liqkb0d2P9tXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D&md5=e275044516e9b0245b71c9603477ef74</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd3367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3367%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DOverington%26aufirst%3DJ.%26atitle%3DProbing%2520the%2520links%2520between%2520in%2520vitro%2520potency%252C%2520ADMET%2520and%2520physicochemical%2520parameters%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D197%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summerhill, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, J. E.</span><span> </span><span class="NLM_article-title">Aromatic chloride to nitrile transformation: medicinal and synthetic chemistry</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">â</span> <span class="NLM_lpage">318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1039%2FC0MD00135J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeku7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=309-318&author=L.+H.+Jonesauthor=N.+W.+Summerhillauthor=N.+A.+Swainauthor=J.+E.+Mills&title=Aromatic+chloride+to+nitrile+transformation%3A+medicinal+and+synthetic+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatic chloride to nitrile transformation: medicinal and synthetic chemistry</span></div><div class="casAuthors">Jones, Lyn H.; Summerhill, Nicholas W.; Swain, Nigel A.; Mills, James E.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">309-318</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review highlights the medicinal and synthetic chem. relevance of replacing an arom. chloride motif with an arom. nitrile.  Desirable features that this transformation can bring in a drug design are explored as are recent synthetic chem. advances that effect this replacement in a single step.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJt7anfomBpLVg90H21EOLACvtfcHk0liqkb0d2P9tXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeku7zO&md5=e0b1cbf19a7bc117e9a8a83af9e19322</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2FC0MD00135J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0MD00135J%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DSummerhill%26aufirst%3DN.%2BW.%26aulast%3DSwain%26aufirst%3DN.%2BA.%26aulast%3DMills%26aufirst%3DJ.%2BE.%26atitle%3DAromatic%2520chloride%2520to%2520nitrile%2520transformation%253A%2520medicinal%2520and%2520synthetic%2520chemistry%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2010%26volume%3D1%26spage%3D309%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Fleming, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravikumar, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shook, B. C.</span><span> </span><span class="NLM_article-title">Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7902</span><span class="NLM_x">â</span> <span class="NLM_lpage">7917</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100762r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7902-7917&author=F.+F.+Flemingauthor=L.+Yaoauthor=P.+C.+Ravikumarauthor=L.+Funkauthor=B.+C.+Shook&title=Nitrile-Containing+Pharmaceuticals%3A+Efficacious+Roles+of+the+Nitrile+Pharmacophore"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore</span></div><div class="casAuthors">Fleming, Fraser F.; Yao, Lihua; Ravikumar, P. C.; Funk, Lee; Shook, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7902-7917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review is structured according to the nature of the nitrile-bearing substituent.  As the no. of nitrile-contg. drug leads is vast, the review has focused on launched nitrile-contg. pharmaceuticals and currently active clin. candidates.  Most nitrile-contg. pharmaceuticals are aroms. with aliph.-, alkene-, and nitrogen-bearing nitriles being progressively less frequent.  Within each class, the bioactive nitriles are collated according to common structural elements and mode of action.  The hope is that this survey will allow greater deployment of this versatile functionality within drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR6kPPdWVuvLVg90H21EOLACvtfcHk0liqkb0d2P9tXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP&md5=040bbaebd9e8c9999d195b9a22221fea</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm100762r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100762r%26sid%3Dliteratum%253Aachs%26aulast%3DFleming%26aufirst%3DF.%2BF.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DRavikumar%26aufirst%3DP.%2BC.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DShook%26aufirst%3DB.%2BC.%26atitle%3DNitrile-Containing%2520Pharmaceuticals%253A%2520Efficacious%2520Roles%2520of%2520the%2520Nitrile%2520Pharmacophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7902%26epage%3D7917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">â</span> <span class="NLM_lpage">6756</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+Flatland%3A+Increasing+Saturation+as+an+Approach+to+Improving+Clinical+Success"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0liT9Jdj5ScuhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520Flatland%253A%2520Increasing%2520Saturation%2520as%2520an%2520Approach%2520to%2520Improving%2520Clinical%2520Success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">SchÃ¼rer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Cabrera, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaeffer, M.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Ligand-Binding Pocket Shape Differences between Sphingosine 1-Phosphate (S1P) Receptors S1P1 and S1P3 Determine Efficiency of Chemical Probe Identification by Ultrahigh-Throughput Screening</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">â</span> <span class="NLM_lpage">498</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb800051m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=486-498&author=S.+C.+Sch%C3%BCrerauthor=S.+J.+Brownauthor=P.+J.+Gonzalez-Cabreraauthor=M.-T.+Schaefferauthor=J.+Chapmanauthor=E.+Joauthor=P.+Chaseauthor=T.+Spicerauthor=P.+Hodderauthor=H.+Rosen&title=Ligand-Binding+Pocket+Shape+Differences+between+Sphingosine+1-Phosphate+%28S1P%29+Receptors+S1P1+and+S1P3+Determine+Efficiency+of+Chemical+Probe+Identification+by+Ultrahigh-Throughput+Screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fcb800051m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb800051m%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%2BC.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DGonzalez-Cabrera%26aufirst%3DP.%2BJ.%26aulast%3DSchaeffer%26aufirst%3DM.-T.%26aulast%3DChapman%26aufirst%3DJ.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DChase%26aufirst%3DP.%26aulast%3DSpicer%26aufirst%3DT.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DLigand-Binding%2520Pocket%2520Shape%2520Differences%2520between%2520Sphingosine%25201-Phosphate%2520%2528S1P%2529%2520Receptors%2520S1P1%2520and%2520S1P3%2520Determine%2520Efficiency%2520of%2520Chemical%2520Probe%2520Identification%2520by%2520Ultrahigh-Throughput%2520Screening%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2008%26volume%3D3%26spage%3D486%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">ValkÃ³, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D.</span><span> </span><span class="NLM_article-title">Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC: A High-Throughput Alternative to log P/log D</span> <span class="citation_source-journal">Anal. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">2022</span><span class="NLM_x">â</span> <span class="NLM_lpage">2029</span></span><div class="citationLinks">[<a href="/doi/10.1021/ac961242d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1997&pages=2022-2029&author=K.+Valk%C3%B3author=C.+Bevanauthor=D.+Reynolds&title=Chromatographic+Hydrophobicity+Index+by+Fast-Gradient+RP-HPLC%3A+A+High-Throughput+Alternative+to+log+P%2Flog+D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fac961242d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac961242d%26sid%3Dliteratum%253Aachs%26aulast%3DValk%25C3%25B3%26aufirst%3DK.%26aulast%3DBevan%26aufirst%3DC.%26aulast%3DReynolds%26aufirst%3DD.%26atitle%3DChromatographic%2520Hydrophobicity%2520Index%2520by%2520Fast-Gradient%2520RP-HPLC%253A%2520A%2520High-Throughput%2520Alternative%2520to%2520log%2520P%252Flog%2520D%26jtitle%3DAnal.%2520Chem.%26date%3D1997%26volume%3D69%26spage%3D2022%26epage%3D2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Skidmore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atcha, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boucherat, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelletti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coppo, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunsdon, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchings, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maskell, E. S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redshaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sehmi, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scoccitti, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theobald, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span> </span><span class="NLM_article-title">The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1,3,4-oxadiazol-2-yl)phenyl) benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3531</span><span class="NLM_x">â</span> <span class="NLM_lpage">3534</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3531-3534&author=J.+Skidmoreauthor=Z.+Atchaauthor=E.+Boucheratauthor=L.+Castellettiauthor=D.+W.+Chenauthor=F.+T.+Coppoauthor=L.+Cutlerauthor=R.+M.+Dunsdonauthor=B.+M.+Heathauthor=R.+Hutchingsauthor=D.+N.+Hurstauthor=S.+Javedauthor=S.+Martinauthor=E.+S.+L.+Maskellauthor=D.+Nortonauthor=D.+J.+Pembertonauthor=S.+Redshawauthor=R.+Rutterauthor=S.+S.+Sehmiauthor=T.+Scoccittiauthor=H.+E.+Templeauthor=P.+Theobaldauthor=R.+W.+Wardauthor=D.+M.+Wilson&title=The+discovery+of+2-fluoro-N-%283-fluoro-4-%285-%28%284-morpholinobutyl%29amino%29-1%2C3%2C4-oxadiazol-2-yl%29phenyl%29+benzamide%2C+a+full+agonist+of+the+alpha-7+nicotinic+acetylcholine+receptor+showing+efficacy+in+the+novel+object+recognition+model+of+cognition+enhancement"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSkidmore%26aufirst%3DJ.%26aulast%3DAtcha%26aufirst%3DZ.%26aulast%3DBoucherat%26aufirst%3DE.%26aulast%3DCastelletti%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DD.%2BW.%26aulast%3DCoppo%26aufirst%3DF.%2BT.%26aulast%3DCutler%26aufirst%3DL.%26aulast%3DDunsdon%26aufirst%3DR.%2BM.%26aulast%3DHeath%26aufirst%3DB.%2BM.%26aulast%3DHutchings%26aufirst%3DR.%26aulast%3DHurst%26aufirst%3DD.%2BN.%26aulast%3DJaved%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMaskell%26aufirst%3DE.%2BS.%2BL.%26aulast%3DNorton%26aufirst%3DD.%26aulast%3DPemberton%26aufirst%3DD.%2BJ.%26aulast%3DRedshaw%26aufirst%3DS.%26aulast%3DRutter%26aufirst%3DR.%26aulast%3DSehmi%26aufirst%3DS.%2BS.%26aulast%3DScoccitti%26aufirst%3DT.%26aulast%3DTemple%26aufirst%3DH.%2BE.%26aulast%3DTheobald%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BW.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DThe%2520discovery%2520of%25202-fluoro-N-%25283-fluoro-4-%25285-%2528%25284-morpholinobutyl%2529amino%2529-1%252C3%252C4-oxadiazol-2-yl%2529phenyl%2529%2520benzamide%252C%2520a%2520full%2520agonist%2520of%2520the%2520alpha-7%2520nicotinic%2520acetylcholine%2520receptor%2520showing%2520efficacy%2520in%2520the%2520novel%2520object%2520recognition%2520model%2520of%2520cognition%2520enhancement%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3531%26epage%3D3534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rager, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardos, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobson, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, I. J.</span><span> </span><span class="NLM_article-title">Evaluation of the MDR-MDCK cell line as a permeability screen for the bloodâbrain barrier</span> <span class="citation_source-journal">Int. J. Pharmaceut.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">â</span> <span class="NLM_lpage">359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm5010336&amp;key=10.1016%2Fj.ijpharm.2004.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm5010336&amp;key=15620875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm5010336&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFGhurvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2005&pages=349-359&author=Q.+Wangauthor=J.+D.+Ragerauthor=K.+Weinsteinauthor=P.+S.+Kardosauthor=G.+L.+Dobsonauthor=J.+Liauthor=I.+J.+Hidalgo&title=Evaluation+of+the+MDR-MDCK+cell+line+as+a+permeability+screen+for+the+blood%E2%80%93brain+barrier"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier</span></div><div class="casAuthors">Wang, Qing; Rager, Joseph D.; Weinstein, Kathryn; Kardos, Paula S.; Dobson, Glenn L.; Li, Jibin; Hidalgo, Ismael J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">349-359</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The objectives of this study were to (1) characterize MDR-MDCK monolayers as an in vitro model to predict brain uptake potential; (2) examine the ability of MDR-MDCK monolayers to identify the brain uptake potential of compds. that interact with P-glycoprotein (P-gp).  The study measured the bi-directional transport of 28 compds. across MDR-MDCK monolayers.  The brain uptake of a subset of the compds. was detd. in the rat brain perfusion model.  Drug concns. were analyzed by LC-MS-MS.  CNS-pos. drugs exhibited absorptive permeability coeffs. (Papp, A-B) values ranging from 3.4 Ã 10-6 to 20.2 Ã 10-6 cm/s; whereas CNS-neg. drugs showed Papp (A-B) ranging from 0.03 Ã 10-6 to 0.83 Ã 10-6 cm/s.  Inhibition of P-gp by cyclosporin A (CsA) significantly reduced secretory flux of compds. known to be P-pg substrates, but only enhanced the absorptive flux of compds. with high efflux ratio (>100).  In vitro results were confirmed by brain perfusion studies on selected compds.  MDR-MDCK monolayers can be used to classify compds. into CNS-pos. or CNS-neg. based on the permeability coeffs. (Papp, A-B).  Under the authors' exptl. conditions, compds. with Papp (A-B) >3 Ã 10-6 cm/s have high brain uptake potential; compds. with Papp (A-B) < 1 Ã 10-6 cm/s are unable to penetrate the blood-brain barrier (BBB); the brain uptake of compds. with Papp (A-B) < 1 Ã 10-6 cm/s and a P-gp-mediated efflux ratio of >100 may be enhanced by inhibiting P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvF-zoLte8trVg90H21EOLACvtfcHk0liT9Jdj5ScuhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFGhurvE&md5=7d2cb9e13b2767b337bf808e73141ae1</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2004.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2004.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DRager%26aufirst%3DJ.%2BD.%26aulast%3DWeinstein%26aufirst%3DK.%26aulast%3DKardos%26aufirst%3DP.%2BS.%26aulast%3DDobson%26aufirst%3DG.%2BL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHidalgo%26aufirst%3DI.%2BJ.%26atitle%3DEvaluation%2520of%2520the%2520MDR-MDCK%2520cell%2520line%2520as%2520a%2520permeability%2520screen%2520for%2520the%2520blood%25E2%2580%2593brain%2520barrier%26jtitle%3DInt.%2520J.%2520Pharmaceut.%26date%3D2005%26volume%3D288%26spage%3D349%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="note"><p class="first last">Further analysis showed that one of the four rats used in the 1 mg/kg study for compound <b>31a</b> had a significantly prolonged lymphopenia compared with the other three rats, hence the average prolonged effect. See <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Bonanomi, G.; Cardullo, F.; Damiani, F.; Gentile, G.; Hamprecht, D.; Micheli, F.; Tarsi, L.</span> (Glaxo Group Limited, U.K.) <span> </span><span class="NLM_article-title">Preparation of fused benzazepines having affinity for the dopamine D3 receptor</span>. Int. Patent Appl. WO2006002928, 12 Jan<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=G.+Bonanomi&author=F.+Cardullo&author=F.+Damiani&author=G.+Gentile&author=D.+Hamprecht&author=F.+Micheli&author=L.+Tarsi&title=Preparation+of+fused+benzazepines+having+affinity+for+the+dopamine+D3+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBonanomi%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520fused%2520benzazepines%2520having%2520affinity%2520for%2520the%2520dopamine%2520D3%2520receptor%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i42"><a href="/doi/suppl/10.1021/jm5010336">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_31636"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures for the synthesis of compounds <b>8</b>â<b>30</b>, in vitro assay protocols for the determination of EC<sub>50</sub>, and protocols for <i>in vivo</i> studies and data correlations. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm5010336/suppl_file/jm5010336_si_001.pdf">jm5010336_si_001.pdf (1.4 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm5010336&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm5010336%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm5010336" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67999e7fde6c2374","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
